adenine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 852 studies
Excerpt | Relevance | Reference |
---|---|---|
"Moving from the recognition that infection control represents an unmet need, the Italian Society of Hematology (SIE) convened a panel of experts who had published and/or expressed an interest in infection complications in CLL." | 6.61 | Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. ( Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL, 2019) |
" He was diagnosed as having fibrinoid syndrome and started on topical prednisolone, brimonidine, timolol-dorzolamide, and orally administered acetazolamide." | 4.98 | Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature. ( Hwang, CK; Kim, BJ; Kolomeyer, AM, 2018) |
" He was diagnosed with type I cryoglobulinemia and treated with rituximab, plasmapheresis, methylprednisolone, and ibrutinib was restarted." | 3.91 | Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). ( Field, J; George, G; Singavi, A; Voshtina, E; Wright, N, 2019) |
" Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias." | 3.91 | Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019) |
" Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively." | 3.11 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. ( Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dearden, C; Ghia, P; Grosicki, S; Hillmen, P; Hsu, E; Kipps, TJ; Li, JY; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Szoke, A; Tedeschi, A; Zhou, C, 2022) |
" Common nonhematologic adverse events were fatigue (56%), nausea (53%), anorexia (41%), and diarrhea (41%) and were mostly low grade." | 3.11 | Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. ( Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA, 2022) |
" Ruxolitinib dosing was based on a previous phase I trial." | 3.01 | Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. ( Gallagher, J; Luo, Y; Shi, Y; Spaner, DE; Tsui, H; Wang, G, 2021) |
"Adverse events were generally mild, but one case of fatal suspected unexpected serious adverse reaction occurred." | 3.01 | Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. ( Akber, M; Aleman, S; Bergman, P; Blennow, O; Blixt, L; Bogdanovic, G; Buggert, M; Chen, MS; Chen, P; Friman, G; Gomez, AC; Hansson, L; Hober, S; Lindgren, G; Ljunggren, HG; Ljungman, P; Loré, K; Mielke, S; Muschiol, S; Nilsson, P; Nordlander, A; Norlin, AC; Nowak, P; Österborg, A; Smith, CIE; Söderdahl, G; Thalme, A; Valentini, D; Vesterbacka, J; Wahren-Borgström, E; Wullimann, D, 2021) |
" Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%)." | 3.01 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. ( Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H, 2021) |
"Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons." | 3.01 | Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. ( Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA, 2021) |
" Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time." | 2.94 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. ( Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dai, S; Dean, JP; Devereux, S; Ghia, P; Grosicki, S; Hillmen, P; Kipps, TJ; Lal, I; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Simpson, D; Tedeschi, A, 2020) |
"Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK." | 2.94 | ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ( Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K, 2020) |
"Lymphocytosis is a common and predictable pharmacodynamic effect of ibrutinib treatment, and in the absence of other signs of progression, does not represent disease progression." | 2.90 | Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. ( Barrientos, JC; Burger, JA; Byrd, JC; Hillmen, P; James, DF; Kipps, TJ; Ninomoto, J; Zhou, C, 2019) |
" The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily." | 2.90 | Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. ( Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L, 2019) |
" The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%])." | 2.90 | Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. ( Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019) |
" Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab." | 2.90 | Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. ( Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O, 2019) |
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)." | 2.90 | Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019) |
"The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax)." | 2.90 | Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. ( Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ, 2019) |
"After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%." | 2.90 | Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019) |
" Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia." | 2.87 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. ( Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018) |
"We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators." | 2.87 | Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J, 2018) |
" To test this postulate, a pilot study (NCT02801578) was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles." | 2.87 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. ( Bose, P; Chen, LS; Cruz, ND; Feng, S; Gandhi, V; Huang, X; Jain, N; Jiang, Y; Keating, MJ; Kroll, MH; Qiao, W; Thompson, PA; Wierda, WG; Wu, Q, 2018) |
"Conclusion Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance." | 2.84 | BTK ( Abruzzo, L; Andritsos, LA; Awan, FT; Blachly, JS; Blum, KA; Byrd, JC; Chase, W; Coleman, J; Davis, M; Doong, TJ; Flynn, JM; Gordon, A; Grever, MR; Guinn, D; Heerema, NA; Jaglowski, S; Johnson, AJ; Jones, D; Jones, JA; Lehman, A; Lozanski, A; Lozanski, G; Lucas, M; Maddocks, K; Mantel, R; McWhorter, S; Ny, F; Rogers, K; Ruppert, AS; Smith, LL; Woyach, JA; Zhao, W, 2017) |
"Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially." | 2.84 | Ibrutinib treatment improves T cell number and function in CLL patients. ( Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA, 2017) |
"Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents." | 2.84 | The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. ( Bozic, I; Burger, JA; Cibulskis, C; Farooqui, MZH; Fein, J; Getz, G; Herman, SEM; Hoellenriegel, J; Landau, DA; Leshchiner, I; Liu, D; Livitz, D; Neuberg, DS; Ravichandran, S; Rosebrock, D; Sivina, M; Sun, C; Underbayev, C; Wiestner, A; Wu, CJ; Zhang, W; Zviran, A, 2017) |
" Safety was consistent with prior experience for each drug, with infusion reactions the most prevalent adverse event." | 2.84 | Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. ( Brooks, HD; Burke, JM; Fanning, S; Farber, CM; Greenwald, DR; Klein, L; Kolibaba, KS; Mahadevan, D; Miskin, HP; Schreeder, MT; Sharman, JP; Sportelli, P; Weiss, MS, 2017) |
"The increasing indications and addition of newer agents to clinical practice and emergence of BTK inhibitor-related cardiac adverse events have complicated the management decisions for utilization of this class of therapy." | 2.82 | Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. ( Awan, FT; Christensen, BW; Zaha, VG, 2022) |
" We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors." | 2.82 | Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. ( Dong, R; Lin, N; Tan, B; Yan, Y; Zeng, X, 2022) |
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)." | 2.82 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016) |
"A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells." | 2.82 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. ( Barrett, DM; Beckwith, KA; Byrd, JC; Cogdill, AP; Cook, DR; Do, P; Fraietta, JA; Gill, S; Hulitt, J; Johnson, AJ; June, CH; Kudchodkar, SB; Lacey, SF; Levine, BL; Long, M; Maddocks, K; Maus, MV; McGettigan, SE; Melenhorst, JJ; Muthusamy, N; Patel, PR; Porter, DL; Ruella, M; Woyach, JA; Xu, J; Zhang, C; Zheng, Z, 2016) |
" We developed a population pharmacokinetic (PK) model for ibrutinib in patients." | 2.80 | Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. ( Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015) |
" When corrected for repeated dosing, pharmacokinetic parameters in healthy participants and patients were comparable." | 2.80 | The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. ( Byrd, JC; Chauhan, V; de Jong, J; Hellemans, P; James, D; Jiao, J; Loury, DJ; Mannaert, E; Murphy, J; O'Brien, S; Skee, D; Sukbuntherng, J, 2015) |
"Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, and rituximab (FCR) for up to 6 cycles with daily ibrutinib (420 mg) until progressive disease or unacceptable toxicity." | 2.80 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. ( Barr, PM; Barrientos, JC; Brown, JR; Burger, JA; Clow, F; Flinn, IW; Friedberg, JW; Graef, T; James, DF; O'Brien, S; Rai, K; Tran, A, 2015) |
" The most frequent adverse events (any grade) were diarrhea (70%), infusion-related reaction (45%), and peripheral sensory neuropathy (44%)." | 2.80 | Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. ( Andritsos, LA; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Hall, N; Heerema, NA; Jaglowski, SM; James, DF; Johnson, AJ; Jones, JA; Lozanski, G; Maddocks, KJ; Munneke, B; Nagar, V; Neuenburg, JK; Ruppert, AS; Smucker, K; Stefanos, M; West, JS; Woyach, JA, 2015) |
"Ibrutinib is associated with bleeding-related adverse events of grade ≤ 2 in severity, and infrequently with grade ≥ 3 events." | 2.80 | Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. ( Cullinane, AM; Farooqui, MZ; Herman, SE; Holland, SM; Lipsky, AH; Lozier, JN; Marti, G; Martyr, S; Nghiem, K; Niemann, CU; Saba, N; Soto, S; Sun, C; Tian, X; Uzel, G; Valdez, J; Wiestner, A, 2015) |
"The kinetics and degree of the treatment-induced lymphocytosis was highly variable; interestingly, in patients with a high baseline ALC the relative increase was mild and resolution rapid." | 2.79 | Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. ( Aue, G; Calvo, KR; Farooqui, M; Geisler, CH; Gyamfi, JA; Herman, SE; Jones, J; Lipsky, A; Liu, D; Maric, I; Marti, GE; Martyr, S; Mustafa, RZ; Niemann, CU; Pedersen, LB; Saba, N; Soto, S; Valdez, J; Wiestner, A, 2014) |
"The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions." | 2.78 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. ( Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Flinn, IW; Furman, RR; Grant, B; Hedrick, E; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Sharman, JP; Sukbuntherng, J; Wierda, WG; Zhao, W, 2013) |
" The pharmacokinetic and pharmacodynamic data of acalabrutinib were also discussed." | 2.72 | Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. ( Li, J; Miao, Y; Xu, W, 2021) |
"Whether this affects infection susceptibility and vaccination efficacy requires further investigation." | 2.72 | BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. ( Mulder, TA; Österborg, A; Palma, M, 2021) |
"The occurrence of adverse events was revealed as a major cause of ibrutinib failure in the real-world." | 2.72 | Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. ( Baek, DW; Cho, HJ; Kim, J; Lee, JM; Moon, JH; Sohn, SK, 2021) |
" In vitro exposure of leukemia cells to CAde showed that it was eight times less toxic as compared to CdA." | 2.71 | Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. ( Albertioni, F; Juliusson, G; Larsson, R; Liliemark, J; Lindemalm, S, 2004) |
"A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL." | 2.66 | Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. ( Matutes, E; Molica, S; Polliack, A; Tam, C, 2020) |
"Advances in the molecular biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and development of molecularly targeted therapies have resulted in treatment innovations." | 2.66 | Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? ( Suzumiya, J; Takizawa, J, 2020) |
"Chronic lymphocytic leukemia is one of the most common lymphoid malignancies." | 2.66 | Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia. ( Hanna, KS, 2020) |
"Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy." | 2.66 | Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review. ( Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R, 2020) |
"Chronic lymphocytic leukemia has a highly variable disease course across patients, thought to be driven by the vast inter- and intrapatient molecular heterogeneity described in several large-scale DNA-sequencing studies conducted over the past decade." | 2.61 | Clonal dynamics in chronic lymphocytic leukemia. ( Gutierrez, C; Wu, CJ, 2019) |
"The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous 2 decades with the introduction of multiple new therapies and new combinations." | 2.61 | Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. ( Woyach, JA, 2019) |
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas." | 2.61 | Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019) |
"Moving from the recognition that infection control represents an unmet need, the Italian Society of Hematology (SIE) convened a panel of experts who had published and/or expressed an interest in infection complications in CLL." | 2.61 | Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. ( Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL, 2019) |
"Waldenström's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients." | 2.61 | Updates in prognostication and treatment of Waldenström's macroglobulinemia. ( Advani, P; Ailawadhi, S; Paulus, A, 2019) |
"Discussion One patient with chronic lymphocytic leukemia/small lymphocytic lymphoma and one patient with mantle cell lymphoma developed laboratory and clinical tumor lysis syndrome following initiation of ibrutinib therapy." | 2.58 | Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( Brown, JN; Hammond, JM; Titus-Rains, KS, 2018) |
"Those who develop disease progression on ibrutinib are a particularly high-risk population with poor outcomes." | 2.58 | Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. ( Ayed, AO; Parikh, SA, 2018) |
"While opportunistic infections and viral reactivations occur with both ibrutinib and idelalisib, these complications are less common and less severe with ibrutinib, especially when used as monotherapy without additional immunosuppressive agents." | 2.58 | Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. ( Pleyer, C; Sun, C; Wiestner, A, 2018) |
"The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years." | 2.58 | Selecting Frontline Therapy for CLL in 2018. ( Jain, N, 2018) |
"Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question." | 2.58 | Relapsed CLL: sequencing, combinations, and novel agents. ( Brown, JR, 2018) |
" With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase." | 2.55 | Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. ( Kaur, V; Swami, A, 2017) |
" Here, we review the available literature on the pharmacokinetic and pharmacodynamic properties of these novel agents to guide the reader in the appropriate use of ibrutinib, idelalisib, and venetoclax." | 2.55 | Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. ( Hill, BT; Waldron, M; Winter, A, 2017) |
"The therapy for chronic lymphocytic leukemia (CLL) is undergoing a major transformation." | 2.55 | Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. ( Molica, S, 2017) |
"Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy." | 2.55 | Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. ( Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL, 2017) |
"Patients with chronic lymphocytic leukemia (CLL) having a chromosomal loss on the short arm of chromosome 17 including the TP53 gene locus (17p deletion) and/or having mutations in TP53 have a short overall survival and, until recently, limited treatment options." | 2.55 | Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. ( Edelmann, J; Gribben, JG, 2017) |
"Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years." | 2.55 | Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. ( Marini, BL; Perissinotti, AJ; Samanas, L, 2017) |
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs." | 2.53 | A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016) |
"The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise." | 2.52 | BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. ( de Rooij, MF; Eldering, E; Kater, AP; Spaargaren, M, 2015) |
"Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab." | 2.52 | Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. ( Burger, JA; Keating, MJ; O'Brien, SM; Sanford, DS; Wierda, WG, 2015) |
" Ibrutinib is an orally bioavailable and highly specific BTK inhibitor that was recently approved for treatment of patients with recurrent CLL and mantle cell lymphoma (MCL)." | 2.52 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ( Lynn Wang, Y; Smith, SM; Zhang, SQ; Zhang, SY, 2015) |
" Discontinuation of ibrutinib is rarely due to adverse events related to the drug." | 2.52 | The clinical safety of ibrutinib in chronic lymphocytic leukemia. ( Molica, S, 2015) |
" Orally bioavailable inhibitors of spleen tyrosine kinase, Bruton's tyrosine kinase, or PI3Kδ, induce high rates of durable responses." | 2.52 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. ( Wiestner, A, 2015) |
"The leukemic B cells from patients with chronic lymphocytic leukemia (CLL) require interactions with non-malignant cells and matrix in the tissue microenvironment to survive and grow." | 1.91 | Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. ( Chen, SS; Chiorazzi, N, 2023) |
"The "accelerated" chronic lymphocytic leukemia (aCLL) is a relatively rare form of CLL progression." | 1.72 | Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica. ( Yavorkovsky, LL, 2022) |
"A 79-year-old female was diagnosed with chronic lymphocytic leukemia seven years prior." | 1.72 | [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia]. ( Kumekawa, H; Mizuchi, D; Tamura, K; Watanabe, D, 2022) |
"Blood was obtained from patients with chronic lymphocytic leukemia, mantle-cell lymphoma and Waldenström macroglobulinemia with and without ibrutinib treatment and perfused through a microfluidic channel with(out) 60% stenosis over Horm type I collagen or human atherosclerotic plaque homogenate." | 1.72 | The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. ( Claushuis, TAM; Cosemans, JMEM; D'Italia, G; Karel, MFA; Kuijpers, MJE; Lemmens, TP; Tullemans, BME, 2022) |
"Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions." | 1.72 | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases. ( Angotzi, F; Bertorelle, R; Binotto, G; Cellini, A; Dei Tos, AP; Pizzi, M; Scarmozzino, F; Trentin, L; Visentin, A, 2022) |
"Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax." | 1.72 | Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients. ( Ferrarini, I; Gandini, F; Rigo, A; Zapparoli, E, 2022) |
"Certain genetic features in chronic lymphocytic leukemia (CLL) are associated with inferior outcomes after chemoimmunotherapy (CIT)." | 1.72 | Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. ( Deering, KL; Harshaw, Q; Huang, Q; Leslie, LA, 2022) |
" Adverse events occurred in 74." | 1.72 | Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. ( Akizuki, R; Fujino, A; Nomura, F; Omi, A; Tsujioka, S, 2022) |
" Toxic effects of the combination of ibrutinib and cetuximab have been reported in a patient with metastatic CRC." | 1.72 | Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia. ( Araz, M; Artaç, M; Çeneli, Ö; Karaağaç, M; Karakurt Eryilmaz, M; Korkmaz, M, 2022) |
"BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm and the most common leukemia in adults in Western countries." | 1.72 | An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation. ( Colaci, E; Giusti, D; Leonardi, G; Luppi, M; Maccaferri, M; Marasca, R; Pioli, V; Potenza, L; Pozzi, S, 2022) |
"Among patients with CLL disease progression on ibrutinib, OS was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy (median not reached) or venetoclax-based treatment (median 29." | 1.72 | Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. ( Ailawadhi, S; Braggio, E; Call, TG; Chanan-Khan, AA; Ding, W; Hampel, PJ; Hanson, CA; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Sher, T; Shi, M; Slager, SL; Van Dyke, DL; Wang, Y, 2022) |
"Chylothorax is an infrequent pleural effusion often caused by traumatic or nontraumatic injury to the thoracic duct." | 1.72 | Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report. ( Cheng, L; Huang, M; Jiang, L; Wei, J; Xu, H; Zhou, M, 2022) |
"Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL)." | 1.62 | Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. ( Abdel-Qadir, H; Austin, PC; Calvillo-Argüelles, O; Lee, DS; Leong, D; Nanthakumar, K; Pang, A; Prica, A; Sabrie, N; Thavendiranathan, P, 2021) |
"In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes." | 1.62 | Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? ( Baratè, C; Biagi, A; Borella, C; Cairoli, R; Cassin, R; Cavalloni, C; Chiarenza, A; Ciolli, S; Coscia, M; Del Poeta, G; Deodato, M; Di Raimondo, F; Fresa, A; Frustaci, AM; Greco, A; Ielo, C; Lapietra, G; Laurenti, L; Mauro, FR; Montillo, M; Morelli, F; Murru, R; Pelle, AC; Postorino, M; Reda, G; Rossi, V; Sportoletti, P; Tedeschi, A; Varettoni, M; Vitale, C; Zamprogna, G, 2021) |
" Patient characteristics, ibrutinib use and adverse drug reactions (ADRs) were collected from medical records." | 1.62 | Patterns of use and safety of ibrutinib in real-life practice. ( Allouchery, M; Delaunay, P; Delwail, V; Guidez, S; Lafay-Chebassier, C; Pérault-Pochat, MC; Salvo, F; Tomowiak, C, 2021) |
"ALK-positive histiocytosis is a recently described entity with few reported cases in literature." | 1.62 | ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. ( Brousset, P; Evrard, SM; Kanoun, S; Laurent, C; Meggetto, F; Péricart, S; Syrykh, C; Ysebaert, L, 2021) |
" Ibrutinib is currently not available in a liquid oral dosage form." | 1.62 | Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. ( Arnall, JR; DiSogra, KY; Janes, A; Moore, DC; Park, SI; Tran, T, 2021) |
"Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports." | 1.62 | A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. ( Aspelund, T; Björkholm, M; Gíslason, GK; Gottfreðsson, M; Kristinsson, SY; Landgren, O; Rögnvaldsson, S; Steingrímsson, V; Turesson, I; Þorsteinsdóttir, S, 2021) |
"Recirculation of chronic lymphocytic leukemia (CLL) cells between the peripheral blood and lymphoid niches plays a critical role in disease pathophysiology, and inhibiting this process is one of the major mechanisms of action for B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib." | 1.62 | FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. ( Amruz Cerna, K; Benes, V; Borsky, M; Brychtova, Y; Doubek, M; Kostalova, L; Kren, L; Krivanek, J; Kudlickova Peskova, M; Liskova, K; Loja, T; Mayer, J; Mladonicka Pavlasova, G; Mraz, M; Musilova Litzmanova, K; Ondrisova, L; Oppelt, J; Panovska, A; Pospisilova, S; Seda, V; Sharma, S; Tan, Z; Verner, J; Vojackova, E; Zhang, S; Zicha, D, 2021) |
" He was placed on intravenous immunoglobulin (IVIg) in combination with ibrutinib." | 1.62 | [Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia]. ( Kawano, K; Kawano, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Uchida, H, 2021) |
"A 77-year-old man with underlying chronic lymphocytic leukemia (CLL) on ibrutinib treatment was admitted because of a superinfected mosquito bite on the left ear and multiple partially necrotic skin lesions disseminated all over the entire body five days after returning from a trip to Colombia." | 1.62 | An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients - a case report. ( Einwächter, H; Konukiewitz, B; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Verbeek, M; Wiedemann, GM, 2021) |
" While 176 adverse events (AEs) were reported in 74 (54." | 1.62 | Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data ( Akay, OM; Akdeniz, A; Akpınar, S; Aydoğdu, İ; Baştürk, A; Batur, DS; Berber, İ; Çekdemir, D; Çetin, G; Davulcu, EA; Demircioğlu, S; Deveci, B; Dinçyürek, HD; Doğu, MH; Durusoy, SS; Ertop, Ş; Ferhanoğlu, B; Güneş, AK; Gürkan, E; İlhan, G; Kaya, E; Kızıklı, A; Kurtoğlu, E; Mehtap, Ö; Okan, V; Okay, M; Özcan, MA; Özcan, Ö; Özet, G; Özkocamaz, V; Pepedil Tanrıkulu, F; Sahip, B; Saydam, G; Sayınalp, N; Seyhanlı, A; Sönmez, M; Terzi, H; Tombak, A; Turgut, B; Uçar, MA; Ümit, EG; Ünal, A; Yavaşoğlu, İ; Yıldırım, R; Yılmaz, M, 2021) |
"NOTCH1 mutations in chronic lymphocytic leukemia (CLL) lead to accumulation of NOTCH1 intracellular domain (NICD) and prolong signaling." | 1.56 | Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. ( Allan, JN; Arruga, F; Bracciamà, V; Coscia, M; D'Arena, G; Deaglio, S; Forconi, F; Furman, RR; Gaidano, G; Gizzi, K; Packham, G; Vaisitti, T; Vitale, N; Yeomans, A, 2020) |
"The case is here reported of a chronic lymphocytic leukemia patient with ibrutinib-induced polyneuropathy." | 1.56 | Ibrutinib-induced polyneuropathy: A case report. ( Albayrak, M; Cömert, P; Öztürk, HB; Reis Aras, M; Şahin, O; Yıldız, A, 2020) |
"Tumor lysis syndrome is an oncologic emergency resulting from rapid and massive tumor cell death that may lead to serious clinical complications including acute kidney injury and cardiac arrest." | 1.56 | Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib. ( Brener, H; Brener, ZZ; Losev, A, 2020) |
"Ibrutinib use in chronic lymphocytic leukemia (CLL) has previously been associated with CNS-A." | 1.56 | Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report. ( Barnes, M; Buttar, B; Gondal, K; Kaell, A; Kumar, V; Le, TH; Siddique, H, 2020) |
" The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter- and intra-individual variability, to evaluate the impact of several covariates on ibrutinib pharmacokinetic parameters, and to examine the relationship between exposure and clinical outcome." | 1.56 | Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. ( Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020) |
" The purpose of this study was to describe treatment patterns, adverse events (AEs), and economic burden among treated patients with CLL." | 1.56 | Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study. ( Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2020) |
"Lysosomes in chronic lymphocytic leukemia (CLL) cells have previously been identified as a promising target for therapeutic intervention in combination with targeted therapies." | 1.56 | Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. ( Chanas-Larue, A; Gibson, SB; Henson, ES; Johnston, JB; Villalpando-Rodriguez, GE, 2020) |
"Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor." | 1.56 | Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis. ( Boutoille, D; Brochard, J; Guimard, T; Le Pape, P; Leterrier, M; Mahe, B; Mahe, J; Morio, F; Morrier, M; Raffi, F, 2020) |
"Novel agents have made the management of chronic lymphocytic leukemia (CLL) more promising and personalized." | 1.56 | Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia. ( Fan, L; Kong, YL; Li, JY; Liang, JH; Pan, BH; Wang, L; Wu, JZ; Xia, Y; Xu, W; Zhu, HY, 2020) |
"Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia, accounting for ≈ 37% of all leukemias in the United States." | 1.56 | Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. ( Borra, S; Huang, Q; Janjan, N; Li, J; Shrestha, S; Sundaram, M; Wang, L, 2020) |
"Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation." | 1.56 | Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. ( Braggio, E; Call, TG; Ding, W; Fonder, AL; Hampel, PJ; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Rabe, KG; Schwager, SM; Slager, SL; Van Dyke, DL; Wang, Y; Witzig, TE, 2020) |
"The clinical course of chronic lymphocytic leukemia (CLL) is often complicated by autoimmune cytopenia (AIC)." | 1.51 | [Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease]. ( Hara, S; Ishikawa, T; Nakamura, M; Yamashita, D; Yoshioka, S, 2019) |
" Submaximal ibrutinib dosing will have to be further systematically evaluated." | 1.51 | Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. ( Banerji, V; Brown, K; Bucher, O; Dawe, DE; Dhaliwal, DH; Geirnaert, M; Hibbert, I; Johnston, JB; Uminski, K, 2019) |
"After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases." | 1.51 | Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. ( Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R, 2019) |
"The median times to disease progression and RT were 33." | 1.51 | Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. ( Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W, 2019) |
"These CLL-like cells show genome instability and dysregulation of multiple CLL-associated cellular processes, including deregulated B cell receptor signaling, which we also identified in human CLL cases." | 1.51 | A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. ( Brooks, AN; Campagna, DR; Carrasco, RD; Cartun, ZJ; Cibulskis, CL; DeCaprio, JA; Ebert, BL; Fan, J; Fleming, MD; Gambe, RG; Getz, G; Ghia, EM; Herman, SEM; Kipps, TJ; Leshchiner, I; Martinez, AZ; Neuberg, D; Obeng, EA; Rassenti, LZ; Reed, R; Regis, FFD; Sun, J; Taylor-Weiner, A; Ten Hacken, E; Wan, Y; Wang, L; Wiestner, A; Wu, CJ; Yin, S, 2019) |
" Emerging real-world-data shows similar response and survival, but higher discontinuation rates due to adverse events (AEs)." | 1.51 | Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. ( Angelopoulou, M; Bitsani, C; Dimou, M; Iliakis, T; Kalyva, S; Koudouna, A; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Pardalis, V; Tsaftaridis, P; Vassilakopoulos, TP, 2019) |
"In primary chronic lymphocytic leukemia (CLL) lymphocytes, pharmacological interference with mitochondrial ATP synthesis or glucose metabolism affects BTK activity." | 1.51 | Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. ( Aloyz, R; Doyon, D; Paliouras, M; Sharif-Askari, B, 2019) |
"Neutrophilic panniculitis is a relatively rare condition, characterized by predominantly neutrophilic inflammation in the subcutaneous fat." | 1.48 | Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. ( Bayers, S; Stewart, J; Vandergriff, T, 2018) |
" To elucidate on-target and pharmacodynamic effects of acalabrutinib, we evaluated several laboratory endpoints, including proteomic changes, chemokine modulation and impact on cell migration." | 1.48 | Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. ( Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG, 2018) |
"Ibrutinib represents a revolution in chronic lymphocytic leukemia treatment scenario providing results never seen before and offering an effective therapy even in high-risk patients with really poor outcome after chemoimmunotherapy." | 1.48 | Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. ( Cairoli, R; Deodato, M; Frustaci, AM; Mazzucchelli, M; Montillo, M; Tedeschi, A, 2018) |
"Results from several recent studies in chronic lymphocytic leukemia (CLL) have demonstrated an association between ibrutinib exposure and the development of atrial fibrillation, estimated incidence of 11% with long-term follow up." | 1.48 | Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. ( Ali, N; Carver, J; Clasen, S; Gashonia, L; Hughes, M; Mato, AR; Nabhan, C; Pickens, P; Rhodes, J; Schuster, S; Svoboda, J, 2018) |
"We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials." | 1.48 | Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. ( Bachow, SH; Barr, P; Brander, DM; Cheson, BD; Claxton, D; Dorsey, C; Goy, A; Hill, B; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Landsburg, D; Mato, AR; Nabhan, C; Nasta, SD; Pu, J; Schuster, SJ; Skarbnik, A; Svoboda, J; Thompson, MC; Timlin, C; Ujjani, CS; Winter, A; Zent, C, 2018) |
"Invasive bacterial infections developed in 23 (53." | 1.48 | Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018) |
"Most patients with chronic lymphocytic leukemia (CLL) present with multiple comorbidities." | 1.48 | Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. ( Alqahtani, H; Amrock, SM; Choi, M; Churnetski, M; Cohen, JB; Danilov, AV; Gordon, MJ; Hoff, S; James, S; Kittai, A; Manda, S; Persky, D; Rivera, X; Spurgeon, SE, 2018) |
"There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib." | 1.48 | Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. ( Gabcova, G; Gajdos, P; Kriegova, E; Manukyan, G; Mikulkova, Z; Papajik, T; Smotkova Kraiczova, V; Turcsanyi, P; Urbanova, R; Zehnalova, S, 2018) |
" These findings suggest deterioration of the humoral immune system is associated with progressive CLL and altering the dosing of IgRT to achieve higher than conventional IgG target levels may have therapeutic activity." | 1.48 | Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. ( Huang, J; Lazarus, A; Norris, P; Shi, Y; Spaner, DE; Venema, R; Wang, G, 2018) |
"Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges." | 1.48 | Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. ( Achille, A; Deng, S; Fonseca, R; Jones, SS; Maharaj, K; Pabon-Saldana, M; Pinilla-Ibarz, J; Powers, JJ; Quayle, SN; Sahakian, E; Sotomayor, EM; Villagra, A, 2018) |
"The established treatment algorithms for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are currently challenged by novel classes of drugs, with ibrutinib being one of the most effective." | 1.46 | Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related? ( Kalpadakis, C; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Tsirkinidis, P; Yiakoumis, X, 2017) |
"Rare cases of transformation to Hodgkin lymphoma (HL) have been reported in the literature with an estimated prevalence of 0." | 1.46 | Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. ( Catherwood, M; Glavey, S; Leader, M; Marafioti, T; McCartney, Y; McCloy, M; Murphy, P; Quinn, J; Sargent, J; Thornton, P, 2017) |
"Fluorizoline induced apoptosis in chronic lymphocytic leukemia cells at concentrations in the low micromolar range." | 1.46 | The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax. ( Albericio, F; Cosialls, AM; de la Banda, E; Gil, J; González-Barca, EM; González-Gironès, DM; Iglesias-Serret, D; Lavilla, R; Núñez-Vázquez, S; Pomares, H; Pons, G; Preciado, S; Saura-Esteller, J, 2017) |
"Richter syndrome (RS) is a rare event in chronic lymphocytic leukemia (CLL) that is influenced by biological factors and prior CLL treatments." | 1.46 | Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( Albi, E; Ascani, S; Aureli, P; Baldoni, S; Del Papa, B; Di Ianni, M; Dorillo, E; Falzetti, F; Sportoletti, P, 2017) |
"Here we show that treatment of chronic lymphocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB transcriptional activity." | 1.46 | Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor. ( Allan, JN; Arruga, F; Deaglio, S; Furman, RR; Gaudino, F; Liou, HC; Moscvin, M; Ouk, S; Serra, S; Vaisitti, T; Vitale, N; Zakrzewski, JL, 2017) |
"The lymph node (LN) is the site of chronic lymphocytic leukemia (CLL) cell activation and proliferation." | 1.46 | Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. ( Abdelghaffar, HA; Abousamra, NK; Anastas, V; Barber, E; Calvo, KR; Corrigan-Cummins, M; Elbaz, O; Farooqui, M; Herman, SE; Saba, NS; Saleh, LM; Sarasua, SM; Sun, C; Wang, W; Wiestner, A; Zhao, Z, 2017) |
"Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2)." | 1.46 | Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. ( Ahn, I; Albitar, A; Albitar, M; DeDios, I; Estella, J; Farooqui, M; Ma, W; Wiestner, A, 2017) |
"A group of experts from the Spanish Chronic Lymphocytic Leukemia Group reviewed all published literature from January 2010 to January 2016, in order to provide recommendations based on clinical evidence." | 1.46 | Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. ( Abrisqueta, P; Bosch, F; Delgado, J; García-Marco, JA; Giraldo, P; González, M; Hernández-Rivas, JA; Jarque, I; Loscertales Pueyo, J; Martínez, R; Ramírez Payer, Á; Terol, MJ; Yáñez, L, 2017) |
"The introduction of miR profiling of chronic lymphocytic leukemia (CLL) patients with different cytogenetic profiles and responses to therapy has allowed incorporation of important miR-mRNA interactions into the understanding of disease biology." | 1.46 | The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. ( Andritsos, LA; Byrd, JC; Fabian, C; Flynn, JM; Guinn, D; Jaglowski, SM; Johnson, AJ; Jones, JA; Lehman, A; Maddocks, K; Woyach, JA; Yu, L, 2017) |
"Central nervous system involvement from chronic lymphocytic leukemia (CLL) occurs infrequently, and manifestations include cognitive and cerebellar dysfunction and cranial nerve palsies." | 1.43 | Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy. ( Almarzouqi, SJ; Chevez-Barrios, P; Khan, K; Lee, AG; Malik, AI; Morgan, ML; Yalamanchili, S, 2016) |
"Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly heterogeneous and no specific markers to predict sensitivity to this drug have been reported." | 1.43 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. ( Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S, 2016) |
"A 70-year-old white man with stage C chronic lymphocytic leukemia who was being successfully treated with ibrutinib and rituximab developed bilateral, purpuric, painful cutaneous nodules." | 1.43 | Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal. ( Magro, CM; Mulvey, JJ; Nuovo, GJ, 2016) |
"Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included in the study between May 2014 and May 2015." | 1.43 | Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. ( Andersson, PO; Asklid, A; Hansson, L; Karlsson, C; Karlsson, K; Lauri, B; Lundin, J; Mattsson, M; Norin, S; Österborg, A; Sandstedt, A; Winqvist, M, 2016) |
" Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo." | 1.42 | Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. ( Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP, 2015) |
"Leukemic cells from Chronic Lymphocytic Leukemia (CLL) patients interact with stromal cells of the surrounding microenvironment." | 1.42 | Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. ( Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R, 2015) |
" Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL." | 1.40 | Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). ( Bojnik, E; Buggy, JJ; Byrd, JC; Chang, BY; Davis, ME; Dubovsky, JA; Efremov, DG; Gobessi, S; Goettl, VM; Harrington, BK; Johnson, AJ; Laurenti, L; MacMurray, J; Ruppert, AS; Smith, LL; Smucker, KA; Stefanovski, MR; Towns, WH; Woyach, JA, 2014) |
"Thus, prolonged lymphocytosis is common following ibrutinib treatment, likely represents the persistence of a quiescent clone, and does not predict a subgroup of patients likely to relapse early." | 1.40 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. ( Byrd, JC; Clow, F; Flynn, J; Furman, RR; Ghia, E; James, DF; Johnson, AJ; Jones, J; Kipps, TJ; Lozanski, A; Lozanski, G; Lucas, D; Maddocks, K; Mantel, R; O'Brien, S; Rassenti, L; Ruppert, AS; Smith, LL; Smucker, K; Williams, K; Woyach, JA; Zhao, W; Zhong, Y, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (0.47) | 29.6817 |
2010's | 540 (63.38) | 24.3611 |
2020's | 308 (36.15) | 2.80 |
Authors | Studies |
---|---|
Abdel-Qadir, H | 1 |
Sabrie, N | 1 |
Leong, D | 1 |
Pang, A | 1 |
Austin, PC | 1 |
Prica, A | 2 |
Nanthakumar, K | 1 |
Calvillo-Argüelles, O | 1 |
Lee, DS | 1 |
Thavendiranathan, P | 1 |
Abrisqueta, P | 2 |
Loscertales, J | 7 |
Terol, MJ | 3 |
Ramírez Payer, Á | 2 |
Ortiz, M | 1 |
Pérez, I | 1 |
Cuellar-García, C | 2 |
Fernández de la Mata, M | 1 |
Rodríguez, A | 1 |
Lario, A | 1 |
Delgado, J | 8 |
Godoy, A | 1 |
Arguiñano Pérez, JM | 1 |
Berruezo, MJ | 1 |
Oliveira, A | 1 |
Hernández-Rivas, JÁ | 3 |
García Malo, MD | 1 |
Medina, Á | 1 |
García Martin, P | 1 |
Osorio, S | 1 |
Baltasar, P | 1 |
Fernández-Zarzoso, M | 1 |
Marco, F | 1 |
Vidal Manceñido, MJ | 1 |
Smucler Simonovich, A | 1 |
López Rubio, M | 1 |
Jarque, I | 2 |
Suarez, A | 1 |
Fernández Álvarez, R | 1 |
Lancharro Anchel, A | 1 |
Ríos, E | 1 |
Losada Castillo, MDC | 1 |
Pérez Persona, E | 1 |
García Muñoz, R | 1 |
Ramos, R | 1 |
Yáñez, L | 2 |
Bello, JL | 1 |
Loriente, C | 1 |
Acha, D | 1 |
Villanueva, M | 1 |
Sivina, M | 12 |
Kim, E | 5 |
Wierda, WG | 40 |
Ferrajoli, A | 23 |
Jain, N | 23 |
Thompson, P | 7 |
Kantarjian, H | 12 |
Keating, M | 8 |
Burger, JA | 57 |
Tedeschi, A | 32 |
Frustaci, AM | 8 |
Mauro, FR | 22 |
Chiarenza, A | 12 |
Coscia, M | 16 |
Ciolli, S | 5 |
Reda, G | 17 |
Laurenti, L | 24 |
Varettoni, M | 6 |
Murru, R | 10 |
Baratè, C | 1 |
Sportoletti, P | 11 |
Greco, A | 1 |
Borella, C | 2 |
Rossi, V | 1 |
Deodato, M | 6 |
Biagi, A | 6 |
Zamprogna, G | 4 |
Pelle, AC | 1 |
Lapietra, G | 1 |
Vitale, C | 7 |
Morelli, F | 4 |
Cassin, R | 9 |
Fresa, A | 2 |
Cavalloni, C | 1 |
Postorino, M | 4 |
Ielo, C | 3 |
Cairoli, R | 5 |
Di Raimondo, F | 9 |
Montillo, M | 13 |
Del Poeta, G | 14 |
Yun, NK | 1 |
Alrifai, T | 1 |
Miller, IJ | 1 |
Larson, ML | 1 |
Kater, AP | 19 |
Slinger, E | 1 |
Cretenet, G | 1 |
Martens, AW | 1 |
Balasubramanian, S | 6 |
Leverson, JD | 1 |
Eldering, E | 6 |
Rigolin, GM | 14 |
Del Giudice, I | 9 |
Bardi, A | 2 |
Melandri, A | 1 |
García-Jacobo, RE | 1 |
Cura, F | 1 |
Raponi, S | 4 |
Ilari, C | 3 |
Cafforio, L | 3 |
Piciocchi, A | 6 |
Arena, V | 3 |
Albano, F | 2 |
Molica, S | 21 |
Trentin, L | 21 |
Marchetti, M | 7 |
Nanni, M | 1 |
Peragine, N | 5 |
Mariglia, P | 4 |
Vignetti, M | 3 |
Guarini, A | 6 |
Foà, R | 22 |
Cuneo, A | 20 |
Allan, JN | 10 |
Siddiqi, T | 8 |
Kipps, TJ | 29 |
Opat, S | 3 |
Badoux, XC | 1 |
Kuss, BJ | 3 |
Jackson, S | 2 |
Moreno, C | 21 |
Jacobs, R | 5 |
Pagel, JM | 9 |
Flinn, I | 1 |
Pak, Y | 1 |
Zhou, C | 11 |
Szafer-Glusman, E | 2 |
Ninomoto, J | 8 |
Dean, JP | 11 |
James, DF | 31 |
Ghia, P | 27 |
Tam, CS | 24 |
Akpinar, S | 2 |
Dogu, MH | 2 |
Celik, S | 1 |
Ekinci, O | 1 |
Hindilerden, IY | 1 |
Dal, MS | 2 |
Davulcu, EA | 2 |
Tekinalp, A | 1 |
Hindilerden, F | 1 |
Ozcan, BG | 1 |
Hacibekiroglu, T | 1 |
Erkurt, MA | 1 |
Bagci, M | 1 |
Namdaroglu, S | 1 |
Korkmaz, G | 1 |
Bilgir, O | 1 |
Cagliyan, GA | 1 |
Ozturk, HBA | 1 |
Serin, I | 1 |
Tiryaki, TO | 1 |
Ozatli, D | 1 |
Korkmaz, S | 1 |
Ulas, T | 1 |
Eser, B | 1 |
Turgut, B | 2 |
Altuntas, F | 2 |
Zimmerman, SM | 1 |
Peer, CJ | 1 |
Figg, WD | 1 |
O'Brien, SM | 15 |
Cappelli, LV | 1 |
Soscia, R | 1 |
De Propris, MS | 3 |
Steingrímsson, V | 2 |
Lund, SH | 1 |
Dickman, PW | 1 |
Weibull, CE | 1 |
Björkholm, M | 2 |
Landgren, O | 2 |
Kristinsson, SY | 2 |
Bloomquist, MS | 1 |
Curry, JL | 1 |
Krishnan, B | 1 |
Rivero, G | 1 |
Curry, CV | 1 |
Diwan, AH | 1 |
Teh, JSK | 1 |
Tam, PCK | 1 |
Badenoch, PR | 1 |
Adamson, PJ | 1 |
Brennan, C | 1 |
Marshman, G | 1 |
Gordon, DL | 1 |
Langerbeins, P | 7 |
Zhang, C | 3 |
Robrecht, S | 9 |
Cramer, P | 16 |
Fürstenau, M | 7 |
Al-Sawaf, O | 6 |
von Tresckow, J | 7 |
Fink, AM | 9 |
Kreuzer, KA | 5 |
Vehling-Kaiser, U | 2 |
Tausch, E | 8 |
Müller, L | 3 |
Eckart, MJ | 1 |
Schlag, R | 1 |
Freier, W | 1 |
Gaska, T | 1 |
Balser, C | 1 |
Reiser, M | 1 |
Stauch, M | 1 |
Wendtner, CM | 13 |
Fischer, K | 11 |
Stilgenbauer, S | 23 |
Eichhorst, B | 16 |
Hallek, M | 26 |
Spaner, DE | 6 |
Luo, Y | 1 |
Wang, G | 5 |
Gallagher, J | 1 |
Tsui, H | 3 |
Shi, Y | 6 |
Wang, H | 2 |
Tian, S | 2 |
Zhao, Q | 2 |
Blumenschein, W | 1 |
Yearley, JH | 1 |
Secreto, CR | 2 |
Sinha, S | 2 |
Call, TG | 16 |
Wang, Y | 8 |
Parikh, SA | 17 |
Kenderian, SS | 10 |
He, R | 2 |
Leis, JF | 16 |
Shi, M | 4 |
Van Dyke, DL | 6 |
Kay, NE | 22 |
Slager, SL | 14 |
Braggio, E | 10 |
Yan, H | 3 |
Ding, W | 18 |
Davis, JE | 1 |
Sharpe, C | 1 |
Mason, K | 1 |
Koldej, RM | 1 |
Ritchie, DS | 1 |
Bergman, P | 1 |
Blennow, O | 1 |
Hansson, L | 4 |
Mielke, S | 1 |
Nowak, P | 1 |
Chen, P | 2 |
Söderdahl, G | 1 |
Österborg, A | 11 |
Smith, CIE | 2 |
Wullimann, D | 1 |
Vesterbacka, J | 1 |
Lindgren, G | 1 |
Blixt, L | 1 |
Friman, G | 1 |
Wahren-Borgström, E | 1 |
Nordlander, A | 1 |
Gomez, AC | 1 |
Akber, M | 1 |
Valentini, D | 1 |
Norlin, AC | 1 |
Thalme, A | 1 |
Bogdanovic, G | 1 |
Muschiol, S | 1 |
Nilsson, P | 1 |
Hober, S | 1 |
Loré, K | 1 |
Chen, MS | 1 |
Buggert, M | 1 |
Ljunggren, HG | 1 |
Ljungman, P | 2 |
Aleman, S | 1 |
Shanafelt, T | 1 |
Wiestner, A | 36 |
Li, J | 8 |
Krigsfeld, G | 2 |
Ahn, IE | 10 |
Steele, L | 1 |
George, C | 1 |
Cerio, R | 1 |
O'Toole, EA | 1 |
Shah, HR | 1 |
Stephens, DM | 5 |
Visentin, A | 15 |
Cibien, F | 1 |
Pietrasanta, D | 5 |
Gentile, M | 15 |
Quaglia, FM | 4 |
Scarfò, L | 10 |
Pravato, S | 2 |
Piazza, F | 5 |
Naylor-Adamson, L | 1 |
Chacko, AR | 1 |
Booth, Z | 1 |
Caserta, S | 1 |
Jarvis, J | 1 |
Khan, S | 2 |
Hart, SP | 1 |
Rivero, F | 1 |
Allsup, DJ | 2 |
Arman, M | 1 |
Bories, P | 1 |
Ysebaert, L | 19 |
Aslan Candır, B | 1 |
Yiğenoğlu, TN | 1 |
Kızıl Çakar, M | 1 |
Purroy, N | 1 |
Tong, YE | 1 |
Lemvigh, CK | 1 |
Cieri, N | 1 |
Li, S | 2 |
Parry, EM | 1 |
Zhang, W | 3 |
Rassenti, LZ | 4 |
Lesnick, C | 1 |
Shanafelt, TD | 16 |
Livak, KJ | 2 |
Kharchenko, PV | 1 |
Neuberg, DS | 2 |
Olsen, LR | 1 |
Fan, J | 3 |
Gohil, SH | 2 |
Wu, CJ | 7 |
Greil, R | 4 |
Demirkan, F | 9 |
Anz, B | 4 |
Larratt, L | 3 |
Simkovic, M | 5 |
Novak, J | 2 |
Strugov, V | 3 |
Gill, D | 6 |
Gribben, JG | 9 |
Kwei, K | 1 |
Dai, S | 5 |
Hsu, E | 5 |
Flinn, IW | 14 |
Tahir, F | 1 |
Sy, J | 1 |
Reddel, S | 1 |
Trotman, J | 1 |
Yavorkovsky, LL | 1 |
Huber, H | 1 |
Edenhofer, S | 1 |
Schneider, C | 2 |
Bloehdorn, J | 2 |
Dreger, P | 5 |
Ritgen, M | 4 |
Illmer, T | 4 |
Illert, AL | 1 |
Dürig, J | 2 |
Böttcher, S | 5 |
Niemann, CU | 17 |
Kneba, M | 4 |
Döhner, H | 3 |
Kumekawa, H | 1 |
Watanabe, D | 1 |
Tamura, K | 1 |
Mizuchi, D | 1 |
Egyed, M | 1 |
Lueff, S | 1 |
Borbely, J | 1 |
Illes, A | 2 |
Giannarelli, D | 8 |
De Paoli, L | 4 |
Moia, R | 8 |
Levato, L | 8 |
Giordano, A | 1 |
Stelitano, C | 1 |
Noto, A | 3 |
Guarente, V | 1 |
Gaidano, G | 18 |
Foa', R | 1 |
Ma, XY | 1 |
Zhao, M | 1 |
Li, YD | 1 |
Chen, Y | 6 |
Wei, L | 1 |
Chen, ZS | 1 |
Barr, PM | 35 |
Bannerji, R | 2 |
Russell, K | 1 |
Wang, E | 1 |
Mi, X | 1 |
Thompson, MC | 4 |
Montoya, S | 1 |
Notti, RQ | 1 |
Afaghani, J | 1 |
Durham, BH | 1 |
Penson, A | 1 |
Witkowski, MT | 1 |
Lu, SX | 1 |
Bourcier, J | 1 |
Hogg, SJ | 1 |
Erickson, C | 1 |
Cui, D | 1 |
Cho, H | 1 |
Singer, M | 1 |
Totiger, TM | 1 |
Chaudhry, S | 1 |
Geyer, M | 1 |
Alencar, A | 1 |
Linley, AJ | 1 |
Palomba, ML | 3 |
Coombs, CC | 2 |
Park, JH | 3 |
Zelenetz, A | 1 |
Roeker, L | 3 |
Rosendahl, M | 1 |
Tsai, DE | 1 |
Ebata, K | 1 |
Brandhuber, B | 1 |
Hyman, DM | 1 |
Aifantis, I | 1 |
Mato, A | 10 |
Taylor, J | 1 |
Abdel-Wahab, O | 1 |
Innocenti, I | 10 |
Motta, M | 2 |
Pennese, E | 2 |
Rughini, A | 1 |
Di Sevo, D | 1 |
Tomasso, A | 1 |
Autore, F | 6 |
Pompili, M | 2 |
Coutre, S | 18 |
McKinney, M | 1 |
Rogers, K | 3 |
Mokatrin, A | 2 |
Valentino, R | 3 |
Szoke, A | 3 |
Deshpande, S | 1 |
Zhu, A | 1 |
Arango-Hisijara, I | 1 |
Osei-Bonsu, K | 1 |
Wang, M | 2 |
O'Brien, S | 46 |
Karel, MFA | 1 |
Tullemans, BME | 1 |
D'Italia, G | 1 |
Lemmens, TP | 1 |
Claushuis, TAM | 1 |
Kuijpers, MJE | 1 |
Cosemans, JMEM | 1 |
Collins, J | 1 |
Stump, SE | 1 |
Heiling, H | 1 |
Muir, M | 1 |
Deal, A | 1 |
Proco, D | 1 |
Nguyen, C | 1 |
Cozad, M | 1 |
Muluneh, B | 1 |
Sorin, B | 1 |
Vigneron, J | 1 |
Fadlallah, J | 1 |
Mondesir, J | 1 |
Fieschi, C | 1 |
Oksenhendler, E | 1 |
Galicier, L | 1 |
Malphettes, M | 4 |
Angotzi, F | 1 |
Scarmozzino, F | 1 |
Cellini, A | 1 |
Bertorelle, R | 1 |
Pizzi, M | 3 |
Binotto, G | 1 |
Dei Tos, AP | 1 |
Matutes, E | 2 |
Polliack, A | 13 |
Owen, C | 9 |
Robak, T | 15 |
Bairey, O | 6 |
Hillmen, P | 32 |
Coutre, SE | 16 |
Dearden, C | 5 |
Grosicki, S | 8 |
McCarthy, H | 4 |
Li, JY | 3 |
Offner, F | 3 |
Wang, XV | 3 |
Hanson, CA | 7 |
Paietta, EM | 2 |
Barrientos, J | 3 |
Jelinek, DF | 2 |
Zhang, CC | 3 |
Cashen, AF | 3 |
Mato, AR | 22 |
Singh, AK | 3 |
Mullane, MP | 3 |
Little, RF | 4 |
Erba, H | 5 |
Stone, RM | 4 |
Litzow, M | 4 |
Tallman, M | 2 |
Christensen, BW | 1 |
Zaha, VG | 1 |
Awan, FT | 10 |
Ferrarini, I | 3 |
Gandini, F | 1 |
Zapparoli, E | 1 |
Rigo, A | 2 |
Black, GS | 1 |
Huang, X | 10 |
Qiao, Y | 1 |
Tarapcsak, S | 1 |
Rogers, KA | 16 |
Misra, S | 2 |
Byrd, JC | 68 |
Marth, GT | 1 |
Woyach, JA | 47 |
Wang, W | 5 |
Zhang, Y | 1 |
Zhao, D | 1 |
Zhou, D | 2 |
AlHaj Issa, Z | 1 |
Altwijri, A | 1 |
Alfayez, M | 1 |
Huang, Q | 3 |
Deering, KL | 2 |
Harshaw, Q | 2 |
Leslie, LA | 2 |
Huang, Y | 6 |
Ruppert, AS | 18 |
Walker, JS | 1 |
Canfield, D | 1 |
Cempre, CB | 1 |
Fu, Q | 1 |
Baker, S | 1 |
Hu, B | 1 |
Shah, H | 1 |
Vadeboncoeur, R | 1 |
Bhat, S | 3 |
Jaglowski, SM | 9 |
Lockman, H | 1 |
Lapalombella, R | 4 |
Dhami, K | 1 |
Chakraborty, A | 1 |
Gururaja, TL | 1 |
Cheung, LW | 1 |
Sun, C | 13 |
DeAnda, F | 1 |
Chiodin, G | 5 |
Drennan, S | 2 |
Martino, EA | 4 |
Ondrisova, L | 3 |
Henderson, I | 1 |
Del Rio, L | 1 |
Tracy, I | 2 |
D'Avola, A | 2 |
Parker, H | 1 |
Bonfiglio, S | 2 |
Sutton, LA | 2 |
Strefford, JC | 1 |
Forster, J | 1 |
Brake, O | 1 |
Potter, KN | 1 |
Sale, B | 1 |
Lanham, S | 1 |
Mraz, M | 5 |
Stevenson, FK | 4 |
Forconi, F | 9 |
Levin, MD | 8 |
Dubois, J | 3 |
Kersting, S | 5 |
Enggaard, L | 3 |
Veldhuis, GJ | 2 |
Mous, R | 4 |
Mellink, CHM | 2 |
van der Kevie-Kersemaekers, AF | 1 |
Dobber, JA | 3 |
Poulsen, CB | 2 |
Frederiksen, H | 3 |
Janssens, A | 9 |
Schjødt, I | 2 |
Dompeling, EC | 2 |
Ranti, J | 3 |
Brieghel, C | 1 |
Mattsson, M | 5 |
Bellido, M | 2 |
Tran, HTT | 3 |
Nasserinejad, K | 4 |
Mulligan, SP | 12 |
Marlton, P | 2 |
Kuss, B | 2 |
Gerungan, P | 1 |
Puig, A | 1 |
McGeachie, M | 1 |
Dhopeshwarkar, N | 1 |
Yang, W | 1 |
Hennessy, S | 1 |
Rhodes, JM | 2 |
Cuker, A | 1 |
Leonard, CE | 1 |
Klaproth, H | 2 |
Eichhorst, BF | 3 |
Wu, Z | 1 |
Wang, L | 7 |
Fan, L | 2 |
Tang, H | 1 |
Zuo, X | 1 |
Gu, D | 1 |
Lu, X | 2 |
Li, Y | 3 |
Wu, J | 3 |
Qin, S | 1 |
Xia, Y | 2 |
Zhu, H | 2 |
Xu, W | 4 |
Jin, H | 1 |
Omi, A | 1 |
Nomura, F | 1 |
Tsujioka, S | 1 |
Fujino, A | 1 |
Akizuki, R | 1 |
Hampel, PJ | 6 |
Rabe, KG | 8 |
Muchtar, E | 8 |
Koehler, AB | 7 |
Parrondo, R | 2 |
Schwager, SM | 11 |
Sigmund, AM | 1 |
Maddocks, K | 7 |
Jaglowski, S | 6 |
Bhat, SA | 3 |
Kittai, AS | 3 |
Grever, MR | 5 |
Roeker, LE | 5 |
Feldman, TA | 1 |
Soumerai, JD | 2 |
Falco, V | 1 |
Panton, G | 1 |
Dorsey, C | 3 |
Zelenetz, AD | 2 |
Falchi, L | 1 |
Straus, DJ | 1 |
Pena Velasquez, C | 1 |
Lebowitz, S | 1 |
Fox, Y | 1 |
Battiato, K | 1 |
Laudati, C | 1 |
McCarthy, E | 1 |
Kdiry, S | 1 |
Martignetti, R | 1 |
Turpuseema, T | 1 |
Purdom, M | 1 |
Paskalis, D | 2 |
Miskin, HP | 6 |
Sportelli, P | 6 |
Li, A | 1 |
Ambruso, SL | 1 |
Oto, OA | 1 |
Barry, M | 1 |
Edelstein, CL | 1 |
Karvaly, GB | 1 |
Vincze, I | 1 |
Balogh, A | 1 |
Köllő, Z | 1 |
Bödör, C | 5 |
Vásárhelyi, B | 1 |
Intoppa, S | 2 |
Milani, ML | 2 |
Mattiello, V | 2 |
Neri, A | 4 |
Vallisa, D | 1 |
Grigg, AP | 1 |
Walker, P | 1 |
Korkmaz, M | 1 |
Karakurt Eryilmaz, M | 1 |
Karaağaç, M | 1 |
Araz, M | 1 |
Çeneli, Ö | 1 |
Artaç, M | 1 |
Perutelli, F | 2 |
Montalbano, MC | 2 |
Boccellato, E | 2 |
Pozzi, S | 1 |
Potenza, L | 6 |
Giusti, D | 1 |
Colaci, E | 1 |
Pioli, V | 1 |
Leonardi, G | 1 |
Maccaferri, M | 4 |
Luppi, M | 6 |
Marasca, R | 9 |
Chanan-Khan, AA | 11 |
Ailawadhi, S | 3 |
Sher, T | 2 |
Liu, Y | 2 |
Song, Y | 1 |
Yin, Q | 2 |
Dong, R | 1 |
Yan, Y | 1 |
Zeng, X | 1 |
Lin, N | 1 |
Tan, B | 1 |
Sundaram, M | 4 |
Trudeau, J | 1 |
Barrientos, JC | 18 |
Takács, F | 1 |
Kotmayer, L | 2 |
Czeti, Á | 1 |
Szalóki, G | 1 |
László, T | 1 |
Mikala, G | 1 |
Márk, Á | 1 |
Masszi, A | 1 |
Farkas, P | 3 |
Plander, M | 1 |
Weisinger, J | 1 |
Demeter, J | 2 |
Fekete, S | 1 |
Szerafin, L | 1 |
Deák, BM | 1 |
Szaleczky, E | 1 |
Sulák, A | 1 |
Borbényi, Z | 1 |
Barna, G | 2 |
Aqil, B | 1 |
Kaur, A | 1 |
Ramos, J | 1 |
Sukhanova, M | 2 |
Ma, S | 4 |
Gao, J | 3 |
Chen, YH | 1 |
Chen, Q | 2 |
Llull-Ramos, A | 1 |
Gracia-Darder, I | 1 |
Hernando, JDP | 1 |
Izquierdo-Herce, N | 1 |
Killock, D | 1 |
Choi, JH | 1 |
Hur, JY | 1 |
Won, YW | 1 |
Koba, Y | 1 |
Kawata, T | 1 |
Tamekane, A | 1 |
Watanabe, M | 1 |
Bomben, R | 9 |
Rossi, FM | 8 |
Vit, F | 1 |
Bittolo, T | 2 |
Zucchetto, A | 10 |
Papotti, R | 1 |
Tissino, E | 4 |
Pozzo, F | 3 |
Degan, M | 1 |
Polesel, J | 2 |
Bulian, P | 2 |
Olivieri, J | 3 |
Laureana, R | 1 |
Del Principe, MI | 2 |
Morabito, F | 6 |
Fronza, G | 4 |
Tafuri, A | 1 |
Zaja, F | 3 |
Gattei, V | 11 |
Esfandiari, N | 1 |
Bombardier, N | 1 |
Pierson, JC | 1 |
Chung, C | 2 |
Umoru, G | 1 |
Abboud, K | 1 |
Hobaugh, E | 1 |
Thompson, PA | 13 |
Keating, MJ | 30 |
Peterson, CB | 1 |
Garg, N | 7 |
Wang, SA | 2 |
Jorgensen, JL | 2 |
Kadia, TM | 1 |
Bose, P | 7 |
Pemmaraju, N | 4 |
Short, NJ | 2 |
DerSarkissian, M | 1 |
Ryan, K | 1 |
Duh, MS | 1 |
Wahlstrom, SK | 1 |
Hakre, S | 1 |
Yu, L | 4 |
Guo, H | 1 |
Chen, SS | 5 |
Chiorazzi, N | 5 |
Yang, S | 1 |
Li, N | 1 |
Zhu, R | 1 |
Feng, Y | 1 |
Zhuo, J | 1 |
Gale, RP | 1 |
Booth, E | 1 |
Backx, M | 1 |
Joshi, A | 1 |
Nizami, H | 1 |
Elmusharaf, N | 1 |
Nierengarten, MB | 1 |
Ambinder, AJ | 1 |
Hambley, B | 1 |
Shanbhag, S | 1 |
Merrill, SA | 1 |
Stirrups, R | 1 |
Simpson, D | 4 |
Stevens, D | 1 |
Lin, J | 2 |
Webb, T | 1 |
Fedorov, V | 1 |
Styles, L | 8 |
Zhou, Y | 1 |
Lu, H | 1 |
Yang, M | 1 |
Xu, C | 1 |
Romero, D | 3 |
Gandhi, V | 15 |
Wierda, W | 9 |
Fraser, G | 6 |
Brown, JR | 39 |
Dilhuydy, MS | 14 |
Jaeger, U | 10 |
Mahler, M | 6 |
Salman, M | 8 |
Eckert, K | 2 |
Solman, IG | 3 |
Cheng, M | 6 |
Londhe, A | 2 |
Howes, A | 10 |
Arruga, F | 2 |
Bracciamà, V | 1 |
Vitale, N | 2 |
Vaisitti, T | 2 |
Gizzi, K | 1 |
Yeomans, A | 2 |
D'Arena, G | 3 |
Furman, RR | 30 |
Packham, G | 3 |
Deaglio, S | 3 |
Carriles, C | 1 |
Ordóñez-Fernández, L | 1 |
Arias-Martínez, A | 1 |
Menárguez-Blanc, R | 1 |
Rosado-María, MC | 1 |
Wright, N | 1 |
Voshtina, E | 1 |
George, G | 1 |
Singavi, A | 1 |
Field, J | 1 |
Ye, CJ | 1 |
Xu, WB | 1 |
Yu, Q | 1 |
Wu, C | 2 |
Huang, L | 1 |
Li, JM | 1 |
Hofland, T | 2 |
de Weerdt, I | 4 |
Ter Burg, H | 1 |
de Boer, R | 1 |
Tannheimer, S | 1 |
Tonino, SH | 3 |
Munir, T | 6 |
Reddy, NM | 6 |
Ruchlemer, R | 2 |
Ben-Ami, R | 1 |
Bar-Meir, M | 1 |
Soussain, C | 1 |
Barzic, N | 1 |
Messina, JA | 1 |
Jain, P | 7 |
Cohen, R | 1 |
Hill, B | 3 |
Nijland, M | 1 |
Herishanu, Y | 7 |
Benjamini, O | 3 |
Tadmor, T | 2 |
Okamoto, K | 1 |
Arthurs, B | 1 |
Gottesman, B | 1 |
Talha, M | 1 |
Korem, M | 1 |
Bogot, N | 1 |
De Boer, F | 1 |
Rowe, JM | 1 |
Lachish, T | 1 |
Mascarella, MA | 1 |
Schweitzer, L | 1 |
Alreefi, M | 1 |
Silver, J | 1 |
Caglar, D | 1 |
Loo, VG | 1 |
Richardson, K | 1 |
Dufresne, P | 1 |
Lee, TC | 1 |
Sadeghi, N | 1 |
Williams, AM | 2 |
Baran, AM | 2 |
Schaffer, M | 2 |
Bushart, J | 1 |
Rich, L | 1 |
Moore, J | 1 |
Zent, CS | 6 |
Merli, M | 1 |
Passamonti, F | 1 |
Devereux, S | 9 |
Lal, I | 1 |
Thermos, G | 1 |
Tosios, KI | 1 |
Zi, F | 1 |
Shi, Q | 1 |
Tang, A | 1 |
Cheng, J | 1 |
Prezzo, A | 1 |
Cavaliere, FM | 1 |
Bilotta, C | 1 |
Pentimalli, TM | 1 |
Iacobini, M | 1 |
Cesini, L | 1 |
Quinti, I | 1 |
Emond, B | 2 |
Romdhani, H | 1 |
Lefebvre, P | 2 |
Wang, S | 4 |
Nakamura, M | 1 |
Yoshioka, S | 1 |
Yamashita, D | 1 |
Hara, S | 1 |
Ishikawa, T | 1 |
Fujinami, H | 1 |
Kusumoto, S | 1 |
Masaki, A | 1 |
Ohshima, Y | 1 |
Tachita, T | 1 |
Sasaki, H | 1 |
Marumo, Y | 1 |
Yoshida, T | 1 |
Narita, T | 1 |
Ito, A | 1 |
Ri, M | 1 |
Komatsu, H | 1 |
Inagaki, H | 1 |
Iida, S | 1 |
Maffei, R | 5 |
Arletti, L | 1 |
Fiorcari, S | 5 |
Benatti, S | 1 |
Michallet, M | 2 |
Sobh, M | 2 |
Koster, L | 1 |
Hoek, J | 1 |
Boumendil, A | 2 |
Scheid, C | 3 |
Fox, CP | 4 |
Wulf, G | 3 |
Krüger, W | 1 |
van Gelder, M | 4 |
Corradini, P | 1 |
Russo, D | 2 |
Passweg, J | 2 |
Schoemans, H | 2 |
Bethge, W | 2 |
Schaap, N | 1 |
Cornelissen, J | 2 |
Browne, P | 1 |
Durakovic, N | 2 |
Montoto, S | 2 |
Kroger, N | 2 |
Schetelig, J | 3 |
Uminski, K | 1 |
Brown, K | 1 |
Bucher, O | 1 |
Hibbert, I | 1 |
Dhaliwal, DH | 1 |
Johnston, JB | 3 |
Geirnaert, M | 1 |
Dawe, DE | 1 |
Banerji, V | 3 |
Petitdemange, A | 1 |
Martin, A | 1 |
Ruch, Y | 1 |
Chatron, E | 1 |
Karol, A | 1 |
Hansmann, Y | 1 |
Liu, Z | 2 |
Liu, J | 1 |
Zhang, T | 1 |
Chen, X | 2 |
Yu, J | 2 |
Tam, C | 10 |
Peri, AM | 2 |
Rossio, R | 1 |
Tafuri, F | 1 |
Benzecry, V | 1 |
Grancini, A | 1 |
Bandera, A | 2 |
Peyvandi, F | 1 |
Salles, G | 5 |
Bachy, E | 1 |
Smolej, L | 3 |
Baseggio, L | 3 |
Panovska, A | 2 |
Besson, H | 1 |
Healy, N | 2 |
Garside, J | 1 |
Iraqi, W | 2 |
Diels, J | 7 |
Pick-Lauer, C | 1 |
Spacek, M | 3 |
Urbanova, R | 2 |
Lysak, D | 1 |
Hermans, R | 1 |
Lundbom, J | 1 |
Callet-Bauchu, E | 2 |
Doubek, M | 7 |
Fakhri, B | 1 |
Andreadis, C | 1 |
Witzig, TE | 3 |
Fonder, AL | 4 |
Sarraf Yazdy, M | 1 |
Rhodes, J | 3 |
Goodfriend, J | 1 |
Narkhede, M | 1 |
Carver, J | 2 |
Gutierrez, C | 1 |
Printz, C | 1 |
Mhibik, M | 2 |
Shibayama, H | 1 |
Teshima, T | 1 |
Choi, I | 1 |
Hatake, K | 1 |
Sekiguchi, N | 1 |
Yoshinari, N | 1 |
Strati, P | 1 |
Schlette, EJ | 1 |
Solis Soto, LM | 1 |
Duenas, DE | 1 |
Estrov, Z | 17 |
Wistuba, II | 1 |
Baumann, T | 3 |
Montserrat, E | 7 |
Quijada-Álamo, M | 1 |
Hernández-Sánchez, M | 1 |
Alonso-Pérez, V | 1 |
Rodríguez-Vicente, AE | 1 |
García-Tuñón, I | 1 |
Martín-Izquierdo, M | 1 |
Hernández-Sánchez, JM | 1 |
Herrero, AB | 1 |
Bastida, JM | 1 |
San Segundo, L | 1 |
Gruber, M | 2 |
García, JL | 1 |
Yin, S | 2 |
Ten Hacken, E | 4 |
Benito, R | 1 |
Ordóñez, JL | 1 |
Hernández-Rivas, JM | 1 |
Gordon, MJ | 2 |
Sitlinger, A | 2 |
Salous, T | 1 |
Alqahtani, H | 2 |
Churnetski, M | 2 |
Rivera, X | 2 |
Wisniewski, P | 1 |
Cohen, J | 1 |
Patel, K | 5 |
Shadman, M | 5 |
Choi, M | 3 |
Stephens, D | 1 |
Persky, D | 2 |
Brander, D | 1 |
Danilov, AV | 8 |
Koehler, A | 1 |
van der Straten, L | 1 |
Visser, O | 1 |
Blijlevens, NMA | 1 |
Cornelissen, JJ | 1 |
Doorduijn, JK | 2 |
Dinmohamed, AG | 1 |
Rendeiro, AF | 2 |
Krausgruber, T | 2 |
Fortelny, N | 1 |
Zhao, F | 1 |
Penz, T | 1 |
Farlik, M | 1 |
Schuster, LC | 1 |
Nemc, A | 1 |
Tasnády, S | 2 |
Réti, M | 2 |
Mátrai, Z | 5 |
Alpár, D | 4 |
Schmidl, C | 2 |
Bock, C | 2 |
Benedetti, D | 2 |
Caldana, C | 1 |
Nanni, P | 1 |
Chivilò, H | 1 |
Cattarossi, I | 1 |
Zaina, E | 1 |
Norris, K | 1 |
Tripepi, G | 5 |
Santinelli, E | 2 |
Pozzato, G | 3 |
Rossi, D | 9 |
Pepper, C | 4 |
Hartmann, TN | 3 |
Cömert, P | 1 |
Albayrak, M | 1 |
Yıldız, A | 1 |
Şahin, O | 1 |
Öztürk, HB | 1 |
Reis Aras, M | 1 |
Brener, ZZ | 1 |
Brener, H | 1 |
Losev, A | 1 |
Boudny, M | 1 |
Trbusek, M | 2 |
Gauthier, J | 1 |
Hirayama, AV | 1 |
Purushe, J | 1 |
Hay, KA | 2 |
Lymp, J | 1 |
Li, DH | 2 |
Yeung, CCS | 1 |
Sheih, A | 1 |
Pender, BS | 1 |
Hawkins, RM | 1 |
Vakil, A | 1 |
Phi, TD | 1 |
Steinmetz, RN | 1 |
Riddell, SR | 1 |
Maloney, DG | 1 |
Turtle, CJ | 2 |
Le, TH | 1 |
Kumar, V | 1 |
Gondal, K | 1 |
Barnes, M | 1 |
Siddique, H | 1 |
Buttar, B | 1 |
Kaell, A | 1 |
Tresckow, JV | 1 |
Bahlo, J | 5 |
Pflug, N | 2 |
Heinz, WJ | 1 |
Hensel, M | 1 |
Sasse, S | 1 |
Huang, SJ | 1 |
Gerrie, AS | 1 |
Young, S | 1 |
Tucker, T | 1 |
Bruyere, H | 1 |
Hrynchak, M | 1 |
Galbraith, P | 1 |
Al Tourah, AJ | 1 |
Dueck, G | 1 |
Noble, MC | 1 |
Ramadan, KM | 1 |
Tsang, P | 1 |
Hardy, E | 1 |
Sehn, L | 1 |
Toze, CL | 2 |
Hanna, BS | 1 |
Yazdanparast, H | 1 |
Demerdash, Y | 1 |
Roessner, PM | 1 |
Schulz, R | 1 |
Lichter, P | 3 |
Seiffert, M | 1 |
Achenbach, SJ | 1 |
McCullough, KB | 2 |
Nedved, AN | 1 |
Smith, MD | 2 |
Finnes, HD | 3 |
Sica, A | 1 |
Sagnelli, C | 1 |
Papa, A | 1 |
Ciccozzi, M | 1 |
Sagnelli, E | 1 |
Calogero, A | 1 |
Martinelli, E | 1 |
Casale, B | 1 |
LoRe, VA | 1 |
Chong, EA | 2 |
Gerson, JN | 1 |
Barta, SK | 1 |
Landsburg, DJ | 2 |
Nasta, SD | 3 |
Svoboda, J | 8 |
Loren, AW | 1 |
Schuster, SJ | 13 |
Lamanna, N | 9 |
Qiu, L | 2 |
Salmi, T | 1 |
Hilger, J | 1 |
Wu, K | 1 |
Cohen, A | 1 |
Huang, J | 2 |
Blum, K | 2 |
Sharman, JP | 8 |
Zhao, W | 10 |
Heerema, NA | 14 |
Luan, Y | 2 |
Liu, EA | 1 |
Ozbagcivan, O | 1 |
Akarsu, S | 1 |
Nazli, EC | 1 |
Lebe, B | 1 |
Fetil, E | 1 |
Lucas, F | 1 |
Larkin, K | 2 |
Gregory, CT | 1 |
Orwick, S | 1 |
Doong, TJ | 3 |
Lozanski, A | 7 |
Lozanski, G | 13 |
Ngankeu, A | 1 |
Ozer, HG | 4 |
Sampath, D | 3 |
Thangavadivel, S | 2 |
Yilmaz, SA | 1 |
Blachly, JS | 5 |
Lin, VS | 1 |
Lew, TE | 2 |
Handunnetti, SM | 1 |
Blombery, P | 2 |
Nguyen, T | 1 |
Westerman, DA | 1 |
Roberts, AW | 1 |
Seymour, JF | 7 |
Anderson, MA | 1 |
İskender, G | 1 |
İskender, D | 1 |
Ertek, M | 1 |
Suzumiya, J | 1 |
Takizawa, J | 1 |
Recchia, AG | 1 |
Condoluci, A | 4 |
Loseto, G | 4 |
Consoli, U | 4 |
Scortechini, I | 5 |
Fraticelli, V | 1 |
Vigna, E | 4 |
Botta, C | 2 |
Arrigo, G | 1 |
Rago, A | 4 |
Angeletti, I | 4 |
Gallais, F | 2 |
Despas, F | 2 |
De Barros, S | 2 |
Dupré, L | 1 |
Quillet-Mary, A | 2 |
Protin, C | 4 |
Thomas, F | 1 |
Obéric, L | 3 |
Allal, B | 2 |
Chatelut, E | 2 |
White-Koning, M | 2 |
Davids, MS | 11 |
Melenhorst, JJ | 2 |
Lewis, T | 1 |
Corcoran, DB | 1 |
Thurston, DE | 1 |
Giles, PJ | 1 |
Ashelford, K | 1 |
Walsby, EJ | 2 |
Fegan, CD | 1 |
Pepper, AGS | 1 |
Miraz Rahman, K | 1 |
Kabadi, SM | 1 |
Near, A | 1 |
Wada, K | 1 |
Burudpakdee, C | 1 |
Allain, EP | 1 |
Rouleau, M | 1 |
Vanura, K | 1 |
Tremblay, S | 1 |
Vaillancourt, J | 1 |
Bat, V | 1 |
Caron, P | 1 |
Villeneuve, L | 1 |
Labriet, A | 1 |
Turcotte, V | 1 |
Le, T | 1 |
Shehata, M | 3 |
Schnabl, S | 2 |
Demirtas, D | 2 |
Hubmann, R | 2 |
Joly-Beauparlant, C | 1 |
Droit, A | 1 |
Jäger, U | 4 |
Staber, PB | 3 |
Lévesque, E | 1 |
Guillemette, C | 1 |
Thibaud, S | 1 |
Tremblay, D | 1 |
Bhalla, S | 1 |
Zimmerman, B | 1 |
Sigel, K | 1 |
Gabrilove, J | 2 |
Anastasopoulou, A | 1 |
DiPippo, AJ | 2 |
Kontoyiannis, DP | 2 |
Archibald, WJ | 1 |
Kabat, BF | 1 |
Herrmann, J | 1 |
Gianfelici, V | 1 |
Hardy-Abeloos, C | 1 |
Pinotti, R | 1 |
Dmitrieva, EA | 1 |
Nikitin, EA | 1 |
Ignatova, AA | 1 |
Vorobyev, VI | 1 |
Poletaev, AV | 1 |
Seregina, EA | 1 |
Voronin, KA | 1 |
Polokhov, DM | 1 |
Maschan, AA | 1 |
Novichkova, GA | 1 |
Panteleev, MA | 1 |
Ptushkin, VV | 1 |
Patel, KK | 1 |
Isufi, I | 2 |
Kothari, S | 1 |
Davidoff, AJ | 1 |
Gross, CP | 1 |
Huntington, SF | 1 |
Frei, M | 1 |
Aitken, SL | 1 |
Zhang, H | 3 |
Zhang, XH | 1 |
Li, BZ | 1 |
Lentini, M | 3 |
Zappalà, D | 1 |
Hochman, MJ | 1 |
Martin, DB | 1 |
Hu, EY | 1 |
Saygin, C | 1 |
Workman, SE | 1 |
Chiang, CL | 1 |
Coombes, KR | 1 |
Jones, D | 4 |
Muthusamy, N | 4 |
Allouchery, M | 1 |
Tomowiak, C | 3 |
Guidez, S | 1 |
Delwail, V | 1 |
Delaunay, P | 1 |
Lafay-Chebassier, C | 1 |
Salvo, F | 1 |
Pérault-Pochat, MC | 1 |
Baumann, TS | 1 |
Quinquenel, A | 5 |
Bijou, F | 1 |
Ferrant, E | 2 |
Michallet, AS | 9 |
De Silva, N | 1 |
Simon, F | 1 |
Hohloch, K | 2 |
Droogendijk, J | 1 |
van der Klift, M | 1 |
van der Spek, E | 2 |
Schöttker, B | 1 |
Gregor, M | 1 |
Haselager, MV | 1 |
Kielbassa, K | 1 |
Ter Burg, J | 1 |
Bax, DJC | 1 |
Fernandes, SM | 3 |
Borst, J | 1 |
Sibaud, V | 2 |
Beylot-Barry, M | 2 |
Vigarios, E | 2 |
Recher, C | 1 |
Lee, J | 2 |
Wang, YL | 8 |
Pula, B | 1 |
Iskierka-Jazdzewska, E | 7 |
Dlugosz-Danecka, M | 2 |
Szymczyk, A | 6 |
Hus, M | 7 |
Szeremet, A | 3 |
Drozd-Sokolowska, J | 1 |
Waszczuk-Gajda, A | 3 |
Zaucha, JM | 4 |
Holojda, J | 1 |
Piszczek, W | 4 |
Steckiewicz, P | 5 |
Wojciechowska, M | 4 |
Osowiecki, M | 3 |
Knopinska-Posluszny, W | 2 |
Dudzinski, M | 2 |
Zawirska, D | 2 |
Subocz, E | 3 |
Halka, J | 1 |
Pluta, A | 1 |
Wichary, R | 1 |
Kumiega, B | 2 |
Budziszewska, BK | 3 |
Jurczak, W | 5 |
Lech-Maranda, E | 3 |
Giannopoulos, K | 2 |
Jamroziak, K | 7 |
Chatzikonstantinou, T | 1 |
Quaresmini, G | 1 |
Garcia-Marco, JA | 3 |
Mirás, F | 1 |
Baile, M | 1 |
Marquet, J | 1 |
Gimeno, E | 1 |
Iyengar, S | 2 |
Ferrari, A | 1 |
Itchaki, G | 1 |
Lista, E | 2 |
Vandenberghe, E | 2 |
Wasik-Szczepanek, E | 1 |
Bron, D | 1 |
De Paolis, MR | 1 |
Farina, L | 3 |
Foglietta, M | 1 |
Herold, T | 1 |
Jaksic, O | 2 |
Malerba, L | 1 |
Orsucci, L | 2 |
Popov, VM | 1 |
Yassin, M | 1 |
Pocali, B | 1 |
Dos Santos, G | 1 |
Nikitin, E | 1 |
Andres, M | 1 |
Dimou, M | 2 |
Enrico, A | 1 |
Hakobyan, Y | 1 |
Kalashnikova, O | 1 |
Ortiz Pareja, M | 1 |
Papaioannou, M | 1 |
Shah, N | 1 |
Shrestha, A | 1 |
Stanca, O | 1 |
Stavroyianni, N | 3 |
Zdrenghea, M | 1 |
Stamatopoulos, K | 4 |
Rossi, G | 1 |
Rambaldi, A | 3 |
Puła, B | 4 |
Długosz-Danecka, M | 2 |
Salomon-Perzyński, A | 1 |
Rybka, J | 3 |
Gil, L | 2 |
Szukalski, Ł | 1 |
Sehn, LH | 1 |
Kuruvilla, P | 1 |
Christofides, A | 2 |
Stakiw, J | 1 |
Lama, TG | 1 |
Kyung, D | 1 |
Marcaillou, M | 1 |
Stéphanie, D | 1 |
Marion, B | 1 |
Julien, S | 1 |
Christophe, B | 1 |
Barnea Slonim, L | 1 |
Behdad, A | 1 |
Fan, F | 1 |
Yoo, HJ | 1 |
Stock, S | 1 |
Schubert, ML | 1 |
Neuber, B | 1 |
Hückelhoven-Krauss, A | 1 |
Gern, U | 1 |
Schmitt, A | 1 |
Müller-Tidow, C | 1 |
Schmitt, M | 1 |
Sellner, L | 1 |
Reynolds, G | 1 |
Slavin, M | 1 |
Teh, BW | 2 |
Chanas-Larue, A | 1 |
Villalpando-Rodriguez, GE | 1 |
Henson, ES | 1 |
Gibson, SB | 2 |
Tian, X | 8 |
de Fabritiis, P | 1 |
Bruno, A | 1 |
Cantonetti, M | 1 |
Aarup, K | 1 |
Rotbain, EC | 1 |
Pedersen, RS | 1 |
Bergmann, OJ | 1 |
Thomsen, RH | 1 |
Frederiksen, M | 1 |
Nielsen, T | 1 |
Christiansen, I | 1 |
Andersen, MA | 1 |
Fraser, GAM | 2 |
Chanan-Khan, A | 8 |
Santucci Silva, R | 1 |
Mayer, J | 8 |
Bartlett, NL | 6 |
Avigdor, A | 4 |
Rule, S | 6 |
Samoilova, O | 5 |
Pavlovsky, MA | 3 |
Goy, A | 9 |
Tamegnon, M | 1 |
Sun, S | 6 |
Connor, A | 1 |
Nottage, K | 1 |
Schuier, N | 1 |
Brochard, J | 1 |
Morio, F | 1 |
Mahe, J | 1 |
Le Pape, P | 2 |
Guimard, T | 1 |
Mahe, B | 3 |
Leterrier, M | 1 |
Morrier, M | 1 |
Raffi, F | 1 |
Boutoille, D | 1 |
Abruzzo, LV | 4 |
Andersen, BL | 2 |
Dean, A | 1 |
Lucas, M | 3 |
Banks, C | 1 |
Grantier, C | 1 |
Maddocks, KJ | 8 |
Valentine, TR | 1 |
Weiss, DM | 2 |
Jones, JA | 16 |
Pleyer, C | 2 |
Rampertaap, S | 1 |
Mu, R | 1 |
Soto, S | 8 |
Superata, J | 1 |
Gaglione, E | 1 |
Lotter, J | 1 |
Stetler-Stevenson, M | 5 |
Yuan, CM | 2 |
Maric, I | 6 |
Pittaluga, S | 4 |
Rosenzweig, S | 1 |
Fleisher, T | 1 |
Liu, W | 1 |
Xu, J | 2 |
Tang, Z | 1 |
Toruner, G | 1 |
Khanlari, M | 2 |
Medeiros, LJ | 2 |
Tang, G | 1 |
Cordoba, R | 3 |
Kong, YL | 1 |
Pan, BH | 1 |
Liang, JH | 1 |
Zhu, HY | 1 |
Wu, JZ | 1 |
Sheng, Z | 1 |
Song, S | 2 |
Yu, M | 1 |
Gao, A | 1 |
Gao, W | 1 |
Ran, X | 1 |
Huo, D | 1 |
Svanberg, R | 1 |
Ostrowski, SR | 1 |
Mattson, M | 1 |
Borra, S | 1 |
Shrestha, S | 1 |
Janjan, N | 1 |
Blum, LK | 2 |
Hoh, HY | 1 |
Lal, ID | 1 |
Mongan, A | 2 |
Lebas, D | 1 |
Preta, LH | 1 |
Leguern, A | 1 |
Modiano, P | 1 |
Wiart, T | 1 |
de Jong, J | 5 |
Mitselos, A | 1 |
Panizo, C | 1 |
Wrobel, T | 3 |
Jiao, J | 2 |
Sukbuntherng, J | 6 |
Ouellet, D | 1 |
Hellemans, P | 2 |
Cherng, HJ | 1 |
McPhail, ED | 1 |
Miranda, RN | 1 |
Lin, P | 1 |
Tawbi, HA | 1 |
Brander, DM | 9 |
Hill, BT | 6 |
Winter, A | 3 |
Lansigan, F | 4 |
Skarbnik, AP | 5 |
Pu, JJ | 5 |
Sehgal, AR | 3 |
Shah, NN | 2 |
Ujjani, CS | 5 |
Orlandi, EM | 2 |
Billio, A | 2 |
Ilariucci, F | 2 |
de la Serna, J | 2 |
Medina Perez, A | 1 |
Cimino, G | 1 |
Cavallari, M | 2 |
Cucci, R | 1 |
Vallerini, D | 1 |
Barozzi, P | 1 |
Marvyin, K | 1 |
Tjønnfjord, EB | 1 |
Breland, UM | 1 |
Tjønnfjord, GE | 3 |
Syrykh, C | 1 |
Péricart, S | 1 |
Evrard, SM | 1 |
Meggetto, F | 1 |
Kanoun, S | 1 |
Brousset, P | 1 |
Laurent, C | 1 |
Pulido-Pérez, A | 1 |
Bergón-Sendín, M | 1 |
Mateos-Mayo, A | 1 |
Parra-Blanco, V | 1 |
Suárez-Fernández, R | 1 |
Carretero-López, F | 1 |
Baldini, L | 1 |
Lafeuille, MH | 1 |
Gupta, D | 1 |
Kirar, S | 1 |
Gogia, A | 1 |
Gupta, R | 1 |
Mallick, S | 1 |
Soddu, S | 1 |
Thi Tuyet Tran, H | 1 |
Mousavi-Fatemi, K | 1 |
Mousavi, SA | 1 |
Khosravi, S | 1 |
Maleki, N | 1 |
Xia, M | 1 |
Luo, TY | 1 |
Harari, D | 1 |
Xiao, L | 2 |
Vaca, A | 1 |
DiSogra, KY | 1 |
Tran, T | 1 |
Arnall, JR | 1 |
Janes, A | 1 |
Moore, DC | 1 |
Park, SI | 1 |
Sora, F | 3 |
Chiusolo, P | 1 |
Giammarco, S | 1 |
Metafuni, E | 1 |
Bacigalupo, A | 1 |
Sica, S | 2 |
Kidoguchi, K | 1 |
Kubato, Y | 1 |
Nishimura, Y | 1 |
Kizuka-Sano, H | 1 |
Kimura, S | 1 |
Letestu, R | 2 |
Le Garff-Tavernier, M | 2 |
Aanei, C | 2 |
Ticchioni, M | 2 |
Subtil, F | 3 |
Rouille, V | 2 |
Laribi, K | 3 |
Villemagne, B | 2 |
Tournilhac, O | 7 |
Delmer, A | 6 |
Portois, C | 2 |
Pegourie, B | 2 |
Leblond, V | 6 |
De Guibert, S | 5 |
Orsini Piocelle, F | 1 |
Banos, A | 2 |
Carassou, P | 2 |
Cartron, G | 2 |
Fornecker, LM | 3 |
Dartigeas, C | 6 |
Truchan-Graczyk, M | 2 |
Vilque, JP | 3 |
Aurran, T | 3 |
Cymbalista, F | 12 |
Lepretre, S | 5 |
Levy, V | 5 |
Nguyen-Khac, F | 2 |
Feugier, P | 5 |
Messori, A | 1 |
Bartoli, L | 1 |
Sharma, S | 3 |
Pavlasova, GM | 1 |
Seda, V | 3 |
Cerna, KA | 1 |
Vojackova, E | 2 |
Filip, D | 1 |
Sandova, V | 1 |
Kostalova, L | 2 |
Zeni, PF | 1 |
Borsky, M | 3 |
Oppelt, J | 2 |
Liskova, K | 2 |
Kren, L | 2 |
Janikova, A | 1 |
Pospisilova, S | 5 |
Pacoureau, L | 1 |
De Menthon, M | 1 |
Boytchev, I | 1 |
Lazure, T | 1 |
Rocher, L | 1 |
Lambotte, O | 1 |
Noël, N | 1 |
Machnicki, MM | 1 |
Górniak, P | 1 |
Pępek, M | 1 |
Bluszcz, A | 1 |
Rydzanicz, M | 1 |
Płoski, R | 1 |
Makuch-Łasica, H | 1 |
Nowak, G | 1 |
Juszczyński, P | 1 |
Stokłosa, T | 1 |
Khountham, S | 1 |
Shindiapina, P | 1 |
Mo, X | 3 |
Lachowiez, C | 1 |
Wiczer, T | 1 |
Mousa, L | 1 |
Andritsos, LA | 10 |
Spurgeon, SE | 4 |
Gíslason, GK | 1 |
Þorsteinsdóttir, S | 1 |
Rögnvaldsson, S | 1 |
Gottfreðsson, M | 1 |
Aspelund, T | 1 |
Turesson, I | 1 |
Cavallini, C | 1 |
Galasso, M | 1 |
Pozza, ED | 1 |
Chignola, R | 1 |
Lovato, O | 1 |
Dando, I | 1 |
Romanelli, MG | 1 |
Krampera, M | 1 |
Pizzolo, G | 1 |
Donadelli, M | 1 |
Scupoli, MT | 1 |
Persky, DO | 1 |
Joseph, RE | 1 |
Amatya, N | 1 |
Fulton, DB | 1 |
Engen, JR | 1 |
Wales, TE | 1 |
Andreotti, A | 1 |
Ghosh, N | 2 |
Rai, KR | 1 |
Reeves, JA | 1 |
Cheson, BD | 9 |
Kambhampati, S | 2 |
Fonseca, GA | 1 |
Hamadeh, IS | 1 |
LaRatta, N | 1 |
Weissbrot, H | 1 |
Luning Prak, ET | 1 |
Tsao, P | 1 |
Weiss, MS | 4 |
Santoro, RC | 1 |
Falbo, M | 1 |
Iannaccaro, P | 1 |
Prejanò, S | 1 |
Nabergoj, S | 1 |
Markovič, T | 1 |
Avsec, D | 1 |
Gobec, M | 1 |
Podgornik, H | 1 |
Jakopin, Ž | 1 |
Mlinarič-Raščan, I | 1 |
Maharaj, D | 1 |
Srinivasan, G | 1 |
Abreu, MM | 1 |
Ko, MW | 1 |
Jewett, A | 1 |
Gouvea, J | 1 |
Bossio, S | 2 |
Al-Janazreh, H | 2 |
Mendicino, F | 2 |
D'Arrigo, G | 2 |
Galimberti, S | 3 |
Monti, P | 2 |
Menichini, P | 2 |
Cutrona, G | 3 |
Ferrarini, M | 3 |
Sieburth, RM | 1 |
Weaver, CD | 1 |
Kirzhner, M | 1 |
Shildkrot, Y | 1 |
Martín-Moro, F | 1 |
García-Cosío, M | 1 |
Marquet-Palomanes, J | 1 |
López-Gutiérrez, M | 1 |
Pian-Arias, H | 1 |
López-Jiménez, FJ | 1 |
Chandrashekar, N | 1 |
McKenney, R | 1 |
Saling, C | 1 |
Feller, F | 1 |
Vikram, HR | 1 |
Mehraban Far, P | 1 |
Rullo, J | 1 |
Farmer, J | 1 |
Urton, T | 1 |
Sato, N | 1 |
Yuda, J | 1 |
Yamauchi, N | 1 |
Kuzume, A | 1 |
Nakamura, H | 1 |
Chi, S | 1 |
Nagata, A | 1 |
Kaku, E | 1 |
Nishizawa, A | 1 |
Minami, Y | 1 |
Irwin, D | 1 |
Wilson, K | 1 |
Thompson, S | 1 |
Choudhry, A | 1 |
Caracciolo, D | 1 |
Durairaj, S | 1 |
Phumphukhieo, P | 1 |
Holding, S | 1 |
Allsup, D | 2 |
Lu, P | 7 |
Franzen, CA | 1 |
Venkataraman, G | 2 |
McClure, R | 1 |
Li, L | 3 |
Wu, W | 1 |
Niu, N | 1 |
Pei, J | 1 |
Baldwin, DA | 1 |
Nejati, R | 1 |
Wasik, MA | 1 |
Khan, N | 2 |
Tu, Y | 1 |
Larson, RA | 3 |
Chen, TL | 2 |
Harrington, B | 1 |
Truxall, J | 1 |
Wasmuth, R | 2 |
Prouty, A | 1 |
Sloan, S | 1 |
Lehman, AM | 4 |
Orlemans, E | 1 |
Baiocchi, RA | 1 |
Alinari, L | 1 |
Hertlein, E | 4 |
Burke, JM | 2 |
Schreeder, MT | 3 |
Lunin, SD | 1 |
Zweibach, A | 1 |
Shtivelband, M | 1 |
Travis, PM | 1 |
Chandler, JC | 1 |
Kolibaba, KS | 3 |
Salvetti, C | 1 |
Griggio, V | 1 |
Porrazzo, M | 1 |
Schiattone, L | 2 |
Vassallo, F | 1 |
Rivela, P | 1 |
Boccadoro, M | 1 |
Atene, CG | 2 |
Martinelli, S | 3 |
Ljungström, V | 1 |
Zucchini, P | 2 |
Forghieri, F | 1 |
Trenti, T | 1 |
Tagliafico, E | 1 |
Quinson, AM | 1 |
Maier, D | 1 |
Smith, D | 1 |
Debbia, G | 1 |
Chen, R | 1 |
Tsai, J | 1 |
Xiong, P | 1 |
Liu, C | 3 |
Burrows, F | 1 |
Plunkett, W | 5 |
Coleman, M | 8 |
Izumi, R | 6 |
Frigault, MM | 2 |
Quah, C | 1 |
Raman, RK | 1 |
Patel, P | 3 |
Wang, MH | 2 |
Beckmann, L | 1 |
Berg, V | 1 |
Dickhut, C | 1 |
Merkel, O | 1 |
Seifert, M | 1 |
da Palma Guerreiro, A | 1 |
Claasen, J | 1 |
Loroch, S | 1 |
Oliverio, M | 1 |
Underbayev, C | 3 |
Vaughn, L | 1 |
Thomalla, D | 1 |
Hülsemann, MF | 1 |
Sickmann, A | 1 |
Zahedi, RP | 1 |
Frenzel, LP | 1 |
Creuzet, E | 1 |
Nourrisson, C | 1 |
Chaleteix, C | 1 |
Poirier, P | 1 |
Moniot, M | 1 |
Loja, T | 1 |
Mladonicka Pavlasova, G | 1 |
Zicha, D | 1 |
Kudlickova Peskova, M | 1 |
Krivanek, J | 1 |
Benes, V | 1 |
Musilova Litzmanova, K | 1 |
Verner, J | 2 |
Brychtova, Y | 1 |
Tan, Z | 1 |
Zhang, S | 1 |
Amruz Cerna, K | 1 |
Phadke, NA | 1 |
Luk, SO | 1 |
Hochberg, EP | 1 |
Banerji, A | 1 |
Miller, CR | 1 |
Labanowska, J | 1 |
Grever, M | 1 |
Hertlein, EK | 1 |
Sakata, M | 1 |
Saburi, M | 1 |
Kawano, K | 1 |
Takata, H | 1 |
Miyazaki, Y | 1 |
Uchida, H | 1 |
Kawano, Y | 1 |
Ohtsuka, E | 1 |
Wiedemann, GM | 1 |
Schneider, J | 1 |
Verbeek, M | 1 |
Konukiewitz, B | 1 |
Spinner, CD | 1 |
Einwächter, H | 1 |
Schmid, RM | 1 |
Rothe, K | 1 |
Baptista, MJ | 2 |
Baskar, S | 1 |
Gaglione, EM | 2 |
Keyvanfar, K | 3 |
D Arrigo, G | 1 |
Koshiishi, M | 1 |
Odate, T | 1 |
Nakagawa, Y | 1 |
Suzuki, J | 1 |
Kumagai, T | 1 |
Kawashima, I | 1 |
Yamamoto, T | 1 |
Nakajima, K | 1 |
Tanaka, M | 1 |
Oishi, N | 1 |
Kondo, T | 1 |
Kirito, K | 1 |
Timofeeva, N | 1 |
Burger, J | 6 |
Takahashi, K | 3 |
Borthakur, G | 3 |
Kadia, T | 4 |
Sasaki, K | 3 |
Konopleva, M | 3 |
Jabbour, E | 3 |
Wang, X | 6 |
Kanagal-Shamanna, R | 5 |
Jorgensen, J | 4 |
Lopez, W | 1 |
Ayala, A | 3 |
Wang, Z | 1 |
Cheung, LWK | 1 |
Nguyen, AN | 1 |
Wimalachandra, M | 1 |
Basu, TN | 1 |
Salisbury, J | 1 |
Attard, N | 1 |
Calonje, E | 1 |
Patten, PEM | 3 |
Ronconi, G | 1 |
Dondi, L | 1 |
Calabria, S | 1 |
Piccinni, C | 1 |
Pedrini, A | 1 |
Esposito, I | 1 |
Martini, N | 1 |
Eik, D | 1 |
Kendall, EK | 1 |
Blackburn, A | 1 |
Qi, J | 1 |
Rader, C | 1 |
Giza, A | 1 |
Pelzer, BW | 1 |
Belliere, J | 1 |
Casemayou, A | 1 |
Colliou, E | 1 |
El Hachem, H | 1 |
Kounde, C | 1 |
Piedrafita, A | 1 |
Feuillet, G | 1 |
Schanstra, JP | 1 |
Faguer, S | 1 |
Krečak, I | 1 |
Čengić, M | 1 |
Skorić, I | 1 |
Nakić, M | 1 |
Gverić-Krečak, V | 1 |
Fowler, N | 2 |
Alvarado, Y | 2 |
Yilmaz, M | 3 |
DiNardo, C | 2 |
Ohanian, M | 3 |
Wei, C | 2 |
Cruz, N | 2 |
Ishdorj, G | 1 |
Nugent, Z | 1 |
Squires, M | 1 |
Kost, S | 1 |
Davidson, L | 1 |
Katyal, CS | 1 |
Marshall, A | 1 |
Shulman, K | 1 |
Kazarin, O | 1 |
Tannous, E | 1 |
Sofer, O | 1 |
Montresor, A | 1 |
Toffali, L | 1 |
Fumagalli, L | 1 |
Constantin, G | 1 |
Vinante, F | 1 |
Laudanna, C | 1 |
Lasica, M | 1 |
Tanigawa, T | 1 |
Sakurai, M | 1 |
Kato, J | 1 |
Mizuno, K | 1 |
Fujita, S | 1 |
Koda, Y | 1 |
Kikuchi, T | 1 |
Shimizu, T | 1 |
Okamoto, S | 1 |
Kataoka, K | 1 |
Sekiguchi, Y | 1 |
Iizuka, H | 1 |
Takizawa, H | 1 |
Mitsumori, T | 1 |
Tomita, S | 1 |
Izumi, H | 1 |
Okubo, M | 1 |
Miyake, K | 1 |
Osawa, T | 1 |
Sawada, T | 1 |
Yoshikawa, S | 1 |
Noguchi, M | 1 |
Booth, AM | 3 |
Nattam, S | 2 |
Kuzma, CS | 1 |
Abramson, JS | 2 |
Smith, SE | 2 |
Mandrekar, SJ | 4 |
Miao, Y | 1 |
Palma, M | 4 |
Mulder, TA | 1 |
Favini, C | 1 |
Ferri, V | 1 |
Forestieri, G | 1 |
Terzi Di Bergamo, L | 1 |
Schipani, M | 1 |
Sagiraju, S | 1 |
Andorno, A | 1 |
Rasi, S | 2 |
Adhinaveni, R | 1 |
Talotta, D | 1 |
Al Essa, W | 1 |
Margiotta Casaluci, G | 1 |
Patriarca, A | 1 |
Boldorini, RL | 1 |
Mateu-Albero, T | 1 |
Juárez-Sánchez, R | 1 |
Mol, W | 1 |
Terrón, F | 1 |
Muñoz-Calleja, C | 1 |
Cuesta-Mateos, C | 1 |
Smith, MR | 2 |
Cronin, JF | 1 |
Weiss, RF | 1 |
Yenerel, MN | 1 |
Kay, N | 1 |
Pinilla-Ibarz, J | 5 |
Rothbaum, W | 1 |
Hamdy, A | 6 |
Higgins, K | 1 |
Sohoni, S | 1 |
Miller, C | 1 |
Goldstein, D | 1 |
Beckwith, K | 2 |
Bond, DA | 2 |
Cheng, L | 1 |
Huang, M | 1 |
Wei, J | 1 |
Xu, H | 1 |
Zhou, M | 1 |
Jiang, L | 2 |
Gángó, A | 3 |
Kiss, R | 3 |
Hanna, E | 1 |
Deák, B | 1 |
Lévai, D | 1 |
Matolcsy, A | 3 |
Timár, B | 1 |
Cheung, MC | 1 |
Mittmann, N | 1 |
Abdel-Samad, N | 1 |
Lam, S | 1 |
Crump, M | 1 |
Sperlich, C | 1 |
van der Jagt, R | 1 |
Couban, S | 1 |
McDonald, G | 1 |
Shepherd, LE | 1 |
Yen, H | 1 |
Chen, BE | 1 |
Hay, AE | 1 |
Coppola, PE | 1 |
Broccoli, A | 1 |
Argnani, L | 1 |
Casadei, B | 1 |
Stefoni, V | 1 |
Bertuzzi, C | 1 |
Sabattini, E | 1 |
Zinzani, PL | 2 |
Cho, HJ | 1 |
Baek, DW | 1 |
Kim, J | 1 |
Lee, JM | 1 |
Moon, JH | 1 |
Sohn, SK | 1 |
Woyach, J | 5 |
Amaya-Chanaga, CI | 1 |
Holowka, T | 1 |
Cheung, H | 1 |
Malinis, M | 1 |
Gan, G | 1 |
Deng, Y | 1 |
Perreault, S | 1 |
Azar, MM | 1 |
Hassan, H | 1 |
Ammad Ud Din, M | 1 |
Jamshed, S | 1 |
Bress, J | 1 |
Mustafa, SS | 1 |
Solano de la Asunción, C | 1 |
Saus, A | 1 |
Olea, B | 1 |
Giménez, E | 1 |
Albert, E | 1 |
López-Jiménez, J | 1 |
Andreu, R | 1 |
García, D | 1 |
Fox, L | 1 |
Remigia, MJ | 1 |
Amat, P | 1 |
Solano, C | 1 |
Navarro, D | 1 |
Tschumper, RC | 1 |
Lesnick, CE | 1 |
Stone, R | 1 |
Litzow, MR | 1 |
Tallman, MS | 1 |
Aslan, B | 1 |
Kismali, G | 1 |
Chen, LS | 3 |
Iles, LR | 1 |
Mahendra, M | 1 |
Peoples, M | 1 |
Gagea, M | 1 |
Fowlkes, NW | 1 |
Zheng, X | 1 |
Wang, J | 3 |
Vellano, CP | 1 |
Marszalek, JR | 2 |
Bertilaccio, MTS | 1 |
Te Raa, D | 1 |
Visser, HPJ | 1 |
Hansenne, A | 1 |
Camboni, A | 1 |
Van Den Neste, E | 3 |
Bailly, S | 1 |
Tombak, A | 1 |
Pepedil Tanrıkulu, F | 1 |
Durusoy, SS | 1 |
Dinçyürek, HD | 1 |
Kaya, E | 1 |
Ümit, EG | 1 |
Yavaşoğlu, İ | 1 |
Mehtap, Ö | 1 |
Deveci, B | 1 |
Özcan, MA | 1 |
Terzi, H | 1 |
Okay, M | 1 |
Sayınalp, N | 1 |
Okan, V | 1 |
Kızıklı, A | 1 |
Özcan, Ö | 1 |
Çetin, G | 1 |
Demircioğlu, S | 1 |
Aydoğdu, İ | 1 |
Saydam, G | 1 |
İlhan, G | 1 |
Uçar, MA | 1 |
Özet, G | 1 |
Berber, İ | 1 |
Kurtoğlu, E | 1 |
Sönmez, M | 1 |
Batur, DS | 1 |
Yıldırım, R | 1 |
Özkocamaz, V | 1 |
Güneş, AK | 1 |
Sahip, B | 1 |
Ertop, Ş | 1 |
Akay, OM | 1 |
Baştürk, A | 1 |
Akdeniz, A | 1 |
Ünal, A | 1 |
Seyhanlı, A | 1 |
Gürkan, E | 1 |
Çekdemir, D | 1 |
Ferhanoğlu, B | 2 |
Hutchinson, L | 1 |
Kaur, V | 2 |
Swami, A | 1 |
Waldron, M | 1 |
Caruthers, S | 1 |
Tu, H | 1 |
Coleman, J | 2 |
Johnson, AJ | 24 |
Suzuki, S | 2 |
Cole, G | 2 |
Shustik, C | 1 |
Bence-Bruckler, I | 2 |
Delage, R | 1 |
Owen, CJ | 1 |
Andrasiak, I | 1 |
Podhorecka, M | 1 |
Goracy, A | 1 |
Kowal, M | 1 |
Ibanez, B | 1 |
Jankowska-Lecka, O | 1 |
Macheta, A | 1 |
Nowaczynska, A | 1 |
Drab-Urbanek, E | 1 |
Chocholska, S | 1 |
Jawniak, D | 1 |
Guinn, D | 6 |
Lehman, A | 6 |
Abruzzo, L | 2 |
Gordon, A | 4 |
Mantel, R | 6 |
Smith, LL | 6 |
McWhorter, S | 1 |
Davis, M | 2 |
Ny, F | 1 |
Chase, W | 1 |
Flynn, JM | 7 |
Blum, KA | 11 |
Martini, V | 4 |
Gattazzo, C | 2 |
Frezzato, F | 5 |
Trimarco, V | 3 |
Severin, F | 3 |
Scomazzon, E | 3 |
Guzzardo, V | 1 |
Saraggi, D | 1 |
Raggi, F | 2 |
Martinello, L | 1 |
Facco, M | 4 |
Brunati, AM | 1 |
Semenzato, G | 5 |
LaPlant, BR | 1 |
Le-Rademacher, J | 1 |
Feldman, AL | 1 |
Habermann, TM | 1 |
Wiseman, GA | 1 |
Lin, Y | 1 |
Asmus, E | 1 |
Nowakowski, GS | 2 |
Conte, MJ | 1 |
Bowen, DA | 2 |
Aitken, CN | 1 |
Greipp, PT | 1 |
Liu, X | 1 |
Wu, X | 3 |
Wellik, LE | 1 |
Micallef, I | 1 |
Viswanatha, DS | 1 |
Dong, H | 1 |
Ansell, SM | 1 |
Aurran-Schleinitz, T | 3 |
Dupuis, J | 6 |
Sinet, P | 1 |
Albrecht, C | 1 |
Howlett, C | 4 |
Kiselev, P | 3 |
Foon, K | 1 |
Lenhart, J | 1 |
Henick Bachow, S | 1 |
Winter, AM | 1 |
Cruz, AL | 1 |
Claxton, DF | 2 |
Daniel, C | 2 |
Isaac, K | 2 |
Kennard, KH | 2 |
Timlin, C | 3 |
Fanning, M | 1 |
Gashonia, L | 2 |
Yacur, M | 1 |
Nabhan, C | 8 |
Aw, A | 3 |
Agathanggelou, A | 2 |
Smith, E | 2 |
Davies, NJ | 1 |
Kwok, M | 2 |
Zlatanou, A | 1 |
Oldreive, CE | 1 |
Mao, J | 1 |
Da Costa, D | 1 |
Yadollahi, S | 1 |
Perry, T | 1 |
Kearns, P | 1 |
Skowronska, A | 1 |
Yates, E | 1 |
Parry, H | 2 |
Reverdy, C | 1 |
Delansorne, R | 1 |
Paneesha, S | 2 |
Pratt, G | 3 |
Moss, P | 2 |
Taylor, AMR | 1 |
Stewart, GS | 1 |
Stankovic, T | 2 |
Hellman, JM | 2 |
Birner, A | 1 |
Mazzucchelli, M | 2 |
Murthy, V | 1 |
Weaving, S | 1 |
Rafei, H | 1 |
Kharfan-Dabaja, MA | 3 |
Sachanas, S | 2 |
Pangalis, GA | 2 |
Moschogiannis, M | 2 |
Yiakoumis, X | 2 |
Koulieris, E | 2 |
Tsirkinidis, P | 1 |
Kalpadakis, C | 2 |
Rontogianni, D | 2 |
Baron, M | 2 |
Zini, JM | 1 |
Challan Belval, T | 1 |
Vignon, M | 2 |
Denis, B | 1 |
Alanio, A | 1 |
Glavey, S | 1 |
Quinn, J | 1 |
McCloy, M | 1 |
Sargent, J | 1 |
McCartney, Y | 1 |
Catherwood, M | 1 |
Marafioti, T | 1 |
Leader, M | 1 |
Murphy, P | 1 |
Thornton, P | 4 |
Van Sanden, S | 2 |
Baculea, S | 3 |
Cote, S | 3 |
Caligaris-Cappio, F | 2 |
DeVos, S | 1 |
Chung, D | 1 |
Gau, L | 1 |
Chang, B | 2 |
Edelmann, J | 1 |
Cosialls, AM | 1 |
Pomares, H | 1 |
Iglesias-Serret, D | 1 |
Saura-Esteller, J | 1 |
Núñez-Vázquez, S | 1 |
González-Gironès, DM | 1 |
de la Banda, E | 1 |
Preciado, S | 1 |
Albericio, F | 1 |
Lavilla, R | 1 |
Pons, G | 1 |
González-Barca, EM | 1 |
Gil, J | 1 |
Tran, PN | 1 |
Thorp, BC | 1 |
Badoux, X | 1 |
Douglas, AP | 1 |
Trubiano, JA | 1 |
Barr, I | 1 |
Leung, V | 1 |
Slavin, MA | 2 |
Winqvist, M | 3 |
Heimersson, K | 1 |
Mellstedt, H | 1 |
Lundin, J | 4 |
Fischer, A | 1 |
Bastian, S | 1 |
Cogliatti, S | 1 |
Mey, U | 1 |
Saub, J | 1 |
Schanz, U | 1 |
Padberg, B | 1 |
Meacham, PJ | 1 |
Feldman, MM | 1 |
Valencia, HE | 1 |
Newsom-Stewart, C | 1 |
Gupta, N | 1 |
Janelsins, MC | 1 |
Albi, E | 1 |
Baldoni, S | 1 |
Aureli, P | 1 |
Dorillo, E | 1 |
Del Papa, B | 1 |
Ascani, S | 1 |
Di Ianni, M | 1 |
Falzetti, F | 1 |
Skopelja-Gardner, S | 1 |
Jones, JD | 1 |
Hamilton, BJ | 1 |
Rigby, WFC | 1 |
Titus-Rains, KS | 1 |
Brown, JN | 1 |
Hammond, JM | 1 |
Long, M | 4 |
Do, P | 2 |
Mundy, BL | 1 |
Cheney, C | 2 |
Awan, F | 2 |
Fraietta, JA | 2 |
June, CH | 2 |
Maus, MV | 2 |
Caligiuri, MA | 1 |
Krämer, I | 1 |
Dietrich, S | 2 |
Zeis, M | 1 |
Stadler, M | 1 |
Bittenbring, J | 1 |
Uharek, L | 1 |
Hegenbart, U | 1 |
Ho, A | 1 |
Schmitz, N | 1 |
Singh, M | 1 |
Mealing, S | 1 |
Whelan, J | 1 |
England, JT | 1 |
Leitch, HA | 1 |
Dutton, D | 1 |
Roach, H | 1 |
Lowry, L | 1 |
Andrick, B | 1 |
Alwhaibi, A | 1 |
DeRemer, DL | 1 |
Quershi, S | 1 |
Khan, R | 1 |
Bryan, LJ | 1 |
Somanath, PR | 1 |
Pantin, J | 1 |
Skrabs, C | 4 |
Pickl, WF | 1 |
Perkmann, T | 1 |
Gessl, A | 1 |
Ali, N | 2 |
Malik, F | 1 |
Jafri, SIM | 1 |
Naglak, M | 1 |
Sundermeyer, M | 1 |
Pickens, PV | 2 |
Buchanan, J | 1 |
Wordsworth, S | 1 |
Clifford, R | 1 |
Robbe, P | 1 |
Taylor, JC | 1 |
Schuh, A | 7 |
Knight, SJL | 1 |
Asklid, A | 3 |
Eketorp-Sylvan, S | 1 |
Repits, J | 1 |
Søltoft, F | 1 |
Koopmans, SM | 1 |
Collett, L | 1 |
Howard, DR | 1 |
McParland, L | 1 |
Oughton, JB | 1 |
Rawstron, AC | 2 |
Hockaday, A | 1 |
Dimbleby, C | 1 |
Phillips, D | 1 |
McMahon, K | 1 |
Hulme, C | 1 |
Bloor, A | 3 |
Saluzzo, S | 1 |
Layer, F | 1 |
Stingl, G | 1 |
Stary, G | 1 |
Gaudino, F | 1 |
Ouk, S | 1 |
Moscvin, M | 1 |
Serra, S | 1 |
Zakrzewski, JL | 1 |
Liou, HC | 1 |
Tang, CPS | 1 |
McMullen, J | 1 |
Wolf, C | 1 |
Garding, A | 1 |
Filarsky, K | 1 |
Becker, N | 1 |
Zucknick, M | 1 |
Rouhi, A | 1 |
Weigel, A | 1 |
Claus, R | 1 |
Weichenhan, D | 1 |
Kuchenbauer, F | 1 |
Plass, C | 1 |
Mertens, D | 3 |
Stewart, J | 1 |
Bayers, S | 1 |
Vandergriff, T | 1 |
Kondo, K | 1 |
Shaim, H | 1 |
Harris, D | 1 |
Daher, M | 1 |
Basar, R | 1 |
Muftuoglu, M | 1 |
Imahashi, N | 1 |
Alsuliman, A | 1 |
Sobieski, C | 1 |
Gokdemir, E | 1 |
Liu, E | 2 |
Shpall, EJ | 1 |
Rezvani, K | 1 |
Saba, NS | 3 |
Wong, DH | 3 |
Tanios, G | 1 |
Iyer, JR | 2 |
Lobelle-Rich, P | 1 |
Dadashian, EL | 2 |
Liu, D | 6 |
Fontan, L | 1 |
Flemington, EK | 1 |
Nichols, CM | 1 |
Safah, H | 1 |
Melnick, A | 1 |
Herman, SEM | 6 |
Sato, R | 1 |
Jacob, J | 1 |
Gaballa, S | 1 |
Patel, VK | 1 |
Lamothe, B | 3 |
Ayres, ML | 1 |
Gay, J | 1 |
Cheung, JP | 1 |
Balakrishnan, K | 4 |
Ivan, C | 1 |
Morse, J | 1 |
Nelson, M | 1 |
Ayed, AO | 1 |
Godet, S | 2 |
Bastie, JN | 1 |
Herbaux, C | 2 |
Ghez, D | 5 |
Brion, A | 1 |
Shen, Y | 1 |
Best, OG | 1 |
Christopherson, RI | 1 |
Jiang, F | 1 |
Verma, P | 1 |
Xu, Y | 2 |
Fahrbach, K | 1 |
Dorman, E | 2 |
Sanden, SV | 1 |
Coulter, EM | 1 |
Pepper, A | 1 |
Mele, S | 1 |
Folarin, N | 1 |
Townsend, W | 1 |
Cuthill, K | 1 |
Phillips, EH | 1 |
Alberelli, MA | 1 |
De Candia, E | 1 |
Knopinska-Posłuszny, W | 2 |
Hołojda, J | 3 |
Hałaburda, K | 1 |
Warzocha, K | 4 |
Zhou, L | 1 |
Chyla, B | 1 |
Salem, AH | 1 |
Verdugo, M | 1 |
Humerickhouse, RA | 1 |
Potluri, J | 1 |
Robier, C | 1 |
Beham-Schmid, C | 1 |
Neubauer, M | 1 |
Landau, DA | 2 |
Rosebrock, D | 1 |
Fein, J | 1 |
Hoellenriegel, J | 3 |
Ravichandran, S | 1 |
Farooqui, MZH | 1 |
Cibulskis, C | 1 |
Zviran, A | 1 |
Livitz, D | 1 |
Bozic, I | 2 |
Leshchiner, I | 2 |
Getz, G | 3 |
Clasen, S | 1 |
Pickens, P | 1 |
Hughes, M | 1 |
Schuster, S | 1 |
Santucci-Silva, R | 1 |
Traina, S | 1 |
Chan, EKH | 1 |
Sengupta, N | 2 |
Chaffee, KG | 5 |
Dal Bo, M | 2 |
Bayer, E | 1 |
Härzschel, A | 1 |
Gutjahr, JC | 1 |
Ayed, A | 1 |
Chigaev, A | 2 |
Sklar, LA | 1 |
Janovska, P | 1 |
Kohoutek, J | 1 |
Bryjova, L | 1 |
Gregorova, M | 1 |
Dzimkova, M | 1 |
Skabrahova, H | 1 |
Radaszkiewicz, T | 1 |
Ovesna, P | 1 |
Vondalova Blanarova, O | 1 |
Nemcova, T | 1 |
Hoferova, Z | 1 |
Vasickova, K | 1 |
Smyckova, L | 1 |
Egle, A | 2 |
Pavlova, S | 1 |
Poppova, L | 1 |
Plevova, K | 1 |
Bryja, V | 1 |
Bosch, F | 3 |
Geisler, CH | 4 |
Patrussi, L | 1 |
Capitani, N | 1 |
Cattaneo, F | 1 |
Manganaro, N | 1 |
Gamberucci, A | 1 |
Pelicci, PG | 1 |
D'Elios, MM | 1 |
Baldari, CT | 1 |
Stankowicz, M | 1 |
Banaszynski, M | 1 |
Crawford, R | 1 |
Lampson, BL | 3 |
Christoforidou, A | 1 |
Kapsas, G | 1 |
Bezirgiannidou, Z | 1 |
Papamichos, S | 1 |
Kotsianidis, Ι | 1 |
Sinha, R | 1 |
Redekop, WK | 1 |
Gaye, E | 1 |
Le Bot, A | 1 |
Talarmin, JP | 1 |
Le Calloch, R | 2 |
Belaz, S | 1 |
Dupont, M | 2 |
Tattevin, P | 1 |
Skarbnik, A | 3 |
Zent, C | 1 |
Pu, J | 1 |
Claxton, D | 1 |
Landsburg, D | 1 |
Bachow, SH | 2 |
Barr, P | 1 |
Aschan, J | 1 |
Wildgust, M | 2 |
Bisi, L | 1 |
Cappelletti, A | 1 |
Colella, E | 1 |
Verga, L | 1 |
Foresti, S | 1 |
Migliorino, GM | 1 |
Gori, A | 1 |
Calleja, A | 1 |
Ledoux, MP | 1 |
Damaj, G | 1 |
Dreyfus, B | 1 |
Paul, F | 1 |
Souchet, L | 1 |
Delavigne, K | 1 |
Sharman, J | 3 |
Jones, J | 9 |
Chu, AD | 5 |
Rozovski, U | 2 |
Harris, DM | 1 |
Li, P | 1 |
Mirabelli, R | 2 |
El Halabi, L | 1 |
Cherif-Rebai, K | 1 |
Michot, JM | 1 |
Porpaczy, E | 3 |
Schwarzinger, I | 1 |
Augustin, D | 1 |
Thalhammer, R | 2 |
Boddy, CS | 1 |
Varughese, T | 1 |
Taur, Y | 1 |
Cohen, N | 1 |
Seo, SK | 1 |
Hohl, TM | 1 |
Redelman-Sidi, G | 1 |
Ito, Y | 1 |
Makita, S | 1 |
Maeshima, AM | 1 |
Hatta, S | 1 |
Suzuki, T | 3 |
Yuda, S | 1 |
Fukuhara, S | 1 |
Munakata, W | 1 |
Maruyama, D | 1 |
Izutsu, K | 1 |
Jin, J | 1 |
Hou, M | 1 |
Hu, J | 1 |
Hu, Y | 1 |
Ke, X | 1 |
Liang, Y | 1 |
Liu, T | 2 |
Lv, Y | 1 |
Ren, H | 1 |
Sun, A | 1 |
Zhao, C | 1 |
Wu, P | 1 |
Samp, JC | 1 |
Gauthier, G | 1 |
Terasawa, E | 1 |
Ujjani, C | 2 |
Trivedi, N | 1 |
Ramzi, P | 1 |
Maddy, LE | 1 |
O'Brien, DP | 1 |
Campbell, PJ | 1 |
Follows, G | 2 |
Perez, AM | 1 |
Musuraca, G | 1 |
Delgado, AR | 1 |
Galieni, P | 1 |
Visco, C | 1 |
Amendola, A | 1 |
Meneghini, V | 1 |
Re, F | 1 |
Gonzalez, M | 2 |
Cortelezzi, A | 3 |
Eyre, TA | 1 |
Kennedy, B | 1 |
Bowles, KM | 1 |
Kopacz, A | 1 |
Czyż, J | 1 |
Dasanu, CA | 1 |
Bosman, P | 1 |
Nagler, A | 2 |
Niederwieser, D | 2 |
Andersen, NS | 1 |
Finke, J | 1 |
Labussiere-Wallet, H | 1 |
Berg, T | 1 |
Bunjes, D | 1 |
Canepari, ME | 1 |
Schaap, M | 1 |
Goyal, NG | 1 |
Westbrook, TD | 1 |
Tomcsányi, J | 1 |
Nényei, Z | 1 |
Bózsik, B | 1 |
Ball, S | 1 |
Vutthikraivit, W | 1 |
Maiti, A | 1 |
Kittai, A | 2 |
Amrock, SM | 1 |
James, S | 1 |
Hoff, S | 1 |
Manda, S | 2 |
Cohen, JB | 2 |
Wanner, D | 1 |
Bohn, JP | 1 |
Rudzki, J | 1 |
Stockhammer, G | 1 |
Steurer, M | 1 |
Buhimschi, AD | 1 |
Armstrong, HA | 1 |
Toure, M | 1 |
Jaime-Figueroa, S | 1 |
Crews, CM | 1 |
Clow, F | 13 |
Fattizzo, B | 1 |
Tonella, T | 1 |
Massari, F | 1 |
Imbergamo, S | 1 |
Bonaldi, L | 1 |
Vio, S | 1 |
Gregianin, M | 1 |
Burei, M | 1 |
Harada, K | 1 |
Brooks, JP | 1 |
Lobo, FM | 1 |
Miyakoshi, S | 1 |
Nanba, A | 1 |
Uchiyama, T | 1 |
Kawamoto, K | 1 |
Aoki, S | 2 |
Reiff, SD | 1 |
Muhowski, EM | 2 |
Fabian, CA | 1 |
Smith, L | 1 |
Young, WB | 2 |
Johnson, AR | 2 |
Liu, L | 1 |
Aldana, G | 1 |
Jimenez, CA | 1 |
Moran, C | 1 |
Hsiehchen, D | 1 |
Arasaratnam, R | 1 |
Raj, K | 1 |
Froehlich, T | 1 |
Anderson, L | 1 |
Shaikh, H | 2 |
Khattab, A | 2 |
Faisal, MS | 2 |
Chilkulwar, A | 1 |
Albrethsen, M | 2 |
Sadashiv, S | 1 |
Fazal, S | 2 |
Hess, G | 1 |
Chang, S | 6 |
Vermeulen, J | 1 |
Graef, T | 4 |
Barnes, JI | 1 |
Divi, V | 1 |
Begaye, A | 1 |
Wong, R | 1 |
Owens, DK | 1 |
Goldhaber-Fiebert, JD | 1 |
Hoffman, C | 1 |
Moran, ME | 1 |
Reid, MA | 1 |
Whitlow, WT | 1 |
Larson, MC | 1 |
Kabat, B | 1 |
Bowen, D | 2 |
Boysen, J | 1 |
Krstic, A | 2 |
Peña Perez, L | 1 |
Berglöf, A | 2 |
Meinke, S | 2 |
Wang, Q | 2 |
Blomberg, KEM | 1 |
Kamali-Moghaddam, M | 1 |
Shen, Q | 1 |
Jaremko, G | 1 |
De Paepe, A | 1 |
Höglund, P | 1 |
Kimby, E | 4 |
Månsson, R | 2 |
Quach, H | 2 |
Maslyak, Z | 2 |
Stevens, DA | 3 |
Gill, DS | 1 |
Handunnetti, S | 2 |
Bhavsar, E | 1 |
Beach, DF | 1 |
Tuncer, HH | 1 |
Manukyan, G | 1 |
Turcsanyi, P | 1 |
Mikulkova, Z | 1 |
Gabcova, G | 1 |
Gajdos, P | 1 |
Smotkova Kraiczova, V | 1 |
Zehnalova, S | 1 |
Papajik, T | 1 |
Kriegova, E | 1 |
Konoplev, S | 2 |
Zuo, Z | 1 |
Venema, R | 1 |
Norris, P | 1 |
Lazarus, A | 1 |
Saenz-de-Viteri, M | 1 |
Cudrnak, T | 1 |
Lameris, R | 1 |
Endstra, S | 1 |
Jongejan, A | 1 |
Moerland, PD | 1 |
de Bruin, RCG | 1 |
Remmerswaal, EBM | 1 |
Ten Berge, IJM | 1 |
Liu, N | 2 |
van der Stelt, M | 1 |
Faber, LM | 1 |
de Gruijl, TD | 1 |
van der Vliet, HJ | 1 |
Cruz, ND | 1 |
Jiang, Y | 1 |
Wu, Q | 1 |
Feng, S | 1 |
Kroll, MH | 1 |
Qiao, W | 1 |
Nagy, N | 2 |
Eyupoglu, E | 2 |
Aczél, D | 2 |
Csomor, J | 1 |
Silva, RS | 2 |
Pristupa, A | 2 |
Pylypenko, H | 2 |
Villa, D | 2 |
Panagiotidis, P | 2 |
Karlsson, C | 4 |
Phelps, C | 2 |
Messina, M | 1 |
Marinelli, M | 1 |
Bonina, S | 1 |
Johnson, PW | 1 |
Steele, AJ | 2 |
Delgado Ramos, GM | 1 |
Almaddah, N | 1 |
Alsafwah, S | 1 |
Jegou, MH | 1 |
Maharaj, K | 1 |
Powers, JJ | 1 |
Achille, A | 1 |
Deng, S | 1 |
Fonseca, R | 1 |
Pabon-Saldana, M | 1 |
Quayle, SN | 1 |
Jones, SS | 1 |
Villagra, A | 1 |
Sotomayor, EM | 1 |
Sahakian, E | 1 |
Kolomeyer, AM | 1 |
Hwang, CK | 1 |
Kim, BJ | 1 |
Namn, Y | 1 |
Crawford, C | 1 |
McAuley, EM | 2 |
Shaffer, AL | 1 |
Young, RM | 2 |
Kruhlak, MJ | 1 |
Staudt, LM | 2 |
Hurria, A | 1 |
Major-Elechi, B | 1 |
Fruth, B | 1 |
Kuzma, C | 1 |
Patel, KP | 1 |
Routbort, M | 1 |
Bueso-Ramos, C | 1 |
Alhalouli, T | 1 |
Khoury, JD | 1 |
Luthra, R | 1 |
Kantarjian, HM | 2 |
Andersson, PO | 2 |
Karlsson, K | 2 |
Lauri, B | 2 |
Norin, S | 2 |
Sandstedt, A | 2 |
Rosenquist, R | 3 |
Späth, F | 1 |
Hermansen, JU | 1 |
Munthe, LA | 1 |
Taskén, K | 1 |
Skånland, SS | 1 |
Ben-Yehuda, D | 2 |
Lih, CJ | 1 |
Nogueras-Gonzalez, GM | 2 |
Andreeff, M | 1 |
Mathew, T | 1 |
Kim, HT | 1 |
Nicotra, A | 1 |
Savell, A | 1 |
Francoeur, K | 1 |
Bazemore, J | 1 |
Stampleman, L | 1 |
Maegawa, R | 1 |
Rueter, J | 1 |
Boruchov, AM | 1 |
Arnason, JE | 1 |
Jacobson, CA | 1 |
Jacobsen, ED | 2 |
Fisher, DC | 1 |
Estenfelder, S | 1 |
Fang, H | 2 |
Reichard, KK | 1 |
Smoley, SA | 1 |
Boudin, L | 1 |
Patient, M | 1 |
Tsitsi Nding Tsogou, P | 1 |
Roméo, E | 1 |
Bladé, JS | 1 |
de Jauréguiberry, JP | 1 |
Akhtar, OS | 1 |
Attwood, K | 1 |
Lund, I | 1 |
Hare, R | 1 |
Hernandez-Ilizaliturri, FJ | 1 |
Torka, P | 1 |
Gounari, M | 1 |
Ntoufa, S | 2 |
Gerousi, M | 1 |
Vilia, MG | 1 |
Moysiadis, T | 1 |
Kotta, K | 2 |
Papakonstantinou, N | 2 |
Agathangelidis, A | 1 |
Fonte, E | 1 |
Ranghetti, P | 1 |
Nenou, A | 1 |
Xochelli, A | 1 |
Muzio, M | 1 |
Tobinai, K | 1 |
Uchida, T | 1 |
Fukuhara, N | 1 |
Nishikawa, T | 1 |
Ho, AKH | 1 |
Koh, XQ | 1 |
Liau, MMQ | 1 |
Tan, KB | 1 |
Tan, CL | 1 |
Chui, W | 1 |
Worth, LJ | 1 |
Thursky, KA | 1 |
Younes, A | 1 |
Brody, J | 1 |
Carpio, C | 1 |
Lopez-Guillermo, A | 2 |
Ozcan, M | 1 |
Avivi, I | 1 |
Caballero Barrigón, MD | 1 |
Hellmann, A | 2 |
Ma, DDF | 1 |
Yağci, M | 1 |
Horowitz, NA | 1 |
Buglio, D | 1 |
Streit, M | 1 |
Hodkinson, BP | 1 |
Alvarez, J | 1 |
Ceulemans, R | 1 |
Wang, SS | 1 |
Fourneau, N | 1 |
Grossi, O | 1 |
Pineau, S | 1 |
Sadot-Lebouvier, S | 1 |
Hay, B | 1 |
Delaunay, J | 1 |
Miailhe, AF | 1 |
Bretonnière, C | 1 |
Jeddi, F | 1 |
Lavergne, RA | 1 |
Vladimer, GI | 1 |
Taubert, C | 1 |
Krall, N | 1 |
Pemovska, T | 1 |
Araghi, M | 1 |
Snijder, B | 1 |
Ringler, A | 1 |
Runggatscher, K | 1 |
de la Fuente, OL | 1 |
Hilgarth, M | 1 |
Hoermann, G | 2 |
Kubicek, S | 1 |
Superti-Furga, G | 1 |
McCaw, L | 2 |
Wang, C | 1 |
Bjarnason, G | 1 |
Pouvaret, A | 1 |
Guery, R | 1 |
Montillet, M | 1 |
Molina, TJ | 1 |
Duréault, A | 1 |
Bougnoux, ME | 1 |
Galliot, R | 1 |
Lanternier, F | 1 |
Delarue, R | 2 |
Lortholary, O | 1 |
Nastoupil, LJ | 1 |
Lunning, MA | 1 |
Vose, JM | 1 |
Flowers, CR | 1 |
Purdom, MA | 1 |
Fowler, NH | 2 |
Gambe, RG | 1 |
Sun, J | 2 |
Martinez, AZ | 1 |
Cartun, ZJ | 1 |
Regis, FFD | 1 |
Wan, Y | 3 |
Brooks, AN | 1 |
Taylor-Weiner, A | 2 |
Ghia, EM | 1 |
Obeng, EA | 1 |
Cibulskis, CL | 1 |
Neuberg, D | 2 |
Campagna, DR | 1 |
Fleming, MD | 1 |
Ebert, BL | 1 |
DeCaprio, JA | 1 |
Reed, R | 1 |
Carrasco, RD | 1 |
Corbingi, A | 2 |
Pasquale, R | 1 |
McWilliams, EM | 1 |
Lucas, CR | 1 |
Chen, T | 1 |
Harrington, BK | 2 |
Campbell, A | 2 |
Cheney, CM | 1 |
Carson, WE | 2 |
Butchar, J | 1 |
Tridandapani, S | 2 |
Castro, CE | 1 |
Lin, T | 1 |
Caldeira, D | 1 |
Alves, D | 1 |
Costa, J | 1 |
Ferreira, JJ | 1 |
Pinto, FJ | 1 |
Morande, PE | 1 |
Uriepero, A | 1 |
Seija, N | 1 |
Berca, C | 1 |
Fresia, P | 1 |
Landoni, AI | 1 |
Di Noia, JM | 1 |
Oppezzo, P | 1 |
Giovanni, B | 1 |
Ibatici, A | 2 |
Sola, S | 1 |
Brunasso, AMG | 1 |
Massone, C | 1 |
Vezan, R | 1 |
Naydenov, AV | 1 |
Taylor, LP | 1 |
Shah, A | 1 |
Goel, K | 1 |
Uchin, J | 1 |
Patibandla, SK | 1 |
Min, Z | 1 |
Bhanot, N | 1 |
Basumallik, N | 1 |
Geyer, MB | 1 |
Rivière, I | 1 |
Sénéchal, B | 1 |
Purdon, TJ | 1 |
Hsu, M | 1 |
Devlin, SM | 1 |
Halton, E | 1 |
Bernal, Y | 1 |
van Leeuwen, DG | 1 |
Sadelain, M | 1 |
Brentjens, RJ | 1 |
Manna, A | 1 |
Aulakh, S | 1 |
Jani, P | 1 |
Ahmed, S | 1 |
Akhtar, S | 1 |
Coignet, M | 1 |
Heckman, M | 1 |
Meghji, Z | 1 |
Bhatia, K | 1 |
Sharma, A | 2 |
Alegria, V | 1 |
Malavasi, F | 1 |
Chini, EN | 1 |
Paulus, A | 2 |
Man, S | 1 |
Henley, P | 1 |
Ohanyan, H | 1 |
Collignon, A | 1 |
Gilardin, L | 1 |
Dmytruk, N | 1 |
Durot, E | 2 |
Roos Weil, D | 1 |
Béné, MC | 1 |
Toussaint, E | 1 |
Merabet, F | 1 |
Evans, R | 1 |
Harasser, M | 1 |
El-Kholy, M | 1 |
Paredes-Moscosso, SR | 1 |
Della Peruta, M | 1 |
Nathwani, AC | 1 |
Ruan, Y | 1 |
Zuo, S | 1 |
Xing, Y | 1 |
Zhao, X | 1 |
Xia, S | 1 |
Bai, R | 1 |
Du, X | 1 |
Ma, CS | 1 |
Georgantopoulos, P | 2 |
Yang, H | 1 |
Norris, LB | 2 |
Bennett, CL | 2 |
Sollena, P | 1 |
Mannino, M | 1 |
De Simone, C | 1 |
Peris, K | 1 |
Fianchi, L | 1 |
Criscuolo, M | 1 |
Pagano, L | 1 |
Diker, O | 1 |
Sengar, M | 1 |
Gogtay, N | 1 |
Jain, H | 1 |
Mercier, T | 1 |
Maertens, J | 1 |
Lavezzi, SM | 1 |
Neyens, M | 1 |
Bartlett, N | 1 |
Ganguly, S | 1 |
De Nicolao, G | 2 |
Poggesi, I | 2 |
Accordi, B | 1 |
Bresolin, S | 1 |
Basso, G | 1 |
Lujan, JV | 1 |
Lengerke-Diaz, PA | 1 |
Jacobs, C | 1 |
Moreno-Cortes, EF | 1 |
Ramirez-Segura, CA | 1 |
Choi, MY | 2 |
McCarthy, C | 1 |
Heinen, A | 1 |
Castro, JE | 1 |
Vijayvargiya, P | 1 |
Girmenia, C | 1 |
Pane, F | 1 |
Tura, S | 1 |
Barosi, G | 1 |
Slupsky, JR | 2 |
Bibikova, E | 1 |
Charuworn, P | 1 |
Linghu, B | 1 |
Tang, PSC | 1 |
Ni, A | 1 |
Darif, M | 1 |
Xing, G | 1 |
Mun, Y | 1 |
Ferrante, L | 1 |
Mobasher, M | 1 |
Stark, T | 1 |
Reddy, V | 1 |
Dreiling, LK | 1 |
Bhargava, P | 1 |
Best, S | 1 |
Bruss, N | 1 |
Berger, A | 1 |
Sondermann, K | 1 |
Gülsaran, SK | 1 |
Baysal, M | 1 |
Demirci, U | 1 |
Baş, V | 1 |
Kirkizlar, HO | 1 |
Umit, E | 1 |
Demir, AM | 1 |
Manohar, S | 1 |
Bansal, A | 1 |
Wanchoo, R | 1 |
Sakhiya, V | 1 |
Lucia, S | 1 |
Jhaveri, KD | 1 |
Advani, P | 1 |
Galik, B | 1 |
Marosvári, D | 1 |
Fésüs, V | 1 |
Nagy, Á | 1 |
Krizsán, S | 1 |
Reiniger, L | 1 |
Kozma, A | 1 |
Ádám, E | 1 |
Gyenesei, A | 1 |
Iliakis, T | 1 |
Pardalis, V | 1 |
Bitsani, C | 1 |
Vassilakopoulos, TP | 1 |
Angelopoulou, M | 1 |
Tsaftaridis, P | 1 |
Papaioannou, P | 1 |
Koudouna, A | 1 |
Kalyva, S | 1 |
Kyrtsonis, MC | 1 |
Panayiotidis, P | 1 |
Hanna, KS | 1 |
O'Dwyer, M | 2 |
Gołos, A | 1 |
Fradley, MG | 1 |
Gliksman, M | 1 |
Emole, J | 1 |
Viganego, F | 1 |
Rhea, I | 1 |
Welter-Frost, A | 1 |
Armanious, M | 1 |
Lee, DH | 1 |
Walko, C | 1 |
Shah, B | 1 |
Chavez, JC | 3 |
McLeod, H | 1 |
Schabath, MB | 1 |
Ghasoub, R | 1 |
Albattah, A | 1 |
Elazzazy, S | 1 |
Alokka, R | 1 |
Nemir, A | 1 |
Alhijji, I | 1 |
Taha, R | 1 |
Chartomatsidou, E | 1 |
Rovida, A | 1 |
Akritidou, MA | 1 |
Belloni, D | 1 |
Ferrero, E | 1 |
Trangas, T | 1 |
Anagnostopoulos, A | 1 |
Brock, K | 1 |
Muñoz-Vicente, S | 1 |
Yates, FJ | 1 |
Bishop, R | 1 |
Boucher, R | 1 |
MacDonald, D | 1 |
Fegan, C | 3 |
McCaig, A | 1 |
Pettitt, A | 1 |
Orsini, F | 1 |
Truchan Graczyk, M | 1 |
Sharif-Askari, B | 1 |
Doyon, D | 1 |
Paliouras, M | 1 |
Aloyz, R | 1 |
Frustaci, A | 1 |
Efremov, DG | 3 |
Gui, F | 1 |
Jiang, J | 1 |
He, Z | 1 |
Deng, Z | 1 |
Lu, Y | 1 |
Chen, G | 1 |
Su, J | 1 |
Zhang, YM | 1 |
Yun, CH | 1 |
Weisberg, E | 1 |
Zhang, J | 2 |
Deng, X | 1 |
Lemal, R | 4 |
Buggy, JJ | 12 |
Rai, K | 2 |
Herman, SE | 12 |
Sun, X | 1 |
Hsieh, MM | 1 |
Raffeld, M | 1 |
Chapman, CM | 1 |
Chen, J | 1 |
Aue, G | 4 |
Tisdale, JF | 1 |
Pérez-Galán, P | 2 |
Singh, K | 1 |
Mazumder, S | 1 |
Kalaycio, M | 1 |
Almasan, A | 1 |
Grant, B | 3 |
Chang, BY | 7 |
Hedrick, E | 2 |
Prins, RC | 1 |
Burke, RT | 1 |
Tyner, JW | 1 |
Druker, BJ | 1 |
Loriaux, MM | 1 |
Sharma, SP | 1 |
Cheng, S | 3 |
Ma, J | 3 |
Guo, A | 6 |
Leonard, JP | 1 |
Liu, M | 1 |
Bojnik, E | 1 |
Stefanovski, MR | 1 |
Goettl, VM | 1 |
Smucker, KA | 1 |
Dubovsky, JA | 3 |
Towns, WH | 1 |
MacMurray, J | 1 |
Davis, ME | 1 |
Gobessi, S | 2 |
Richards, DA | 1 |
Bhatt, V | 1 |
Alejandro, L | 1 |
Michael, A | 1 |
Ganetsky, A | 2 |
Smucker, K | 2 |
Zhong, Y | 3 |
Lucas, D | 1 |
Williams, K | 2 |
Rassenti, L | 1 |
Ghia, E | 1 |
Flynn, J | 3 |
Dias, AL | 1 |
Jain, D | 1 |
Cameron, F | 1 |
Sanford, M | 1 |
Guha, M | 1 |
Mustafa, RZ | 3 |
Gyamfi, JA | 2 |
Farooqui, M | 7 |
Lipsky, A | 3 |
Saba, N | 3 |
Martyr, S | 5 |
Valdez, J | 7 |
Calvo, KR | 5 |
Pedersen, LB | 2 |
Marti, GE | 4 |
Tang, CH | 1 |
Ranatunga, S | 1 |
Kriss, CL | 1 |
Cubitt, CL | 1 |
Tao, J | 1 |
Pinilla-Ibarz, JA | 1 |
Del Valle, JR | 1 |
Hu, CC | 1 |
Wodarz, D | 3 |
Komarova, NL | 2 |
James, D | 4 |
Porter, DL | 3 |
Aschenbrenner, DS | 1 |
Setty, M | 1 |
Perez, AR | 2 |
Racchumi, J | 1 |
Xu, G | 1 |
Wu, H | 1 |
Steggerda, SM | 2 |
Leslie, C | 1 |
Liu, TM | 2 |
Zapatka, M | 2 |
Xue, L | 1 |
Versele, M | 1 |
Dave, SS | 1 |
Yilmaz, AS | 1 |
Pocock, C | 1 |
de Vos, S | 1 |
Jones, JJ | 2 |
Fardis, M | 2 |
McGreivy, J | 2 |
Mannis, G | 1 |
Wu, D | 1 |
Dea, T | 1 |
Mauro, T | 1 |
Hsu, G | 1 |
Zhuang, SH | 2 |
Viganò, M | 2 |
Mangia, G | 1 |
Lampertico, P | 2 |
McDermott, J | 1 |
Jimeno, A | 1 |
Spaargaren, M | 3 |
de Rooij, MF | 3 |
Koskinas, JS | 1 |
Deutsch, M | 1 |
Adamidi, S | 1 |
Skondra, M | 1 |
Tampaki, M | 1 |
Alexopoulou, A | 1 |
Manolakopoulos, S | 1 |
Pectasides, D | 1 |
Bruhn, C | 1 |
Kamel, S | 1 |
Horton, L | 1 |
Levade, M | 1 |
Burbury, K | 1 |
Tan, S | 1 |
Cole-Sinclair, M | 1 |
Reynolds, J | 1 |
Filshie, R | 1 |
Schischka, S | 1 |
Khot, A | 1 |
Sandhu, S | 2 |
Nandurkar, H | 1 |
Hartmann, E | 1 |
Rosin, NY | 2 |
Jeyakumar, G | 1 |
Cardenas-Turanzas, M | 1 |
Lerner, S | 1 |
Zacharian, G | 1 |
Rosenwald, A | 1 |
Smith, DD | 1 |
Goldstein, L | 1 |
Kunkel, LA | 1 |
Dong, S | 2 |
Kutok, J | 1 |
Da Roit, F | 1 |
Engelberts, PJ | 1 |
Taylor, RP | 1 |
Breij, EC | 1 |
Gritti, G | 1 |
Introna, M | 1 |
Parren, PW | 1 |
Beurskens, FJ | 1 |
Golay, J | 1 |
Buggins, AG | 1 |
Jones, CH | 1 |
Lee, R | 1 |
Marostica, E | 1 |
Loury, D | 1 |
de Trixhe, XW | 1 |
Vermeulen, A | 1 |
Advani, R | 1 |
Badar, T | 1 |
Lee, CS | 1 |
Rattu, MA | 1 |
Kim, SS | 1 |
Mehta, P | 2 |
Johnsurd, J | 1 |
Govindarajan, R | 1 |
Desai, AV | 1 |
El-Bakkar, H | 1 |
Abdul-Hay, M | 1 |
Lin, TS | 1 |
Larson, R | 1 |
Marcucci, G | 1 |
McMullen, JR | 1 |
Boey, EJ | 1 |
Ooi, JY | 1 |
Famà, R | 1 |
Ciardullo, C | 1 |
Monti, S | 1 |
Rossi, F | 1 |
D'Agaro, T | 1 |
Farooqui, MZ | 8 |
Marti, G | 3 |
Hughes, TE | 1 |
Yuan, C | 3 |
Lee, YS | 4 |
Arthur, DC | 1 |
Childs, R | 1 |
Young, NS | 1 |
Cervantes-Gomez, F | 3 |
George, B | 1 |
Dangi-Garimella, S | 1 |
Till, KJ | 1 |
Pettitt, AR | 1 |
Giri, S | 1 |
Hahn, A | 1 |
Yaghmour, G | 1 |
Martin, MG | 1 |
Shaw, Y | 1 |
Bilotti, E | 1 |
Dunbar, N | 1 |
Marx-Wood, CR | 1 |
Skee, D | 1 |
Murphy, J | 1 |
Loury, DJ | 1 |
Chauhan, V | 1 |
Mannaert, E | 1 |
Tsang, M | 1 |
Conte, M | 2 |
Tran, A | 1 |
Friedberg, JW | 1 |
Kim, ES | 1 |
Dhillon, S | 1 |
Borah, BJ | 1 |
Sanford, DS | 1 |
Bergmann, M | 2 |
Kuil, A | 2 |
Kersten, MJ | 1 |
Pals, ST | 2 |
Hing, ZA | 1 |
Beckwith, KA | 2 |
Williams, E | 1 |
Faderl, S | 1 |
Shpall, E | 1 |
Hosing, C | 1 |
Khouri, IF | 1 |
Champlin, R | 1 |
Zhang, SQ | 1 |
Smith, SM | 3 |
Zhang, SY | 1 |
Lynn Wang, Y | 1 |
Wang, SY | 1 |
Ebert, T | 1 |
Jaekel, N | 1 |
Schubert, S | 1 |
Al-Ali, HK | 1 |
Peluso, M | 1 |
Fu, M | 1 |
Faia, K | 1 |
Kutok, JL | 1 |
Chamakhi, I | 1 |
Toze, C | 1 |
Assaily, W | 1 |
Robinson, S | 1 |
Strattan, E | 1 |
Zhang, X | 3 |
Spoelstra, SL | 1 |
Xargay-Torrent, S | 2 |
López-Guerra, M | 2 |
Rosich, L | 2 |
Montraveta, A | 2 |
Roldán, J | 2 |
Rodríguez, V | 1 |
Villamor, N | 2 |
Aymerich, M | 2 |
Lagisetti, C | 1 |
Webb, TR | 1 |
López-Otín, C | 1 |
Campo, E | 2 |
Colomer, D | 2 |
Hamasy, A | 1 |
Smith, CI | 1 |
Nagar, V | 1 |
Stefanos, M | 1 |
Munneke, B | 1 |
West, JS | 1 |
Neuenburg, JK | 1 |
Hall, N | 1 |
Thieblemont, C | 2 |
Rhein, C | 1 |
Stingo, F | 1 |
Smith, SC | 1 |
Rogers, M | 1 |
Wotherspoon, A | 1 |
Grisafi, D | 1 |
Maestro, A | 1 |
Grumi, C | 1 |
Piazzoni, L | 1 |
Tirone, G | 1 |
Fiore, W | 1 |
Tessari, R | 1 |
Gianardi, V | 1 |
Gatti, M | 1 |
Tasca, F | 1 |
Generali, D | 1 |
Ravelli, A | 1 |
Lanza, F | 1 |
Scaglione, F | 1 |
de Claro, RA | 1 |
McGinn, KM | 1 |
Verdun, N | 1 |
Lee, SL | 1 |
Chiu, HJ | 1 |
Saber, H | 1 |
Brower, ME | 1 |
Chang, CJ | 1 |
Pfuma, E | 1 |
Habtemariam, B | 1 |
Bullock, J | 1 |
Nie, L | 1 |
Chen, XH | 1 |
Lu, DR | 1 |
Al-Hakim, A | 1 |
Kane, RC | 1 |
Kaminskas, E | 1 |
Justice, R | 1 |
Farrell, AT | 1 |
Pazdur, R | 1 |
Skarzynski, M | 1 |
Salem, D | 2 |
Gunti, S | 1 |
Kardava, L | 1 |
Moir, S | 1 |
Notkins, AL | 1 |
Gayko, U | 1 |
Fung, M | 1 |
Faust, E | 1 |
Price, S | 1 |
Doyle, M | 1 |
Bari, S | 1 |
Dietrich, MF | 1 |
Collins, RH | 1 |
Gerber, DE | 1 |
Lipsky, AH | 1 |
Cullinane, AM | 1 |
Nghiem, K | 1 |
Uzel, G | 1 |
Holland, SM | 1 |
Lozier, JN | 1 |
Boissard, F | 1 |
Fournié, JJ | 1 |
Poupot, M | 1 |
Khan, K | 1 |
Malik, AI | 1 |
Almarzouqi, SJ | 1 |
Morgan, ML | 1 |
Yalamanchili, S | 1 |
Chevez-Barrios, P | 1 |
Lee, AG | 1 |
Patel, V | 1 |
Bingman, A | 1 |
Goede, V | 2 |
Thirdborough, SM | 1 |
Valle-Argos, B | 1 |
Linley, A | 1 |
Krysov, S | 1 |
Hidalgo, MS | 1 |
Leonard, E | 1 |
Ishfaq, M | 1 |
Wagner, SD | 1 |
Willis, AE | 1 |
Coldwell, MJ | 1 |
Ave, E | 1 |
Lessi, F | 1 |
Giorgi, CA | 1 |
Castelli, M | 1 |
Zambello, R | 1 |
Davies, N | 1 |
Oldreive, C | 1 |
Petermann, E | 1 |
Stewart, G | 1 |
Brown, J | 1 |
Lau, A | 1 |
Taylor, M | 1 |
Ren, L | 1 |
Gautam, S | 1 |
Elavazhagan, S | 1 |
Fatehchand, K | 1 |
Stiff, A | 1 |
Reader, BF | 1 |
Butchar, JP | 1 |
Suri, D | 1 |
Brower, V | 1 |
Gomez-Rodriguez, J | 1 |
Biancotto, A | 1 |
Braylan, RC | 1 |
Lee-Vergés, E | 1 |
Jiménez, L | 1 |
Cabezas, S | 1 |
Clot, G | 1 |
Pinyol, M | 1 |
Arimany-Nardí, C | 1 |
Roué, G | 2 |
Pastor-Anglada, M | 1 |
Islam, P | 1 |
Strelec, L | 1 |
Kaye, AH | 1 |
Brooks, S | 1 |
Nasta, S | 1 |
de Jésus Ngoma, P | 1 |
Kabamba, B | 1 |
Dahlqvist, G | 1 |
Sempoux, C | 1 |
Lanthier, N | 1 |
Shindano, T | 1 |
Horsmans, Y | 1 |
Galanina, N | 2 |
Link, CS | 1 |
Teipel, R | 1 |
Heidenreich, F | 1 |
Rücker-Braun, E | 1 |
Schmiedgen, M | 1 |
Reinhardt, J | 1 |
Oelschlägel, U | 1 |
von Bonin, M | 1 |
Middeke, JM | 1 |
Muetherig, A | 1 |
Trautmann-Grill, K | 1 |
Platzbecker, U | 1 |
Bornhäuser, M | 1 |
Foluso, O | 1 |
Glick, A | 1 |
Stender, M | 1 |
Jaiyesimi, I | 1 |
Patel, PR | 1 |
Ruella, M | 1 |
Zheng, Z | 1 |
Barrett, DM | 1 |
Lacey, SF | 1 |
McGettigan, SE | 1 |
Cook, DR | 1 |
Hulitt, J | 1 |
Kudchodkar, SB | 1 |
Cogdill, AP | 1 |
Gill, S | 1 |
Levine, BL | 1 |
Dougé, A | 1 |
Ravinet, A | 1 |
Bay, JO | 1 |
Guièze, R | 1 |
Kimber, T | 1 |
Shumilov, E | 1 |
Ströbel, P | 1 |
Hasenkamp, J | 1 |
Hellige, N | 1 |
Bleckmann, A | 1 |
Haase, D | 1 |
Braulke, F | 1 |
Jung, W | 1 |
Schanz, J | 1 |
Binder, M | 2 |
Trümper, L | 1 |
Bacher, U | 1 |
Malcikova, J | 1 |
Vela, CM | 1 |
McBride, A | 1 |
Bitar, C | 1 |
Bray, A | 1 |
Cowen, EW | 1 |
Sicre de Fontbrune, F | 1 |
Pannetier, M | 1 |
Michonneau, D | 1 |
Socié, G | 1 |
Peffault De Latour, R | 1 |
Wanquet, A | 2 |
Birsen, R | 2 |
Hunault, M | 1 |
Cavazzini, F | 1 |
Formigaro, L | 1 |
Konoplev, SN | 1 |
Yigit, B | 1 |
Halibozek, PJ | 1 |
O'Keeffe, MS | 1 |
Arnason, J | 1 |
Avigan, D | 1 |
Bhan, A | 1 |
Cen, O | 1 |
Longnecker, R | 1 |
Wang, N | 1 |
Engel, P | 1 |
Terhorst, C | 1 |
Mulvey, JJ | 1 |
Nuovo, GJ | 1 |
Magro, CM | 1 |
Damon, LE | 1 |
Li, PP | 1 |
Lu, K | 1 |
Geng, LY | 1 |
Zhou, XX | 1 |
Li, XY | 1 |
Bojarczuk, K | 1 |
Sasi, BK | 1 |
Tucker, DL | 1 |
Mihailescu, L | 1 |
Riordan, R | 1 |
Kumar Patel, V | 1 |
Sarosiek, K | 1 |
Stewart, C | 1 |
Dubuc, AM | 1 |
Fraser, C | 1 |
Han, Y | 1 |
Zou, L | 1 |
Sougnez, C | 1 |
Carter, SL | 1 |
Cibulskis, K | 1 |
Zenz, T | 1 |
Werner, L | 1 |
Dal Cin, P | 1 |
Kharchencko, P | 1 |
Lander, E | 1 |
Gabriel, S | 1 |
Letai, A | 2 |
Weitz, DA | 1 |
Nowak, MA | 1 |
Schliffke, S | 1 |
Akyüz, N | 1 |
Ford, CT | 1 |
Mährle, T | 1 |
Thenhausen, T | 1 |
Krohn-Grimberghe, A | 1 |
Knop, S | 1 |
Bokemeyer, C | 1 |
Manzoni, D | 1 |
Catallo, R | 1 |
Chebel, A | 1 |
Roualdes, O | 1 |
Magaud, JP | 1 |
Ffrench, M | 1 |
Hallek, MJ | 1 |
Lee, HJ | 1 |
Gallardo, M | 1 |
Ma, H | 1 |
Larsson, CA | 1 |
Mejia, A | 1 |
Hornbaker, MJ | 1 |
Qi, Y | 1 |
Su, X | 1 |
Pageon, LR | 1 |
Quintas-Cardama, A | 1 |
Post, SM | 1 |
Oppermann, S | 1 |
Ylanko, J | 1 |
Hariharan, S | 1 |
Oakes, CC | 1 |
Brauer, PM | 1 |
Zúñiga-Pflücker, JC | 1 |
Leber, B | 1 |
Andrews, DW | 1 |
Chan, KL | 1 |
Lokan, J | 1 |
Prince, HM | 1 |
Marini, BL | 1 |
Samanas, L | 1 |
Perissinotti, AJ | 1 |
Colombatti, A | 1 |
Saleh, LM | 1 |
Anastas, V | 1 |
Barber, E | 1 |
Corrigan-Cummins, M | 1 |
Sarasua, SM | 1 |
Zhao, Z | 1 |
Abousamra, NK | 1 |
Elbaz, O | 1 |
Abdelghaffar, HA | 1 |
Lutz, M | 1 |
Schulze, AB | 1 |
Rebber, E | 1 |
Wiebe, S | 1 |
Zoubi, T | 1 |
Grauer, OM | 1 |
Keßler, T | 1 |
Kerkhoff, A | 1 |
Lenz, G | 1 |
Berdel, WE | 1 |
Pavlasova, G | 1 |
Cerna, K | 1 |
Osickova, J | 1 |
Calogero, R | 1 |
Jerussi, T | 1 |
Gea-Banacloche, J | 1 |
Couzens, L | 1 |
Eichelberger, MC | 1 |
Walliser, C | 1 |
Hermkes, E | 1 |
Schade, A | 1 |
Wiese, S | 1 |
Deinzer, J | 1 |
Désiré, L | 1 |
Gierschik, P | 1 |
Kohli, PB | 1 |
Katewa, A | 1 |
Gogol, E | 1 |
Belmont, LD | 1 |
Choy, R | 1 |
Penuel, E | 1 |
Burton, L | 1 |
Eigenbrot, C | 1 |
Yu, C | 1 |
Ortwine, DF | 1 |
Bowman, K | 1 |
Franke, Y | 1 |
Estevez, A | 1 |
Mortara, K | 1 |
Li, H | 1 |
Lin, M | 1 |
Bergeron, P | 1 |
Crawford, JJ | 1 |
Tsui, ST | 1 |
Strelec, LE | 1 |
Vandegrift, A | 1 |
Fitzpatrick, DM | 1 |
Feldman, T | 1 |
Kaur, G | 1 |
Porter, D | 1 |
Evens, AM | 1 |
Audrito, V | 1 |
Grisendi, G | 1 |
Ward, CM | 1 |
Whalley, D | 1 |
Hilmer, SN | 1 |
Al Nawakil, C | 1 |
Goudot, FX | 1 |
Meune, C | 1 |
Kadri, S | 1 |
Van Slambrouck, C | 1 |
Long, B | 1 |
Ming, M | 1 |
Furtado, LV | 1 |
Segal, JP | 1 |
Stock, W | 1 |
Tang, WJ | 1 |
Karouzakis, P | 1 |
Thirman, MJ | 1 |
Ilhan, O | 1 |
Stevens-Brogan, M | 1 |
Berger, JR | 1 |
Sartor, O | 1 |
Carson, KR | 1 |
Hrushesky, WJ | 1 |
Raisch, DW | 1 |
Armitage, JO | 1 |
Voltan, R | 1 |
Rimondi, E | 1 |
Melloni, E | 1 |
Casciano, F | 1 |
Arcidiacono, MV | 1 |
Celeghini, C | 1 |
Zauli, G | 1 |
Secchiero, P | 1 |
Gozzetti, A | 1 |
Candi, V | 1 |
Brambilla, CZ | 1 |
Papini, G | 1 |
Fabbri, A | 1 |
Bocchia, M | 1 |
Sławińska, M | 1 |
Barańska-Rybak, W | 1 |
Sobjanek, M | 1 |
Wilkowska, A | 1 |
Mital, A | 1 |
Nowicki, R | 1 |
Reinhardt, HC | 1 |
Koffman, B | 1 |
Schorr, A | 1 |
Jeyakumar, D | 1 |
El-Asmar, J | 1 |
Hamadani, M | 1 |
Ayala, E | 1 |
Poole, A | 1 |
Girard, N | 1 |
Clayton, F | 1 |
Tantravahi, SK | 1 |
Goldschmidt, N | 1 |
Rund, D | 1 |
Bottoni, A | 1 |
Rizzotto, L | 1 |
Lai, TH | 1 |
Reiff, S | 1 |
El-Gamal, D | 1 |
Issara, K | 1 |
Yossi, S | 1 |
Caraivan, I | 1 |
Ryan, CE | 1 |
Sahaf, B | 1 |
Logan, AC | 1 |
Dyer, MJ | 1 |
Rezvani, AR | 1 |
Miklos, DB | 1 |
Merten, JA | 1 |
Bartoo, GT | 1 |
Leis, J | 1 |
Hussaini, MO | 1 |
Rehman, A | 1 |
Horna, P | 1 |
Bonnet, C | 1 |
Boubaya, M | 1 |
Choquet, S | 1 |
Re, D | 1 |
Fahri, J | 1 |
Lamy, T | 1 |
Troussard, X | 1 |
Dietrich, PY | 1 |
Noseworthy, PA | 1 |
Chen, L | 1 |
Cui, B | 1 |
Zhang, L | 1 |
Widhopf Ii, GF | 1 |
Kazianka, L | 1 |
Drucker, C | 1 |
Thomas, W | 1 |
Melchardt, T | 1 |
Struve, S | 1 |
Einberger, C | 1 |
Heinz, M | 1 |
Hauswirth, A | 1 |
Raderer, M | 1 |
Pabinger, I | 1 |
Quehenberger, P | 1 |
Jilma, B | 1 |
Quintela, A | 1 |
Sujobert, P | 1 |
Farber, CM | 1 |
Mahadevan, D | 1 |
Brooks, HD | 1 |
Fanning, S | 1 |
Klein, L | 1 |
Greenwald, DR | 1 |
Katchman, H | 1 |
Sorensen, S | 1 |
Trambitas, C | 1 |
Robins, H | 1 |
Yusko, E | 1 |
Vignali, M | 1 |
Coffey, G | 1 |
Conley, P | 1 |
Pandey, A | 1 |
Deeks, ED | 1 |
Deng, J | 1 |
Isik, E | 1 |
Mikudina, B | 1 |
Goodall, M | 1 |
Adler, AI | 1 |
Li, KW | 1 |
Amer, AM | 1 |
Hellerstein, MK | 1 |
Turner, SM | 1 |
Emson, CL | 1 |
Yan, XJ | 1 |
Kreiniz, N | 1 |
Bejar, J | 1 |
Plascencia, C | 1 |
Chan, TS | 1 |
Au-Yeung, R | 1 |
Chim, CS | 1 |
Wong, SC | 1 |
Kwong, YL | 1 |
Compagno, M | 1 |
Pighi, C | 1 |
Cheong, TC | 1 |
Meng, FL | 1 |
Poggio, T | 1 |
Yeap, LS | 1 |
Karaca, E | 1 |
Blasco, RB | 1 |
Langellotto, F | 1 |
Ambrogio, C | 1 |
Voena, C | 1 |
Kasar, SN | 1 |
Gostissa, M | 1 |
Alt, FW | 1 |
Chiarle, R | 1 |
Albitar, A | 1 |
Ma, W | 1 |
DeDios, I | 1 |
Estella, J | 1 |
Ahn, I | 1 |
Albitar, M | 1 |
Banerjee, R | 1 |
Glynn, RJ | 1 |
Walewska, R | 1 |
Savage, KJ | 1 |
Michaud, GF | 1 |
Moslehi, JJ | 1 |
Loscertales Pueyo, J | 1 |
Giraldo, P | 1 |
Martínez, R | 1 |
Piggin, A | 1 |
Bayly, E | 1 |
Mądro, E | 1 |
Piotrowska, M | 1 |
Drozd-Sokołowska, J | 1 |
Kyrcz-Krzemień, S | 1 |
Hałka, J | 1 |
Wieszczy, P | 1 |
Vojdeman, FJ | 1 |
Kirkby, N | 1 |
van T' Veer, MB | 1 |
Itälä-Remes, MA | 1 |
Wu, KL | 1 |
Alemayehu, WG | 1 |
Wittebol, S | 1 |
Kozak, T | 1 |
Walewski, J | 1 |
Abrahamse-Testroote, MCJ | 1 |
van Oers, MHJ | 1 |
Lee, A | 1 |
Imlay-Gillespie, L | 1 |
Mulligan, S | 1 |
Shumack, S | 1 |
Campidelli, A | 1 |
Lequeu, H | 1 |
Jerkeman, M | 1 |
Dreyling, M | 1 |
Staudt, L | 1 |
Fabian, C | 1 |
Yeh, P | 1 |
Hunter, T | 1 |
Sinha, D | 1 |
Ftouni, S | 1 |
Wallach, E | 1 |
Jiang, D | 1 |
Chan, YC | 1 |
Wong, SQ | 1 |
Silva, MJ | 1 |
Vedururu, R | 1 |
Doig, K | 1 |
Lam, E | 1 |
Arnau, GM | 1 |
Semple, T | 1 |
Wall, M | 1 |
Zivanovic, A | 1 |
Agarwal, R | 1 |
Petrone, P | 1 |
Jones, K | 1 |
Westerman, D | 1 |
Papenfuss, AT | 1 |
Dawson, MA | 1 |
Dawson, SJ | 1 |
Merle-Béral, H | 1 |
Barbier, S | 1 |
Bras, M | 1 |
Sarfati, M | 1 |
Susin, SA | 1 |
Gordon, AL | 1 |
Ramanunni, A | 1 |
Ponader, S | 1 |
Geest, CR | 1 |
Winer, ES | 1 |
Ingham, RR | 1 |
Castillo, JJ | 1 |
Advani, RH | 1 |
Boyd, TE | 1 |
Rodriguez, S | 1 |
Lindemalm, S | 1 |
Liliemark, J | 1 |
Juliusson, G | 1 |
Larsson, R | 1 |
Albertioni, F | 1 |
Moshynska, O | 1 |
Moshynskyy, I | 1 |
Misra, V | 1 |
Saxena, A | 1 |
Zilioli, VR | 1 |
Fantini, NN | 1 |
Pasquini, MC | 1 |
Deliliers, GL | 1 |
Colombo, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT02910583] | Phase 2 | 323 participants (Actual) | Interventional | 2016-09-28 | Active, not recruiting | ||
A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia Patients With Risk of Early Disease Progr[NCT02863718] | Phase 3 | 515 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487] | Phase 3 | 269 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia o[NCT02264574] | Phase 3 | 229 participants (Actual) | Interventional | 2014-10-06 | Completed | ||
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02048813] | Phase 3 | 529 participants (Actual) | Interventional | 2014-02-20 | Active, not recruiting | ||
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733] | Phase 2 | 86 participants (Actual) | Interventional | 2012-01-05 | Active, not recruiting | ||
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346] | Phase 3 | 232 participants (Actual) | Interventional | 2012-08-28 | Completed | ||
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma[NCT02303392] | Phase 1 | 34 participants (Actual) | Interventional | 2015-03-11 | Active, not recruiting | ||
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations[NCT03226301] | Phase 2 | 230 participants (Anticipated) | Interventional | 2017-06-23 | Active, not recruiting | ||
Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392] | Phase 3 | 24 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients[NCT02689141] | Phase 2 | 66 participants (Actual) | Interventional | 2016-02-04 | Completed | ||
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT03734016] | Phase 3 | 652 participants (Actual) | Interventional | 2018-11-01 | Active, not recruiting | ||
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069] | Phase 2 | 199 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.[NCT02824159] | 121 participants (Actual) | Observational | 2016-04-30 | Completed | |||
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in [NCT02950051] | Phase 3 | 926 participants (Actual) | Interventional | 2016-12-13 | Active, not recruiting | ||
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090] | Phase 3 | 578 participants (Actual) | Interventional | 2012-09-19 | Completed | ||
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2015-08-03 | Active, not recruiting | ||
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207] | Phase 1 | 25 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions[NCT02015208] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib[NCT02912754] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2017-03-31 | Not yet recruiting | ||
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898] | Phase 2 | 135 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)[NCT02301156] | Phase 3 | 126 participants (Actual) | Interventional | 2015-01-27 | Completed | ||
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy[NCT02717611] | Phase 2 | 60 participants (Actual) | Interventional | 2016-03-08 | Active, not recruiting | ||
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and Ibrutinib (BIG) Followed by GA101 and Ibrutinib Maintenance in CLL Patients (CLL2-BIG Protocol)[NCT02345863] | Phase 2 | 66 participants (Actual) | Interventional | 2015-01-16 | Completed | ||
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL Patients[NCT02401503] | Phase 2 | 66 participants (Actual) | Interventional | 2015-05-06 | Active, not recruiting | ||
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02756897] | Phase 2 | 234 participants (Actual) | Interventional | 2016-07-07 | Active, not recruiting | ||
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)[NCT01886872] | Phase 3 | 547 participants (Actual) | Interventional | 2013-12-09 | Active, not recruiting | ||
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia[NCT02477696] | Phase 3 | 533 participants (Actual) | Interventional | 2015-07-28 | Active, not recruiting | ||
Prospective Economic Analysis: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib + Rituximab vs Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)[NCT02414022] | 55 participants (Actual) | Observational | 2015-04-15 | Active, not recruiting | |||
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)[NCT02332980] | Phase 2 | 65 participants (Actual) | Interventional | 2015-02-19 | Completed | ||
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia[NCT02029443] | Phase 1/Phase 2 | 306 participants (Actual) | Interventional | 2014-01-30 | Active, not recruiting | ||
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)[NCT01589302] | Phase 2 | 154 participants (Actual) | Interventional | 2012-05-21 | Active, not recruiting | ||
Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia[NCT00281983] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955] | Phase 2 | 8 participants (Actual) | Interventional | 2018-06-12 | Completed | ||
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy[NCT02141282] | Phase 2 | 127 participants (Actual) | Interventional | 2014-09-10 | Completed | ||
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents[NCT03816683] | 229 participants (Actual) | Observational | 2019-04-01 | Active, not recruiting | |||
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100] | Phase 2 | 55 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL[NCT02200848] | Phase 1 | 5 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Recruitment difficulties and toxicity) | ||
A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)[NCT02801578] | Phase 2/Phase 3 | 11 participants (Actual) | Interventional | 2016-07-06 | Completed | ||
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment[NCT04059081] | Phase 2 | 31 participants (Anticipated) | Interventional | 2019-07-09 | Recruiting | ||
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)[NCT02007044] | Phase 2 | 208 participants (Anticipated) | Interventional | 2013-12-06 | Active, not recruiting | ||
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies[NCT02268851] | Phase 1 | 45 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies[NCT02329847] | Phase 1/Phase 2 | 144 participants (Actual) | Interventional | 2015-03-11 | Completed | ||
A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.[NCT02006485] | Phase 1 | 160 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2007-03-21 | Active, not recruiting | ||
A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication[NCT04560322] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-10-19 | Recruiting | ||
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947] | Phase 2 | 3 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470] | 92 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients[NCT01520519] | Phase 2 | 40 participants (Actual) | Interventional | 2012-02-27 | Completed | ||
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma[NCT01236391] | Phase 2 | 115 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654] | Phase 1 | 66 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias[NCT02580552] | Phase 1 | 66 participants (Actual) | Interventional | 2016-02-09 | Completed | ||
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
Zanubrutinib in Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: a Prospective Cohort Study[NCT05922839] | Phase 2 | 22 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects[NCT01866033] | Phase 1 | 8 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765[NCT01820936] | Phase 1 | 52 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01292135] | Phase 1 | 33 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749] | Phase 1/Phase 2 | 71 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
Exploring Patient Experiences of Individuals Joining Chronic Lymphocytic Leukemia Clinical Trials[NCT05899543] | 500 participants (Anticipated) | Observational | 2024-07-31 | Not yet recruiting | |||
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)[NCT01747486] | Phase 2 | 42 participants (Actual) | Interventional | 2013-01-02 | Completed | ||
The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients With Chronic Lymphocytic Leukemia[NCT03231579] | 85 participants (Actual) | Observational | 2017-07-21 | Completed | |||
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)[NCT02514083] | Phase 2 | 29 participants (Actual) | Interventional | 2015-12-09 | Active, not recruiting | ||
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy[NCT02742090] | Phase 2 | 51 participants (Actual) | Interventional | 2016-04-21 | Completed | ||
An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)[NCT01744691] | Phase 2 | 145 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)[NCT01752426] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2012-12-17 | Completed | ||
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria.[NCT03868722] | Phase 2/Phase 3 | 212 participants (Anticipated) | Interventional | 2019-10-11 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 55.9 |
FD Cohort: All Treated | 55.3 |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 24 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 96.1 |
FD Cohort: All Treated | 94.7 |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to time of death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 97.7 |
FD Cohort: All Treated | 98.1 |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of PFS rate at 24 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Median) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 96.2 |
FD Cohort: All Treated | 94.8 |
ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD up to primary analysis data cutoff date of 15 December 2020. Median follow-up time was 27.9 months at the time of the primary analysis.
Intervention | percentage of participants (Number) |
---|---|
FD Cohort, Non-Del 17p Population: All Treated | 95.6 |
FD Cohort: All Treated | 96.2 |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Intervention | percentage of participants (Number) |
---|---|
FD Cohort: All Treated | 94.1 |
DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia [IWCLL] criteria [Halleck et al]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time. (NCT02910583)
Timeframe: 1 year after randomization
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 62.8 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 72.1 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 60.5 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 74.2 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 56.3 |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of DOR at 36 months landmark time was presented. (NCT02910583)
Timeframe: From initial documentation of a response, until PD or death from any cause, whichever occurs first. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 94.7 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 96.7 |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of OS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 99.4 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 38.2 months study follow-up, the Kaplan-Meier estimate of PFS rate at 36 months landmark time was presented. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD or death. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 95.6 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 95.3 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 96.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 96.7 |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. (NCT02910583)
Timeframe: From the first dose of ibrutinib to the first confirmed PD (up to primary analysis data cutoff date of 15 December 2020). Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 97.0 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 100.0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 88.5 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | L/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 833 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | 1/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 0.132 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng*h/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 48993 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | L/h (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 8.16 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng/mL (Geometric Mean) |
---|---|
MRD Cohort: All Treated | 3034 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | hours (Median) |
---|---|
MRD Cohort: All Treated | 6.00 |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) < 5 cm AND absolute lymphocyte count (ALC) < 25 x 10^9/L; Medium=Any LN 5 cm to < 10 cm OR ALC ≥ 25 x 10^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10^9/L AND any LN ≥ 5 cm. (NCT02910583)
Timeframe: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Intervention | percentage of participants (Number) |
---|---|
MRD Cohort: All Treated | 90.0 |
MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB. (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 27.9 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) | ||
---|---|---|---|
BM or PB | BM | PB | |
FD Cohort, Non-Del 17p Population: All Treated | 78.7 | 61.8 | 76.5 |
FD Cohort: All Treated | 78.6 | 59.7 | 76.7 |
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the FD cohort was 13.3 months for ibrutinib and 11.1 for venetoclax.
Intervention | percentage of participants (Number) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Any Grade >=3 TEAE | Any Ibrutinib (Ibr)-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Venetoclax (Ven)-Related TEAE | Any Grade >=3 Venetoclax-Related TEAE | Any TEAE Leading to Ibr or Ven Discontinuation | Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | Any TEAE Leading to Ibr or Ven Dose Reduction | Any TEAE Leading to Ibr Only Dose Reduction | Any TEAE Leading to Ven Only Dose Reduction | Any TEAE Leading to Both Ibr and Ven Dose Reduction | Any SAE | Any Grade >= 3 SAE | Any SAE Related to Ibr or Ven | Any Ibr-related SAE | Any Ven-related SAE | Fatal TEAE | Major Hemorrhage TEAE | Grade >= 3 Major Hemorrhage TEAE | Major Hemorrhage SAE | |
FD Cohort: All Treated | 99.4 | 62.3 | 92.5 | 44.7 | 84.3 | 44.7 | 5.0 | 3.1 | 0 | 1.9 | 20.8 | 5.7 | 11.3 | 3.8 | 22.6 | 19.5 | 13.2 | 11.3 | 8.2 | 0.6 | 1.9 | 1.3 | 1.3 |
"MRR is defined as the percentage of participants who achieve MRD-negativity in either peripheral blood (PB) or bone marrow (BM) and achieve confirmed clinical response PR or better per 2008 IWCLL criteria (Halleck et al.). MRD-negativity is defined as <1 CLL cell per 10,000 leukocytes (<1 x 10^4), as assessed by flow cytometry of a PB or BM aspirate sample. Confirmed MRD-negative response for randomization purposes requires MRD-negativity serially over at least 3 cycles, with negativity in both BM and PB.~This rate is calculated in the uMRD Not Confirmed randomized population during the period from randomization date and before any reintroduced treatment." (NCT02910583)
Timeframe: From randomization date until before any reintroduced treatment. Overall median follow-up time was 38.2 months at the time of the primary analysis (data cutoff date: 15 December 2020).
Intervention | percentage of participants (Number) | ||
---|---|---|---|
PB or BM | BM | PB | |
MRD Cohort: All Treated | 81.1 | 76.8 | 79.3 |
MRD Cohort/uMRD Not Confirmed: All Participants | 63.5 | 54.0 | 58.7 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 51.6 | 41.9 | 48.4 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 75.0 | 65.6 | 68.8 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization >24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug. (NCT02910583)
Timeframe: From first dose until 30 days following last dose of study drug (up to data cutoff date of 15 Dec 2020). Treatment duration for the MRD cohort was 28.7 months for ibrutinib and 15.4 for venetoclax.
Intervention | percentage of participants (Number) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Any Grade >=3 TEAE | Any Ibrutinib (Ibr)-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Venetoclax (Ven)-Related TEAE | Any Grade >=3 Venetoclax-Related TEAE | Any TEAE Leading to Ibr or Ven Discontinuation | Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | Any TEAE Leading to Ibr or Ven Dose Reduction | Any TEAE Leading to Ibr Only Dose Reduction | Any TEAE Leading to Ven Only Dose Reduction | Any TEAE Leading to Both Ibr and Ven Dose Reduction | Any SAE | Any Grade >= 3 SAE | Any SAE Related to Ibr or Ven | Any Ibr-related SAE | Any Ven-related SAE | Fatal TEAE | Major Hemorrhage TEAE | Grade >= 3 Major Hemorrhage TEAE | Major Hemorrhage SAE | |
MRD Cohort: All Treated | 100.0 | 73.8 | 94.5 | 57.9 | 80.5 | 44.5 | 12.8 | 7.3 | 1.2 | 4.3 | 24.4 | 14.6 | 5.5 | 4.3 | 31.1 | 26.2 | 18.3 | 15.9 | 5.5 | 0.6 | 2.4 | 1.8 | 2.4 |
MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | 100.0 | 79.1 | 93.0 | 55.8 | 86.0 | 51.2 | 4.7 | 2.3 | 2.3 | 0 | 20.9 | 14.0 | 4.7 | 2.3 | 27.9 | 25.6 | 16.3 | 11.6 | 4.7 | 0 | 2.3 | 2.3 | 2.3 |
MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | 100.0 | 65.1 | 93.0 | 48.8 | 76.7 | 34.9 | 0 | 0 | 0 | 0 | 23.3 | 9.3 | 11.6 | 2.3 | 18.6 | 16.3 | 11.6 | 9.3 | 7.0 | 0 | 0 | 0 | 0 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | 100.0 | 71.0 | 96.8 | 61.3 | 80.6 | 45.2 | 9.7 | 9.7 | 0 | 0 | 22.6 | 16.1 | 0 | 6.5 | 35.5 | 29.0 | 22.6 | 19.4 | 9.7 | 3.2 | 3.2 | 3.2 | 3.2 |
MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax | 100.0 | 75.0 | 93.8 | 62.5 | 96.9 | 56.3 | 12.5 | 3.1 | 0 | 9.4 | 31.3 | 21.9 | 3.1 | 6.3 | 37.5 | 28.1 | 18.8 | 18.8 | 3.1 | 0 | 6.3 | 3.1 | 6.3 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | ng*h/mL (Geometric Mean) | |
---|---|---|
AUC0-24h | AUClast | |
MRD Cohort: All Treated | 504 | 480 |
(NCT02910583)
Timeframe: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Intervention | hours (Median) | ||
---|---|---|---|
tmax | tlast | t1/2term | |
MRD Cohort: All Treated | 2.00 | 24.0 | 5.30 |
ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib | 82.4 |
Chlorambucil | 35.3 |
OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | NA |
"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | 18.9 |
The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 45.6 |
Chlorambucil | 20.3 |
In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 84.3 |
Chlorambucil | 45.5 |
The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 27.2 |
Chlorambucil | 11.3 |
In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 77.1 |
Chlorambucil | 42.9 |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified CR, CRi, nPR or PR per investigator assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 91.2 |
CLB+OB | 81.0 |
"OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.~As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 48 [final analysis]) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 80.5 |
CLB+OB | 81.3 |
"PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 74.0 |
CLB+OB | 22.0 |
"PFS was analyzed within the high-risk population of participants with del17p or TP53 mutation or del 11q or IGHV unmutated at baseline per central lab results. PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented." (NCT02264574)
Timeframe: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 70.3 |
CLB+OB | 8.0 |
Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 24.8 |
CLB+OB | 17.2 |
Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 44.2 |
CLB+OB | 44.0 |
Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 30.1 |
CLB+OB | 14.7 |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), or partial response (PR) per IRC assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 88.5 |
CLB+OB | 73.3 |
"OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.~As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier landmark estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 30 [primary analysis]) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 85.5 |
CLB+OB | 84.9 |
"PFS was analyzed within the high-risk sub-population of participants with del17p or TP53 mutation or del 11q at baseline per central lab results. PFS was defined as time from the date randomization to the date of first IRC-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.~As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 82.4 |
CLB+OB | 14.1 |
"PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.~The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented." (NCT02264574)
Timeframe: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 78.5 |
CLB+OB | 31.1 |
Percentage of participants with EQ-5D-5L utility score increase ≥ 0.08 points over baseline at or prior to initiation of subsequent antineoplastic therapy. The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life, comprising 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. Participants with missing EQ-5D-5L data were considered not achieving clinically meaningful improvement. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 54.9 |
CLB+OB | 56.0 |
Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 20.4 |
CLB+OB | 17.2 |
Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase ≥ 2 g/dL over baseline continuously for ≥ 56 days without blood transfusions or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 39.8 |
CLB+OB | 44.0 |
Percentage of participants with platelet counts increase ≥ 50% over baseline continuously for ≥ 56 days without blood transfusion or growth factors. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) |
---|---|
IBR+OB | 29.2 |
CLB+OB | 13.8 |
Percentage of participants experiencing grade ≥ 3 (severe or life threatening) or serious IRR adverse events that started on the day of an obinutuzumab infusion and were assessed as related or possibly related to obinutuzumab. Categories included those events with the Medical Dictionary for Regulatory Activities (MedDRA) dictionary preferred term of IRR and those events which are among the customized standardized MedDRA query (SMQ) for IRR. (NCT02264574)
Timeframe: Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Intervention | percentage of participants (Number) | |
---|---|---|
IRR (Preferred Term) | By Customized SMQ | |
CLB+OB | 8.6 | 9.5 |
IBR+OB | 2.7 | 4.4 |
Overall survival was defined as time from randomization to death from any cause or date last known alive. Overall survival rate at 3 years was estimated using the method of Kaplan-Meier. (NCT02048813)
Timeframe: Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5, up to 4 years and 8 months
Intervention | Proportion of participants (Number) |
---|---|
Arm A (Ibrutinib, Rituximab) | 0.988 |
Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 0.915 |
"PFS was defined as the time from randomization to CLL progression or death, whichever occurred first. Progression is characterized by any of the following:~≥ 50% increase from nadir since start of treatment (tx) in the sum of the products of at least 2 lymph nodes on 2 consecutive examinations 2 weeks apart~≥ 50% increase from nadir since start of tx in the size of liver and/or spleen~≥ 50% increase in the absolute number of circulating lymphocytes not due to tumor flare reaction. The absolute lymphocyte count must be ≥ 5x10^9/L to qualify as disease progression.~Transformation to a more aggressive histology (e.g. Richter's syndrome or prolymphocytic leukemia with > 55% prolymphocytes). For patients who achieve a complete response or nodular partial response, progression is defined as recurrence of circulating leukemia cell clone in the peripheral blood and an absolute lymphocyte count > 5x10^9/L and/or recurrence of palpable lymphadenopathy > 1.5 cm by physical exam." (NCT02048813)
Timeframe: Assessed every 3 months until progression up to 4 years and 8 months
Intervention | Proportion of participants (Number) |
---|---|
Arm A (Ibrutinib, Rituximab) | 0.894 |
Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 0.729 |
"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
Elderly Cohort | 93.9 |
TP53 Cohort | 95.8 |
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 65.1 |
Ibrutinib (Arm B) | 67.7 |
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 4.1 |
Ibrutinib (Arm B) | 42.6 |
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) |
---|---|
Ofatumumab (Arm A) | 22.4 |
Ibrutinib (Arm B) | 87.7 |
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | NA |
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | months (Median) |
---|---|
Ofatumumab (Arm A) | 8.1 |
Ibrutinib (Arm B) | 44.1 |
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
Intervention | percentage of participants (Number) | |
---|---|---|
Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
Ibrutinib (Arm B) | 69.7 | 78.4 |
Ofatumumab (Arm A) | 32.6 | 9.4 |
"ORR is the percentage of participants with PR or higher, (CR/CRi) + PR + nodular PR per IRC assessment using the modified 2008 IWCLL guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for NHL for participants with SLL" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months
Intervention | Percentage of participants (Number) |
---|---|
Zanubrutinib | 86.2 |
Ibrutinib | 75.7 |
"ORR is percentage of participants with partial response (PR) or higher, (defined as Complete response/ Complete response with incomplete bone marrow recovery (CR/CRi) + PR + nodular PR) per investigator assessment using the modified 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for non-Hodgkin lymphoma (NHL)) for participants with Small lymphocytic lymphoma (SLL)" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months
Intervention | Percentage of participants (Number) |
---|---|
Zanubrutinib | 83.5 |
Ibrutinib | 74.2 |
All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 42 |
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH | 199 |
A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
IBRUTINIB/PCI-32765 | 70 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
Intervention | (Number) |
---|---|
Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
Intervention | Participants (Number) |
---|---|
PCI-32765 | 116 |
Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 71 |
Relapsed/ Refractory | 75.3 |
Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 96.3 |
Relapsed/ Refractory | 73.6 |
Food- Effect | NA |
Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)
Intervention | milligram per liter (mg/L) (Mean) |
---|---|
Ibrutinib+BR | -0.46 |
Placebo+BR | -0.23 |
"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -2.1 |
Placebo+BR | -4.1 |
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | 0.0 |
Placebo+BR | 0.0 |
The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -4.3 |
Placebo+BR | 4.0 |
FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -0.9 |
Placebo+BR | 0.0 |
Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years
Intervention | Months (Number) |
---|---|
Ibrutinib+BR | 6.5 |
Placebo+BR | 4.6 |
Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 52 |
Placebo+BR | 61 |
The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 0 |
Placebo+BR | 0 |
ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 87.2 |
Placebo+BR | 66.1 |
OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | NA |
Placebo+BR | NA |
MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 28.7 |
Placebo+BR | 5.9 |
PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | 65.12 |
Placebo+BR | 14.32 |
The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on the scale (Mean) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lost weight | Dry mouth | Bruises | Abdominal discomfort | Temperature going up and down | Night sweats | Skin problems | Feel ill | Feel lethargic | Felt slowed down | Limited in planning activities | Worried about health in the future | Trouble with chest infections | Trouble with other infections | Repeated courses of antibiotics | Worried about picking up infection | |
Ibrutinib+BR | 0.1 | 0.3 | 0.1 | 0.1 | 0.1 | -0.6 | 0.4 | 0.1 | 0.1 | 0.3 | 0.2 | 0.0 | 0.2 | 0.7 | 0.9 | 0.3 |
Placebo+BR | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -0.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 |
Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of Participants (Number) | |
---|---|---|
Hemoglobin | Platelets | |
Ibrutinib+BR | 36.7 | 30.8 |
Placebo+BR | 29.1 | 21.8 |
The CR rate was defined as the percentage of participants who achieved CR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets ≥100 x 10^9/L, Hgb ≥110 g/L. (NCT02301156)
Timeframe: Up to 62 months
Intervention | percentage of participants (Number) |
---|---|
Ublituximab + Ibrutinib | 18.8 |
Ibrutinib | 4.8 |
DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC<4x10^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC>1.5x10^9/L,Platelets≥100x10^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC<4x10^9/L,>=50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC>1.5x10^9/L,Platelets>100x10^9/L,Hgb>110 g/L or >=50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of >50% in platelets/>20g/L in Hgb from highest on-study count. (NCT02301156)
Timeframe: From the first dose of study drug until the first documentation of PD or death whichever occurs first or up to 62 months
Intervention | months (Median) |
---|---|
Ublituximab + Ibrutinib | NA |
Ibrutinib | 39.1 |
MRD negativity rate was defined as the percentage of participants who were MRD negative post-baseline. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. (NCT02301156)
Timeframe: Up to 62 months
Intervention | percentage of participants (Number) |
---|---|
Ublituximab + Ibrutinib | 45.3 |
Ibrutinib | 9.7 |
ORR: Percentage of participants with best overall response of partial response(PR) and complete response(CR). CR criteria: No evidence of new disease; Absolute lymphocyte count(ALC)<4x10^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters(cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)>1.5x10^9/L,platelets≥100x10^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR criteria: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC<4x10^9/L or >=50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC>1.5x10^9/L,platelets>100x10^9/L,Hgb>110g/L or >=50% increase over baseline in any of these. (NCT02301156)
Timeframe: Up to 62 months
Intervention | percentage of participants (Number) |
---|---|
Ublituximab + Ibrutinib | 84.4 |
Ibrutinib | 69.4 |
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related. (NCT02301156)
Timeframe: From the first dose up to 30 days after the last dose of study drug (up to 57.3 months)
Intervention | percentage of participants (Number) |
---|---|
Ublituximab + Ibrutinib | 100 |
Ibrutinib | 100 |
PFS was defined as the time from the date of randomization until the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. PD requires at least one of the following: New nodes >1.5 cm in the LD and >1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, >50% decrease from the highest on-study platelet count, >20 g/L decrease from the highest on-study Hgb. (NCT02301156)
Timeframe: From the randomization until the first documentation of PD or death whichever occurs first or up to 62 months
Intervention | months (Median) |
---|---|
Ublituximab + Ibrutinib | NA |
Ibrutinib | 47.2 |
TTR was defined as the interval from the randomization to the first documentation of CR or PR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets ≥100 x 10^9/L, Hgb ≥110 g/L. PR criteria: No evidence of new disease; Response in 2 of following when abnormal at baseline: ALC<4 x 10^9/L or >=50% decrease from baseline in SPD of target nodal lesions; splenomegaly; hepatomegaly; >=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; and Response in 1 of the following: ANC>1.5 x 10^9/L, platelets>100 x 10^9/L, Hgb>110 g/L or >=50% increase over baseline in any of these. (NCT02301156)
Timeframe: From the randomization up to 62 months
Intervention | months (Median) |
---|---|
Ublituximab + Ibrutinib | 2.0 |
Ibrutinib | 3.9 |
"The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1." (NCT02717611)
Timeframe: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Intervention | Months (Median) |
---|---|
Acalabrutinib | NA |
The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
Intervention | Months (Median) |
---|---|
Acalabrutinib | NA |
"The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1." (NCT02717611)
Timeframe: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
Intervention | Months (Median) |
---|---|
Acalabrutinib | NA |
"The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment." (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days
Intervention | Percentage of participants (Number) |
---|---|
Acalabrutinib | 70.0 |
"The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy.~TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows:~(Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation." (NCT02717611)
Timeframe: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Intervention | Months (Median) |
---|---|
Acalabrutinib | 44.0 |
The Kaplan-Meier method will be used to estimate median DOR. DOR is the time from first objective status to progression or death. CR requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. PR requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL). (NCT01886872)
Timeframe: From the date of first response until progression or death, performed at 2.5 years after the last patient enrolled; up to 4 years.
Intervention | months (Median) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 50 |
Arm B (Ibrutinib) | NA |
Arm C (Ibrutinib, Rituximab) | NA |
The Kaplan-Meier method will be used to estimate the rate of overall survival at 2 years in each treatment arm. OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point. (NCT01886872)
Timeframe: From the date of registration to the date of death, assessed up to 2 years
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 95 |
Arm B (Ibrutinib) | 90 |
Arm C (Ibrutinib, Rituximab) | 94 |
Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. Complete response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 26 |
Arm B (Ibrutinib) | 7 |
Arm C (Ibrutinib, Rituximab) | 12 |
Complete response (CR) requires all of the following: absence of lymphadenopathy >1.5 cm on physical exam/CT scan, no hepatomegaly/splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate & biopsy must be normocellular for age. Partial response (PR) requires >= 50% decrease in peripheral lymphocyte count from pre-treatment value, >= 50% reduction in lymphadenopathy, and/or ≥ 50% reduction in splenomegaly/hepatomegaly. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). PR with the exception of having less than a 50% reduction in peripheral lymphocyte count will be considered a PR except persistent lymphocytosis (PRL).Overall response rate and corresponding exact binomial 95% CI provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled;up to 4 years.
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 75 |
Arm B (Ibrutinib) | 93 |
Arm C (Ibrutinib, Rituximab) | 94 |
Complete response (CR) requires all of the following: absence of lymphadenopathy > 1.5 cm on physical exam/CT scan, no hepatomegaly or splenomegaly on physical exam, no clonal B-cells in the blood, Normal CBC, bone marrow aspirate and biopsy must be normocellular for age. CR with exception of having bone marrow lymphoid CLL nodules will be considered a nodular PR (nPR). CR with exception of not having a bone marrow biopsy performed will be considered a clinical CR (CCR). Response rate and corresponding exact binomial 95% confidence intervals provided. (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 33 |
Arm B (Ibrutinib) | 10 |
Arm C (Ibrutinib, Rituximab) | 23 |
Estimated using the number of patients who achieve minimal residual disease divided by the total number randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for MRD rates will be calculated. (NCT01886872)
Timeframe: Cycle 9 Day 1 Evaluation
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 8 |
Arm B (Ibrutinib) | 1 |
Arm C (Ibrutinib, Rituximab) | 4 |
The Kaplan-Meier method will be used to estimate the progression free survival distributions for each arm, with median estimates provided. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50% with >= 5000 B lymphocytes/mL in patients on Arm A or those on Arms 2 or 3 no longer receiving ibrutinib, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death. The analysis was event driven, performed at 2.5 years after the last patient enrolled;up to 4 years.
Intervention | months (Median) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 43 |
Arm B (Ibrutinib) | NA |
Arm C (Ibrutinib, Rituximab) | NA |
The Kaplan-Meier method will be used to estimate the rate of progression free survival at 2 years in each treatment arm. Progression is defined as any one of the following: an increase in number of blood lymphocytes by >= 50%, >= 50% increase in the products of at least 2 lymph nodes on 2 consecutive determination 2 weeks apart, >= 50% increase in the size of the liver/spleen, transformation to a more aggressive histology, progression of any cytopenia (i.e. decrease of Hb levels > 2g/dL). Progression free survival time will be the time to either progression or death whichever occurs first. (NCT01886872)
Timeframe: Time from study entry to the time of documented disease progression or death, assessed up to 2 years
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 74 |
Arm B (Ibrutinib) | 87 |
Arm C (Ibrutinib, Rituximab) | 88 |
The rate of grade 3, 4, or 5 treatment-related non-hematologic adverse events (toxicities) by arm; excludes adverse events occurring post-crossover for patients in Arm A (NCT01886872)
Timeframe: Performed at 2.5 years after the last patient enrolled; up to 4 years.
Intervention | percentage of patients (Number) |
---|---|
Arm A (Rituximab, Bendamustine Hydrochloride) | 41 |
Arm B (Ibrutinib) | 48 |
Arm C (Ibrutinib, Rituximab) | 39 |
Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) |
---|---|
Acalabrutinib | 32 |
Ibrutinib | 49 |
Number of participants with treatment-emergent infections Grade >=3 are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) |
---|---|
Acalabrutinib | 98 |
Ibrutinib | 101 |
Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) |
---|---|
Acalabrutinib | 13 |
Ibrutinib | 14 |
The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)
Intervention | Months (Median) |
---|---|
Acalabrutinib | NA |
Ibrutinib | NA |
Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of >= 50% compared with baseline and a postbaseline assessment of > 5000/μL in the peripheral blood are reported. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Percentage of participants (Number) |
---|---|
Acalabrutinib | 72.5 |
Ibrutinib | 74.3 |
The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia [iwCLL] 2008 criteria): Lymphocytes >= 50% increase over baseline, or >= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or >= 50% platelets or > 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Intervention | Months (Median) |
---|---|
Acalabrutinib | 38.4 |
Ibrutinib | 38.4 |
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate). (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abnormal loss of weight | Blood pressure fluctuation | Blood pressure increased | Blood pressure decreased | Blood pressure systolic increased | Body temperature decreased | Body temperature increased | Bradycardia | Breath sounds abnormal | Cardiac murmur | Dyspnoea | Dyspnoea exertional | Heart rate increased | Heart rate irregular | Hypertension | Hypotension | Hyperpyrexia | Orthostatic hypotension | Palpitations | Pyrexia | Tachycardia | Weight decreased | Weight increased | White coat hypertension | |
Acalabrutinib | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 3 | 0 | 1 | 40 | 2 | 0 | 1 | 26 | 15 | 1 | 2 | 12 | 66 | 7 | 29 | 13 | 0 |
Ibrutinib | 1 | 1 | 3 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 27 | 5 | 1 | 0 | 70 | 7 | 0 | 1 | 15 | 55 | 7 | 23 | 10 | 1 |
Number of participants with ECG abnormality at baseline are reported. (NCT02477696)
Timeframe: Baseline (Days -28 to -1)
Intervention | Participants (Count of Participants) | |
---|---|---|
Abnormal, not clinically significant | Abnormal, clinically significant | |
Acalabrutinib | 86 | 4 |
Ibrutinib | 98 | 1 |
The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported. (NCT02477696)
Timeframe: Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Baseline=0; Postbaseline=3 | Baseline=1; Postbaseline=3 | Baseline=2; Postbaseline=3 | Baseline=0; Postbaseline=4 | Baseline=1; Postbaseline=4 | Baseline=2; Postbaseline=4 | |
Acalabrutinib | 0 | 3 | 4 | 0 | 0 | 0 |
Ibrutinib | 1 | 5 | 1 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) | |
---|---|---|
Any TEAEs | Any TESAEs | |
Acalabrutinib | 262 | 161 |
Ibrutinib | 259 | 177 |
Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry. (NCT02477696)
Timeframe: Day 1 through 83.5 months (maximum observed duration)
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Absolute neutrophil count (decreased) | Haemoglobin (decreased) | Platelets (decreased) | Leukocytes (decreased) | Leukocytes (increased) | Absolute lymphocyte count (ALC) (decreased) | ALC (increased) | Alanine aminotransferase (increased) | Albumin (decreased) | Alkaline phosphatase (increased) | Aspartate aminotransferase (increased) | Bilirubin (increased) | Calcium (decreased) | Calcium (increased) | Creatinine (increased) | Glucose (decreased) | Glucose (increased) | Phosphate (decreased) | Potassium (decreased) | Potassium (increased) | Sodium (decreased) | Sodium (increased) | Urate (increased) | |
Acalabrutinib | 124 | 139 | 119 | 60 | 68 | 66 | 71 | 73 | 31 | 66 | 42 | 46 | 56 | 15 | 164 | 5 | 21 | 93 | 27 | 62 | 26 | 70 | 70 |
Ibrutinib | 135 | 131 | 116 | 64 | 84 | 65 | 72 | 70 | 44 | 60 | 58 | 69 | 71 | 11 | 168 | 13 | 23 | 74 | 40 | 52 | 37 | 46 | 96 |
Will be defined as complete response or incomplete blood count recovery. Estimated by the number of patients who achieve an incomplete blood count recovery or complete response divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true complete response rate will be calculated in each arm. (NCT02332980)
Timeframe: 1 year
Intervention | proportion of participants (Number) |
---|---|
Arm A (CLL) | 0.0400 |
Arm B (NHL) | 0 |
Arm C (CLL With Richters) | 0 |
Arm A (Continuation Phase) | 0.4000 |
Arm C (Continuation Phase) | 0 |
Confirmed response rate will be estimated by the number of patients with an objective status of complete response, incomplete blood count recovery, nodular partial response, clinical complete response or partial response while on the combination therapy divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate to the combination will be calculated. In addition, the responders on this study will be further examined in an exploratory manner to determine if there are any patterns in prognostic factors or disease characteristics, including whether the patient had a Richter's transformation or ibrutinib-resistant disease, for both single agent pembrolizumab and combination therapy responders. (NCT02332980)
Timeframe: 1 year
Intervention | proportion of participants (Number) |
---|---|
Arm A (Continuation Phase) | 0.6000 |
Arm C (Continuation Phase) | 0.1538 |
The distribution of duration of response will be estimated using the method of Kaplan-Meier. Duration of response (DR) is defined for all evaluable patients who have achieved a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) as the date at which the patient's objective status is first noted to be a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) to the earliest date relapse is documented. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (CLL) | 6.9 |
Arm A (Continuation Phase) | 5.9 |
Arm C (Continuation Phase) | NA |
Will be measured per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Adverse events will be evaluated for single-agent pembrolizumab in each arm and also for the combination of pembrolizumab and the signal inhibitor in Arm A and Arm C. This outcome is reported in the adverse events section of this report. (NCT02332980)
Timeframe: 1 year
Intervention | Participants (Count of Participants) |
---|---|
Arm A (CLL) | 25 |
Arm B (NHL) | 23 |
Arm C (CLL With Richters) | 17 |
Arm A (Continuation Phase) | 5 |
Arm C (Continuation Phase) | 13 |
The distribution of overall survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (CLL) | 10.6 |
Arm B (NHL) | 48.6 |
Arm C (CLL With Richters) | 11.5 |
Arm A (Continuation Phase) | 11.7 |
Arm C (Continuation Phase) | 13.3 |
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (CLL) | 2.8 |
Arm B (NHL) | 4.2 |
Arm C (CLL With Richters) | 2.2 |
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (Continuation Phase) | 7.6 |
Arm C (Continuation Phase) | 5.4 |
Confirmed response is defined to be a partial response, nodular partial response, clinical complete response, confirmed response with incomplete blood count recovery or confirmed response (Arm A and B), or complete metabolic response, partial metabolic response, partial response, or confirmed response (Arm C). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated. (NCT02332980)
Timeframe: 1 year
Intervention | proportion of responders (Number) |
---|---|
Arm A (CLL) | 0.0800 |
Arm B (NHL) | 0 |
Arm C (CLL With Richters) | 0 |
The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (Continuation Phase) | 7.7 |
Arm C (Continuation Phase) | 3.2 |
The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (CLL) | 3.0 |
Arm B (NHL) | 5.3 |
Arm C (CLL With Richters) | 3.0 |
The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (Continuation Phase) | 7.7 |
Arm C (Continuation Phase) | 3.2 |
The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years
Intervention | Months (Median) |
---|---|
Arm A (CLL) | 2.7 |
Arm B (NHL) | 4.6 |
Arm C (CLL With Richters) | 2.9 |
The DoR is defined as the time from the date of achieving the first CR, CRi, or PR to the date of progressive disease (PD) or death due to any cause, whichever occurred first. The CR, CRi, or PR are defined in the above outcome measure. For CLL/SLL, PD is defined as lympho >=50% increase from baseline with >= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or >= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of >=50% from baseline secondary to CLL or < 100,000/µL and worsening bone marrow or Hb decrease of > 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The DoR was estimated using Kaplan-Meier method. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Months (Median) |
---|---|
Cohort 1 | 33.3 |
Cohort 2a | 26.7 |
Cohort 2b | 77.3 |
Cohort 2c | 43.0 |
Cohort 3 | NA |
Cohort 4a | 64.1 |
Cohort 4b | NA |
Cohort 7 | NA |
Cohort 11 | NA |
Participants with DLTs in Phase 1 are reported. The DLT was defined as any of the following events unless the adverse event is clearly related to disease progression or the participant's current medical history and associated comorbidities: (1) Any Grade 3 or greater nonhematologic toxicity with the exceptions of alopecia and Grade 3 nausea, vomiting, and diarrhea that respond to supportive therapy; (2) Hematologic toxicities including Grade 4 neutropenia lasting more than 5 days, Grade 4 or Grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion, Grade 3 or greater febrile neutropenia (body temperature of 38.5 degrees Celsius or more), or Grade 4 anemia, unexplained by underlying disease; or (3) Dosing delay due to toxicity for > 7 consecutive days. (NCT02029443)
Timeframe: From Day 1 to Day 28 after first dose of study drug
Intervention | Participants (Count of Participants) |
---|---|
Cohort 1 | 0 |
Cohort 2a | 0 |
Cohort 2b | 0 |
Cohort 3 | 0 |
Cohort 4a | 0 |
Cohort 4b | 0 |
For CLL/SLL, OR is defined as complete remission (CR), CR with incomplete marrow recovery (CRi), or partial remission (PR). CR: lymphocytes (lympho) <4×10^9/L, normocellular bone marrow (BM), normal lymph nodes (NLN), liver and spleen (L/S), absolute neutrophil count (ANC) >1.5×10^9/L, platelets >100×10^9/L, hemoglobin (Hb) >11g/dL. Cri: lympho <4×10^9/L, hypocellular BM, NLN, L/S, persistent anemia, hrombocytopenia, or neutropenia. PR: >=50% reduction in lymphadenopathy and/or enlargement of L/S or lympho (<5×10^9/L or >=50% decrease from baseline) and criteria of ANC/platelets/Hb per CR or >=50% improvement over baseline. Hematology result were without exogenous growth factors/transfusion. For RS, OR as CR or PR by Cheson et al. 2014 based on PET/CT scans and bone marrow. CR: disappearance of all detectable clinical evidence of disease and disease-related symptoms and PR: >=50% decrease in sum of the product diameter of 6 largest nodal masses and no new sites of disease. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Percentage of participants (Number) |
---|---|
Cohort 1 | 100.0 |
Cohort 2a | 75 |
Cohort 2b | 92.1 |
Cohort 2c | 93.8 |
Cohort 3 | 100.0 |
Cohort 4a | 100.0 |
Cohort 4b | 100.0 |
Cohort 7 | 97.3 |
Cohort 11 | 100.0 |
The PFS is defined as the time from the date of first dose of study drug to the date of first PD or death due to any cause, whichever occurred first. For CLL/SLL, PD is defined as lympho >= 50 % increase from baseline with >= 5000 B lymphocytes/µL, progressive cytopenias by bone marrow biopsy, appearance of any new lesion or new appearance of hepatomegaly or splenomegaly or >= 50 % increase in lymphadenopathy/hepatomegaly/splenomegaly, platelets decrease of >= 50 % from baseline secondary to CLL or < 100,000/µL and worsening bone marrow or Hb decrease of > 2 g/dL from baseline secondary to CLL or decrease to less than 100 g/L and worsening bone marrow. For RS, PD is defined as an increase by 25 % in longest diameter, new lesion or assessable disease progression. The PFS was estimated using Kaplan-Meier method. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Months (Median) |
---|---|
Cohort 1 | 38.3 |
Cohort 2a | 33.1 |
Cohort 2b | 79.1 |
Cohort 2c | 46.6 |
Cohort 3 | NA |
Cohort 4a | 67.8 |
Cohort 4b | NA |
Cohort 7 | NA |
Cohort 11 | NA |
The CL/F of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | L/hr (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 114 | 176 |
Cohort 10 | 156 | 167 |
Cohort 11 | 137 | 188 |
Cohort 2a | 193 | 216 |
Cohort 2b | 212 | 162 |
Cohort 2c | 112 | 122 |
Cohort 3 | 265 | 131 |
Cohort 4a | 169 | 344 |
Cohort 4b | 108 | 191 |
Cohort 7 | 315 | 389 |
Cohort 8a | 352 | 94.5 |
Cohort 8b | 311 | 336 |
Cohort 9 | 142 | 132 |
The Vz/F of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | L (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 268 | 286 |
Cohort 10 | 235 | 533 |
Cohort 11 | 158 | 234 |
Cohort 2a | 574 | 302 |
Cohort 2b | 450 | 333 |
Cohort 2c | 182 | 165 |
Cohort 3 | 2100 | 172 |
Cohort 4a | 1480 | 739 |
Cohort 4b | 133 | 384 |
Cohort 7 | 930 | 1180 |
Cohort 8a | 2600 | 125 |
Cohort 8b | 422 | 726 |
Cohort 9 | 171 | 179 |
The AUC0-6 of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours postdose on Day 1 and Day 8
Intervention | hr*ng/mL (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 971 | 631 |
Cohort 10 | 1100 | 1250 |
Cohort 11 | 789 | 642 |
Cohort 2a | 1250 | 1180 |
Cohort 2b | 819 | 858 |
Cohort 2c | 2170 | 1660 |
Cohort 3 | 1880 | 1750 |
Cohort 4a | 2960 | 1630 |
Cohort 4b | 1950 | 1690 |
Cohort 7 | 1740 | 1480 |
Cohort 8a | 362 | 2080 |
Cohort 8b | 670 | 834 |
Cohort 9 | 1690 | 1860 |
The AUC0-inf of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | hr*ng/mL (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 1040 | 621 |
Cohort 10 | 1350 | 1580 |
Cohort 11 | 940 | 652 |
Cohort 2a | 1320 | 1200 |
Cohort 2b | 855 | 956 |
Cohort 2c | 2440 | 1990 |
Cohort 3 | 2050 | 2360 |
Cohort 4a | 3250 | 1750 |
Cohort 4b | 1970 | 1780 |
Cohort 7 | 1910 | 1540 |
Cohort 8a | 574 | 2120 |
Cohort 8b | 801 | 963 |
Cohort 9 | 1770 | 1750 |
The AUC0-last of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | hr*ng/mL (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 1030 | 729 |
Cohort 10 | 1100 | 1260 |
Cohort 11 | 850 | 660 |
Cohort 2a | 1270 | 1180 |
Cohort 2b | 795 | 850 |
Cohort 2c | 2280 | 1850 |
Cohort 3 | 2030 | 2020 |
Cohort 4a | 3430 | 1750 |
Cohort 4b | 1950 | 1560 |
Cohort 7 | 1790 | 1400 |
Cohort 8a | 539 | 1180 |
Cohort 8b | 570 | 748 |
Cohort 9 | 1860 | 1710 |
The Cmax of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | ng/mL (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 685 | 521 |
Cohort 10 | 727 | 610 |
Cohort 11 | 930 | 633 |
Cohort 2a | 754 | 805 |
Cohort 2b | 706 | 812 |
Cohort 2c | 1950 | 1350 |
Cohort 3 | 1350 | 1350 |
Cohort 4a | 1550 | 902 |
Cohort 4b | 1600 | 1320 |
Cohort 7 | 1390 | 1020 |
Cohort 8a | 206 | 939 |
Cohort 8b | 554 | 616 |
Cohort 9 | 1190 | 1460 |
Participants with clinically abnormal vital signs (blood pressure, respiratory rate, pulse rate, or body temperature) reported as TEAEs are reported. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Participants (Count of Participants) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tachycardia | Bradycardia | Pyrexia | Hyperpyrexia | Hypothermia | Procedural hypotension | Blood pressure increased | Dyspnoea | Dyspnoea exertional | Hypertension | Hypotension | Orthostatic hypotension | Essential hypertension | Hypertensive crisis | Malignant hypertension | Palpitations | |
Ibrutinib Relapsed/Refractory Cohort | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Ibrutinib-intolerant Cohort | 2 | 0 | 10 | 0 | 0 | 0 | 0 | 6 | 1 | 6 | 5 | 1 | 1 | 0 | 0 | 0 |
Relapsed/Refractory Cohort | 3 | 6 | 39 | 0 | 0 | 0 | 0 | 27 | 5 | 30 | 7 | 0 | 0 | 1 | 0 | 13 |
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | 3 | 0 | 6 | 1 | 0 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
Treatment-naive Cohort | 8 | 1 | 14 | 0 | 1 | 1 | 1 | 18 | 5 | 28 | 12 | 5 | 0 | 0 | 0 | 4 |
Participants with clinically important laboratory abnormalities with CTCAE Grade 3 or more are reported. Laboratory analysis included hematology, clinical chemistry, amylase, lipase, cardiac troponin I, hepatitis B and C testing, and urinalysis. The CTCAE version 4.03 is a descriptive terminology is used for AE reporting. The CTCAE v4.03 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 3 as severe AE, Grade 4 as life-threatening or disabling AE, and Grade 5 as death related to AE. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hemoglobin, platelets or neutrophils decreased | Absolute neutrophil count (decreased) | Hemoglobin (decreased) | Platelets (decreased) | Leukocytes (decreased) | Leukocytes (increased) | Absolute lymphocyte count (decreased) | Absolute lymphocyte count (increased) | Urate (increased) | Sodium (decreased) | Phosphate (decreased) | Potassium (increased) | Glucose (increased) | Alanine aminotransferase (increased) | Calcium (increased) | Aspartate aminotransferase (increased) | Magnesium (increased) | Potassium (decreased) | Albumin (decreased) | Calcium (decreased) | Alkaline phosphatase (increased) | Amylase (increased) | Bilirubin (increased) | Creatinine (increased) | Lipase (increased) | |
Ibrutinib Relapsed/Refractory Cohort | 4 | 3 | 3 | 1 | 0 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ibrutinib-intolerant Cohort | 14 | 11 | 3 | 4 | 3 | 7 | 2 | 7 | 8 | 2 | 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Relapsed/Refractory Cohort | 72 | 57 | 17 | 20 | 12 | 29 | 20 | 29 | 24 | 12 | 9 | 3 | 3 | 3 | 5 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | 19 | 13 | 8 | 5 | 6 | 0 | 6 | 3 | 5 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Treatment-naive Cohort | 30 | 23 | 5 | 3 | 2 | 21 | 7 | 8 | 15 | 5 | 1 | 5 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Participants (Count of Participants) | |
---|---|---|
Any TEAEs | Any TESAEs | |
Ibrutinib Relapsed/Refractory Cohort | 6 | 3 |
Ibrutinib-intolerant Cohort | 33 | 20 |
Relapsed/Refractory Cohort | 134 | 86 |
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | 28 | 18 |
Treatment-naive Cohort | 99 | 50 |
The treatment emergent ECI included the events identified based on preclinical findings, emerging data from clinical studies relating to acalabrutinib, and pharmacological effects of approved Bruton's tyrosine kinase (BTK) inhibitors and reported after the first dose of the study drug. (NCT02029443)
Timeframe: Day 1 through the final data cutoff date (approximately 7 years 6 months)
Intervention | Participants (Count of Participants) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | Ventricular tachyarrhythmias | Anemia | Neutropenia | Other Leukopenia | Thrombocytopenia | Major hemorrhage | Hepatotoxicity | Hypertension | Infections | Interstitial lung disease/Pneumonitis | Second primary malignancies, excluding non-melanoma skin | Tumor lysis syndrome | |
Ibrutinib Relapsed/Refractory Cohort | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 | 0 |
Ibrutinib-intolerant Cohort | 4 | 0 | 4 | 5 | 1 | 4 | 4 | 1 | 7 | 25 | 0 | 3 | 0 |
Relapsed/Refractory Cohort | 12 | 2 | 22 | 26 | 2 | 10 | 11 | 4 | 31 | 118 | 1 | 23 | 1 |
Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort | 3 | 0 | 10 | 13 | 0 | 4 | 0 | 3 | 2 | 18 | 0 | 1 | 0 |
Treatment-naive Cohort | 6 | 0 | 10 | 9 | 1 | 1 | 8 | 4 | 29 | 86 | 3 | 14 | 0 |
The t1/2 of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | Hours (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 1.48 | 1.09 |
Cohort 10 | 1.01 | 1.67 |
Cohort 11 | 0.781 | 0.811 |
Cohort 2a | 1.44 | 0.942 |
Cohort 2b | 0.914 | 0.995 |
Cohort 2c | 0.993 | 0.902 |
Cohort 3 | 2.89 | 0.886 |
Cohort 4a | 3.52 | 1.38 |
Cohort 4b | 0.869 | 1.13 |
Cohort 7 | 1.41 | 1.02 |
Cohort 8a | 4.83 | 0.914 |
Cohort 8b | 0.900 | 1.25 |
Cohort 9 | 0.798 | 0.867 |
The λz of acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | 1/hr (Mean) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 0.679 | 0.655 |
Cohort 10 | 0.706 | 0.603 |
Cohort 11 | 0.916 | 0.894 |
Cohort 2a | 0.750 | 0.744 |
Cohort 2b | 0.848 | 0.793 |
Cohort 2c | 0.755 | 0.798 |
Cohort 3 | 0.502 | 0.797 |
Cohort 4a | 0.557 | 0.578 |
Cohort 4b | 0.804 | 0.679 |
Cohort 7 | 0.756 | 0.745 |
Cohort 8a | 0.373 | 0.758 |
Cohort 8b | 0.784 | 0.623 |
Cohort 9 | 0.880 | 0.857 |
The Tmax of Acalabrutinib is reported. (NCT02029443)
Timeframe: Predose and at 0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 hours postdose on Day 1 and Day 8
Intervention | Hours (Median) | |
---|---|---|
Day 1 | Day 8 | |
Cohort 1 | 1.01 | 1.05 |
Cohort 10 | 1.00 | 1.58 |
Cohort 11 | 0.642 | 0.533 |
Cohort 2a | 0.917 | 0.517 |
Cohort 2b | 0.750 | 0.750 |
Cohort 2c | 1.00 | 1.03 |
Cohort 3 | 1.00 | 1.00 |
Cohort 4a | 1.00 | 0.700 |
Cohort 4b | 0.758 | 0.758 |
Cohort 7 | 0.783 | 0.750 |
Cohort 8a | 1.30 | 1.49 |
Cohort 8b | 0.783 | 0.908 |
Cohort 9 | 0.992 | 1.00 |
Cancer-Specific Stress was measured by the Impact of Event Scale-Revised Participants rated the intensity of these feelings using a five-point Likert scale ranging from 0=not at all to 4=extremely. Patients rated the frequency of their feelings or events for the previous week before treatment. The items were summed for a total score that ranged from 0 to 64 (NCT01589302)
Timeframe: Up to 2 years
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 9.18 |
The Beck Depression Inventory-2nd edition is a 21-item measure of depressive symptoms. Scores were calculated representing the cognitive-affective and the somatic symptoms associated with depression (e.g. sadness, pessimism, loss of pleasure) during past month on scale from 0 to 3. Items were summed, with higher scores indicating more depressive symptoms. The scores on the scale from range from 0 to 42. (NCT01589302)
Timeframe: at 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 1.88 |
The number of participants with successful Allogenic Stem Cell Transplant (NCT01589302)
Timeframe: Up to 2 years
Intervention | participants (Number) |
---|---|
Treatment (Ibrutinib) | 1 |
The Fatigue Interference quality of life measures is a 11-item self reported questionnaire used to measure frequency, severity and daily pattern of fatigue Symptoms as well as impact of QOL in the past week. The Total Disruption Index (TDI) an 7 item subset of FSI was used. Items were rated on a 11-point Likert scale from 0=no interference to 10=extreme interference. Total scores could range from 0 to 70, with higher scores indicating greater fatigue interference. (NCT01589302)
Timeframe: at 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 9.70 |
SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: at 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 53.98 |
The Profile of Mood States-Short Form (POMS-SF) yields six subscales, Tension, Depression, Anger, Vigor, Fatigue, and Confusion. A total mood disturbance score is found by summing the six subscales. Total Mood Disturbance (TMD) scores range from -24 to 124 with higher scores indicating greater mood disturbance. (NCT01589302)
Timeframe: at 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 0.89 |
Physical Health Quality of life measures were administered during screening and on Days 1 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru Cycle 24 and at time of progression and /or end of treatment. SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: up to 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 44.23 |
Percentage of patients with BTK C481S mutation or PLCG2 mutation (NCT01589302)
Timeframe: Up to 4 years
Intervention | percentage of patients (Number) |
---|---|
Treatment (Ibrutinib) | 13.2 |
Sleep problems quality of life measures is a six-item sleep problems index I of the Medical Outcomes Study-Sleep Scale used to assess sleep problems. Participants reported how often they experience six specific difficulties with sleep on a 6-point Likert scale (1=All of the time to 6=None of the time). Scores transformed into a 0-100 scale with higher scores indicating greater sleep problems. (NCT01589302)
Timeframe: at 5 months
Intervention | units on a scale (Mean) |
---|---|
Treatment (Ibrutinib) | 24.08 |
Time from date of first treatment with ibrutinib until the date of progression or death from any cause. Those alive and progression free are censored at the date of last clinical assessment. (NCT01589302)
Timeframe: 2 years
Intervention | percent of patients (Number) | ||
---|---|---|---|
All patients | Del(17p) | non-Del(17p) | |
Treatment (Ibrutinib) | 69 | 66 | 72 |
Responders were subjects who achieved a complete response (CR), partial response (PR) or PR with persistent lymphocytosis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01589302)
Timeframe: up to 2 years
Intervention | percentage of patients (Number) | ||
---|---|---|---|
All patients | Del(17p) | non-Del(17p) | |
Treatment (Ibrutinib) | 63 | 66 | 59 |
We will summarize our findings for this endpoint independently as well within each cohort (del17p vs other cytogenetic groups). We will evaluate the proportion of patients who are progression-free and alive at two years or have gone on to transplant (treatment successes) over the total number of evaluable patients; eligible patients who received at least one dose of therapy are considered evaluable. Assuming that the number of treatment successes as defined above is binomially distributed, we will also include 95% binomial confidence intervals for the estimates corresponding to each cohort. (NCT01589302)
Timeframe: up to 2 years
Intervention | percentage of patients (Number) | ||
---|---|---|---|
All patients | Del(17p) | non-Del(17p) | |
Treatment (Ibrutinib) | 64 | 64 | 64 |
The 6 month overall response rates overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT01589302)
Timeframe: Up to 6 months
Intervention | patients (Number) | ||
---|---|---|---|
All patients | Del(17p) | Non-del(17p) | |
Treatment (Ibrutinib) | 63 | 66 | 59 |
Adverse events grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with the attribution of either definite, possible or probable related. (NCT01589302)
Timeframe: Up to 2 years post treatment
Intervention | patients (Number) | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anemia | Febrible Neutropenia | Leukocytosis | Atrial Fibrillation | Diarrhea | Gastric Hemorrhage | Gastrointestinal Disorders-other | Mucositis Oral | Nausea | Death | Edema Limb | Fatigue | General Disorders and Admin Site Conditions | Cholecystitis | Bronchial Infection | Infections and Infestations-other | Lung Infection | Otitis Media | Sepsis | Skin Infection | Urinary Tract Infection | Alanine Aminotransferase Increased | Blood Bilirubin Increased | Lymphocyte Count Decreased | Lymphocyte Count Increased | Neutrophil Count Decreased | Platelet Count Decreased | White Blood Cell Decreased | Hyperuricemia | Hypophosphatemia | Arthralgia | Arthritis | Hematuria | Hypoxia | Respiratory Failure | Rash Maculo-papular | Hematoma | Hypertension | |
Treatment (Ibrutinib) | 13 | 2 | 18 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 10 | 1 | 2 | 2 | 1 | 1 | 1 | 14 | 54 | 40 | 8 | 10 | 4 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 7 |
Time from date of first treatment with ibrutinib until the date of death from any cause or the date of last contact for those alive. (NCT01589302)
Timeframe: 2 years
Intervention | percent of patients (Number) | ||
---|---|---|---|
All patients | Del(17p) | non-Del(17p) | |
Treatment (Ibrutinib) | 78 | 75 | 81 |
"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
Intervention | score on a scale (Mean) |
---|---|
MMT-8 Score at 3 Months | 143.3 |
MMT-8 Score at 6 Months | 144.5 |
"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
Intervention | score on a scale (Mean) |
---|---|
DLQI Score at 3 Months | 6.3 |
DLQI Score at 6 Months | 4.2 |
"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months
Intervention | score on a scale (Mean) |
---|---|
CDASI Score at 3 Months | 16.9 |
CDASI Score at 6 Months | 14 |
"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Participants (Count of Participants) |
---|---|
Dermatomyositis Patients With Refractory Cutaneous Disease | 7 |
"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Headache Grade 1-2 | Nausea Grade 1-2 | Diarrhea Grade 1-2 | Herpes Zoster Grade 1-2 | Influenza Grade 1-2 | Pneumonia Grade 1-2 | Acute sinusitis Grade 1-2 | Hypertension Grade 1-2 | Ocular pressure Grade 1-2 | |
Dermatomyositis Patients With Refractory Cutaneous Disease | 7 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 1 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Change (Number) | |
---|---|---|
Down regulated genes | Up regulated genes | |
Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling | 123 | 72 |
Skin Biopsy at Baseline for Gene Expression Profiling | 0 | 0 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Percentage of positive cell detection (Mean) | |
---|---|---|
STAT1 | STAT3 | |
Skin Biopsy at 3 Months Into Apremilast Therapy for IHC | 50.1 | 17.4 |
Skin Biopsy at Baseline for IHC | 96.2 | 44.3 |
DOR is defined as the number of days from the date of first response (complete response [CR], complete response with incomplete marrow recovery [CRi], nodular partial remission [nPR], or partial remission [PR]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Intervention | months (Median) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 35.1 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 55.4 |
Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Intervention | percentage of participants (Number) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 64.8 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 69.4 |
OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Intervention | months (Median) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 69.6 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | NA |
PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology. (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Intervention | months (Median) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 24.7 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 43.4 |
TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology. (NCT02141282)
Timeframe: Collected every 3 months for a period of 5 years after the last participant had enrolled into the study
Intervention | months (Median) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 24.0 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 37.8 |
"TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD).~TTP was analyzed by Kaplan-Meier (K-M) methodology." (NCT02141282)
Timeframe: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Intervention | months (Median) |
---|---|
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 36.1 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 43.4 |
The rate of MRD response is defined as the percentage of participants who had MRD negative status. (NCT02141282)
Timeframe: Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported
Intervention | percentage of participants (Number) | |
---|---|---|
Peripheral blood | Bone marrow | |
ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 30.8 | 6.6 |
ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 25.0 | 11.1 |
BTK occupancy level measured by fluorescent affinity probe just before dosing and at 4 and 24 hours post-dosing on days 1, 8, and 28 (but before the first dose of the next cycle) of each cycle. (NCT02801578)
Timeframe: 3 cycles, up to 90 days
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib | 8 |
To assess the safety of TGR1202 in combination with ibrutinib relapsed or refractory CLL or MCL. DLT is based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. DLT refers to toxicities experienced at any time during the study treatment, defined as Grade 4 anemia; Grade 4 neutropenia lasting >7 days (while receiving growth factor support); Grade 4 thrombocytopenia lasting > 7 days; Grade ≥3 febrile neutropenia; and Grade ≥3 thrombocytopenia with Grade >2 hemorrhage;Grade ≥ 3 non-hematologic toxicity unresponsive to standard supportive care measure with the exception of asymptomatic Grade ≥3 lab abnormalities that resolve to ≤ Grade 1 or baseline within 7 days;treatment delay of ≥14 days due to unresolved toxicity; and non-hematologic toxicity of Grade 2 (at any time during treatment) that, in the judgment of the Investigators, Study Chair, and the Medical Monitor, is dose-limiting. (NCT02268851)
Timeframe: Participants were assessed every week or more often as needed during Cycle 1 or more often for up to 28 days to assess Dose-limiting toxicities (DLTs) during Phase I
Intervention | Participants (Count of Participants) |
---|---|
CLL: Phase I Cohort 1 | 0 |
MCL: Phase 1 Cohort 1 | 0 |
CLL: Phase I Cohort 2 | 0 |
MCL: Phase I Cohort 2 | 0 |
CLL Phase I/IICohort 3 (RPD2) | 0 |
MCL Phase I/II Cohort 3 (RPD2) | 0 |
DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (>=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Months (Median) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 11.5 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 19.2 |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 10.2 |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 6.9 |
Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years and 11 months
Intervention | Months (Median) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 24.8 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 20.8 |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 17.38 |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 14.55 |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 14.1 |
ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/L, platelets >100*10^9/L, Hgb >11 g/dL and absolute lymphocyte count <4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- >=50% drop in lymphocyte count from baseline or <=4.0*10^9/L with following: >=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, >=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils >1.5*10^9/L, Platelets>100000/mcL and Hgb>11 g/dL or >=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL) | 63.3 |
ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) >= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib and Nivolumab: Small Lymphocytic Lymphoma (SLL) | 50.0 |
Ibrutinib and Nivolumab: Follicular Lymphoma (FL) | 32.5 |
Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL) | 37.8 |
Ibrutinib and Nivolumab: Richter | 65.0 |
OS was defined as duration from the date of first dose of study drug to the date of the participant's death. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Months (Median) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 12.4 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | NA |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | NA |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 19.0 |
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 10.3 |
Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Percentage of Participants (Number) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 14.3 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 42.9 |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 74.3 |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 25.7 |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 54.1 |
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 60.0 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent. (NCT02329847)
Timeframe: Up to 6 years 10 months
Intervention | Percentage of Participants (Number) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 100 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 100 |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 100 |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 100 |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 97.3 |
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 95.0 |
PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months
Intervention | Months (Median) |
---|---|
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 2.0 |
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 9.1 |
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 21.6 |
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 7.6 |
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 3.2 |
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 5.0 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib Plus Rituximab | 0 |
Over all Response = complete remission (CR) + partial remission (PR). Complete remission (CR), requiring absence of peripheral blood clonal lymphocytes by immunophenotyping, absence of lymphadenopathy, absence of hepatomegaly or splenomegaly, absence of constitutional symptoms and satisfactory blood counts; positive or negative minimal residual disease (MRD); Partial remission (PR), defined as ≥ 50% fall in lymphocyte count, ≥ 50% reduction in lymphadenopathy or ≥ 50% reduction in liver or spleen, together with improvement in peripheral blood counts (NCT01520519)
Timeframe: 7 months
Intervention | Participants (Count of Participants) |
---|---|
Rituximab + PCI-32765 | 37 |
Progression free survival defined as the time interval from treatment to progressive disease or death, whichever happens earlier. Participants in complete remission (CR), partial remission (PR) or stable disease (SD) are all counted as progression-free. Survival or times to progression functions estimated using the Kaplan-Meier method. (NCT01520519)
Timeframe: up to 50 months
Intervention | Months (Median) |
---|---|
Rituximab + PCI-32765 | 45 |
Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change. (NCT01236391)
Timeframe: From Baseline to Cycle 5 (Week 20)
Intervention | scores on a scale (Mean) |
---|---|
EORTC QLQ-C30 | 0.6 |
Number of participants who had experienced at least one treatment emergent AE (NCT01236391)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
Intervention | participants (Number) |
---|---|
PCI-32765 | 111 |
Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h) (NCT01236391)
Timeframe: Performed During the First Month of Receiving PCI-32765
Intervention | AUC0-24h (ng*h/mL) (Mean) |
---|---|
PCI-32765 - Day 8 | 953 |
PCI-45227 (Metabolite)- Day 8 | 1263 |
The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a >/= 50% decrease in the sum of the product of diameters of the target lesions, and >/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions. (NCT01236391)
Timeframe: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months
Intervention | percentage of participants with response (Number) |
---|---|
PCI-32765 | 67.6 |
(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 53.3 |
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 33.3 |
(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 0 |
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 0 |
(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 66.7 |
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 0 |
(NCT01292135)
Timeframe: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 20 |
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 33.3 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits. (NCT01292135)
Timeframe: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 93.3 |
PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 100 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01292135)
Timeframe: From first dose of any study medication to 12 months after first dose to progressive disease or death or the last clinical assessment before receiving new anticancer therapy or loss to follow-up, whichever occured the earliest.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 85.9 |
PCI- 32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) | 100 |
(NCT01292135)
Timeframe: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Intervention | Percentage of Participants (Number) |
---|---|
PCI-32765 Plus Bendamustine/Rituximab (BR) | 76.2 |
Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure
Intervention | participants (Number) |
---|---|
Group 1 | 27 |
Group 2 | 20 |
Group 3 | 24 |
The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months
Intervention | percentage of participants (Number) |
---|---|
Group 1 | 92.6 |
Group 2 | 80.0 |
Group 3 | 70.8 |
"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months
Intervention | percentage of event free participants (Mean) |
---|---|
Group 1 | 88.7 |
Group 2 | 85.0 |
Group 3 | 75.0 |
Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2
Intervention | participants who experienced DLT (Number) |
---|---|
Group 1 | 0 |
Group 2 | 0 |
Number of participants who had experienced at least one treatment emergent AE (NCT01744691)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
Intervention | participants (Number) |
---|---|
PCI-32765 | 144 |
The primary objective of this study is to evaluate the efficacy of ibrutinib in terms of ORR according to an Independent Review Committee (IRC). ORR based upon IRC assessment is the proportion of responders in the all treated population. Responders were subjects who achieved partial response (PR) or better, ie, complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR, per IWCLL 2008 criteria with the clarification for treatment-related lymphocytosis. (NCT01744691)
Timeframe: The median time on study for all treated participants is 33.3 (range 0.5 - 40.1) months
Intervention | % of participants with response by PI (Number) |
---|---|
Ibrutinib | 77.8 |
Stable isotopic labeling with deuterated water (2^H2O) to measure directly the effects of PCI-32765 (ibrutinib) on leukemia cell death in the peripheral blood of participants . (NCT01752426)
Timeframe: every three months, up to one year
Intervention | percentage of cell death (Median) | |
---|---|---|
Daily death rate of blood cells before therapy | Daily death rate of blood cells after therapy | |
Heavy Water + PCI-32765 | 0.18 | 1.5 |
Measurement of the fraction of recently born versus older leukemia cells in the peripheral blood of participants before and during PCI-32765 therapy, to determine the effects of PCI-32765 (ibrutinib) therapy on the birth rates of the leukemia cells. (NCT01752426)
Timeframe: every three months, up to one year
Intervention | percentage of leukemia cells (Median) | |
---|---|---|
Daily cell birth rate before therapy | Daily cell birth rate during therapy | |
Heavy Water + PCI-32765 | 0.39 | 0.05 |
150 reviews available for adenine and B-Cell Chronic Lymphocytic Leukemia
Article | Year |
---|---|
[Chimeric antigen receptor T cells].
Topics: Adenine; Antibodies, Bispecific; Antigens, CD19; Antigens, Neoplasm; Cell Engineering; Clinical Tria | 2021 |
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical | 2022 |
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Hypertension; Leukemia, Lympho | 2022 |
Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
Topics: Adenine; CD79 Antigens; Central Nervous System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymp | 2022 |
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; T-Lymp | 2022 |
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cardiotoxicity; Humans; Leukemia, Lymphocytic, Chronic | 2022 |
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis | 2023 |
Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 2023 |
Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans | 2019 |
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Topics: Abdominal Pain; Adenine; Constipation; Diarrhea; Female; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2019 |
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Ibrutinib in CLL/SLL: From bench to bedside (Review).
Topics: Adenine; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidine | 2019 |
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Invasive Fungal Infections; Leukemia, Lymphocy | 2020 |
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2020 |
Clonal dynamics in chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Epigenesis, Genetic; Gene Expression Regulation, L | 2019 |
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplasti | 2019 |
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Immunotherapy; Leukemia, Lymphocytic, | 2019 |
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2020 |
An oral drug for chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Atrial Fibrillation; Hemorrhage; Humans; Hyper | 2020 |
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 2020 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compou | 2020 |
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi | 2020 |
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2020 |
Ibrutinib dose modifications in the management of CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biotransformation; Clinical Stu | 2020 |
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Er | 2020 |
Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Biomarkers, Tumor; Drug Resistance, Neo | 2020 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Decision-Making; Clinical | 2020 |
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2020 |
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2020 |
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2021 |
Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2021 |
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a | 2021 |
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Genomics of Resistance to Targeted Therapies.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Genomics; Humans; Leuke | 2021 |
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt | 2021 |
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Com | 2021 |
Targeting Bruton's Tyrosine Kinase in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Le | 2021 |
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Le | 2021 |
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leu | 2021 |
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Topics: Adenine; Aged; COVID-19; Disease Management; Drug Interactions; Drug-Related Side Effects and Advers | 2021 |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; D | 2017 |
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Interactions; Food-Dru | 2017 |
Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2017 |
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoi | 2017 |
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, | 2017 |
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug Discovery; Graft vs Host Dis | 2017 |
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Allografts; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Huma | 2018 |
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2017 |
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Humans; Leukemia, Lymp | 2017 |
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Clinical Trials as Topic; Disea | 2018 |
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidi | 2018 |
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Intera | 2017 |
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2017 |
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anticoagulants; Antineoplastic Agents; Atrial Fibrilla | 2018 |
Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocy | 2018 |
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Trials as Topic; Disease P | 2018 |
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2018 |
How should we sequence and combine novel therapies in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicycl | 2017 |
How I treat CLL patients with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Autoimmunity; Communicable Diseases; Disease | 2018 |
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus, | 2018 |
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Drug Resistance, Neoplasm; Humans; Leukemia, | 2018 |
Optimal management of the young patient CLL patient.
Topics: Adenine; Age Factors; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunotherapy; Leuke | 2018 |
Chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di | 2018 |
Frontline Therapy of CLL: Evolving Treatment Paradigm.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Immunoglobulin Heavy Chains; Immu | 2018 |
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Autoimmunity; B-Lympho | 2018 |
Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
Topics: Adenine; Aged; Antineoplastic Agents; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, | 2018 |
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi | 2019 |
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Adenine; Administration, Topical; Aged; Anterior Chamber; Antihypertensive Agents; Antineoplastic Ag | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Delet | 2018 |
Relapsed CLL: sequencing, combinations, and novel agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cl | 2018 |
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Anti-Infective Agents; Anticoagulants; Arthralgia; Atrial Fibrillation; Drug Resistan | 2019 |
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Topics: Adenine; Atrial Fibrillation; Databases, Factual; Humans; Hypertension; Leukemia, Lymphocytic, Chron | 2019 |
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cel | 2019 |
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
Topics: Adenine; B-Lymphocytes; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Pip | 2019 |
Targeting BTK in CLL: Beyond Ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr | 2019 |
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Hematology; Humans; Infection Control; Infe | 2019 |
Ibrutinib induced acute tubular injury: A case series and review of the literature.
Topics: Acute Kidney Injury; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pip | 2019 |
Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Bone Marrow; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperid | 2019 |
Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp | 2020 |
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cellulitis; Ecthyma; Humans; Leukemia, Lymphocyt | 2020 |
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.
Topics: Adenine; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, | 2019 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; B-Lymphocytes; Drug Eval | 2013 |
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic, | 2014 |
[Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Topics: Adenine; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Ce | 2013 |
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; B-Lymphocytes; Clinical T | 2013 |
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Topics: Adenine; Animals; Disease Management; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non- | 2014 |
Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia | 2013 |
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 2014 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclo | 2014 |
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chron | 2014 |
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Topics: Adenine; Animals; Clinical Trials as Topic; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Ant | 2014 |
Update on ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2013 |
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine- | 2014 |
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lympho | 2014 |
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Humans; Leukemia, Lymphocytic, | 2015 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2014 |
[Targeted treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leu | 2014 |
Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; | 2014 |
Ibrutinib: a paradigm shift in management of CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2014 |
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human | 2016 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicycl | 2015 |
Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.
Topics: Adenine; Allografts; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemi | 2015 |
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To | 2015 |
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Ch | 2015 |
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2015 |
Why patients prescribed oral agents for cancer need training: a case study.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Caregivers; Dose-Response Relationship, Drug; | 2015 |
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD20; Ant | 2015 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho | 2015 |
[Ibrutinib: A new drug of B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53 | 2015 |
Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Cost-Benefit Analysis; Creatin | 2015 |
Ibrutinib in B lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top | 2015 |
Ibrutinib: from bench side to clinical implications.
Topics: Adenine; Antineoplastic Agents; Biomedical Research; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2015 |
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph | 2015 |
The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular T | 2015 |
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Ant | 2015 |
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal; Antibodies, Monoclona | 2015 |
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemi | 2015 |
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Drug Resistance, | 2016 |
Ibrutinib for treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Clinical Trials as Topic; Humans; Leukemia, Lymphocyti | 2016 |
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2016 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Com | 2016 |
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocyti | 2017 |
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2016 |
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2016 |
Second-generation inhibitors of Bruton tyrosine kinase.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazo | 2016 |
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Ta | 2016 |
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Proliferation; Dose-Respon | 2017 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2016 |
The 21st century revolution in CLL: Why this matters to patients.
Topics: Adenine; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 2016 |
B cell receptor inhibition as a target for CLL therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Age Factors; Atrial Fibrillation; Diarrhea; Hemorrhage | 2016 |
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Topics: Adenine; Allografts; Antibodies, Monoclonal; Antibodies, Neoplasm; Bridged Bicyclo Compounds, Hetero | 2016 |
[Primary lymphoma of the skull: Case report and literature review].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Craniotomy; Fema | 2016 |
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Humans; L | 2017 |
Front-line treatment of CLL in the era of novel agents.
Topics: Adenine; Aged; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2017 |
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocyt | 2017 |
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Novel agents versus chemotherapy as frontline treatment of CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Hum | 2017 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans | 2017 |
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morp | 2012 |
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Drug De | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Morphol | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship | 2012 |
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Human | 2013 |
136 trials available for adenine and B-Cell Chronic Lymphocytic Leukemia
Article | Year |
---|---|
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Human | 2021 |
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Het | 2021 |
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Humans; K | 2022 |
Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Topics: Adenine; Aged; Female; Humans; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle A | 2021 |
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Topics: Adenine; Antibodies, Viral; BNT162 Vaccine; COVID-19; Female; Hematopoietic Stem Cell Transplantatio | 2021 |
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chron | 2022 |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb | 2022 |
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2022 |
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; M | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine | 2022 |
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Topics: Adenine; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine | 2022 |
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Huma | 2022 |
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, | 2022 |
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2022 |
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Heterocyclic Compou | 2022 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphoc | 2019 |
A cross-trial comparison of single-agent ibrutinib
Topics: Adenine; Antibodies, Monoclonal, Humanized; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B- | 2020 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Topics: Adenine; Aged; Aged, 80 and over; Chlorambucil; Disease-Free Survival; Drug Administration Schedule; | 2020 |
Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Aged; Asian People; Female; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi | 2019 |
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Male; Middle Age | 2020 |
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamus | 2021 |
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chronic Disease; Clinical Trials, Phase III as Topic; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Be | 2020 |
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Gene Expression | 2020 |
Ibrutinib for Chronic Lymphocytic Leukemia with
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Follow- | 2020 |
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemi | 2020 |
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2020 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survi | 2020 |
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2020 |
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace | 2020 |
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2021 |
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL)
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cr | 2020 |
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Com | 2021 |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cardio | 2021 |
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunophenotyping; Leukemia | 2021 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Topics: Adenine; Administration, Intravenous; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Age | 2021 |
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoimmune | 2021 |
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemot | 2021 |
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inh | 2021 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2021 |
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; H | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, | 2021 |
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease-Free Survival; Dose-Res | 2017 |
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Female; Guideline Adherence; Hemorrhage; Human | 2017 |
BTK
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2017 |
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cell Transformation, Neoplastic | 2017 |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2018 |
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Alemtuzumab; Antineoplastic Combined Chemotherap | 2018 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be | 2017 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be | 2017 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be | 2017 |
Ibrutinib treatment improves T cell number and function in CLL patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Be | 2017 |
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
Topics: Adenine; Adult; Aged; Alemtuzumab; Allografts; Antineoplastic Agents, Immunological; Combined Modali | 2017 |
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Disease-Free Survival; Female; | 2017 |
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chem | 2017 |
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2018 |
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine | 2017 |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl | 2018 |
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Topics: Adenine; Adult; Animals; beta-Arrestins; Case-Control Studies; Cells, Cultured; Endosomes; Germ-Line | 2018 |
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2018 |
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Topics: Adenine; Aspergillosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; P | 2018 |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L | 2018 |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L | 2018 |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L | 2018 |
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; L | 2018 |
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2018 |
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2018 |
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2018 |
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2018 |
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; | 2018 |
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Topics: Adenine; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoieti | 2019 |
Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; B-Cell Activating Factor; Biomarkers, Tumor; Cell Proliferation; Female; Humans; Immu | 2018 |
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Topics: Adenine; Adult; Aftercare; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 17 | 2018 |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2018 |
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2018 |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Hum | 2018 |
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Dose-Response Relationship, Drug; Female; Humans | 2018 |
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers; Follow-Up Studies; Humans; Leukemia, Lymph | 2019 |
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Drug Therapy, Combination; Female; Fol | 2018 |
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Ch | 2019 |
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2019 |
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Heterocycl | 2019 |
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Topics: Adenine; Asian People; Female; Follow-Up Studies; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-C | 2019 |
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic | 2019 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dose-Response Relationship, Drug; Fema | 2019 |
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Topics: Adenine; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocyti | 2019 |
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Cell Proliferation; Cytidine Deaminase; Down-Re | 2019 |
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal | 2019 |
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal | 2019 |
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal | 2019 |
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Femal | 2019 |
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemo | 2019 |
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
Topics: Adenine; Aged; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pipe | 2019 |
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2019 |
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Topics: Adenine; Autoimmune Diseases; Disease-Free Survival; Female; Hematologic Diseases; Humans; Leukemia, | 2019 |
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
Topics: Adenine; Adolescent; Adult; Child; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocy | 2019 |
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2019 |
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzam | 2019 |
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cl | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati | 2019 |
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2019 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr | 2019 |
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Imm | 2019 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2013 |
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Coculture Techni | 2014 |
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym | 2014 |
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym | 2014 |
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym | 2014 |
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym | 2014 |
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Topics: Adenine; Aged; Bone Marrow; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymp | 2014 |
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
Topics: Adenine; Aged; Blood Viscosity; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2014 |
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lym | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Anti | 2015 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Topics: Adenine; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2015 |
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; B-Lymp | 2014 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cross-Over Stud | 2015 |
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Cohort Studies; Female | 2015 |
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antib | 2015 |
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Double-Blind Me | 2015 |
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Bone Marrow; F | 2015 |
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Factor VIII; Female; Follow-Up Studies; Hemorrhage; Humans; | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr | 2016 |
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Topics: Adenine; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Marrow; Cell Communication; C | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Topics: Adenine; Administration, Oral; Aged; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cy | 2016 |
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Female | 2016 |
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Anemia; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
Topics: Adenine; Aged; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; P | 2016 |
Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Topics: Adenine; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Influenza Vaccines; Influenza, | 2016 |
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Genes, p53; Humans; Leukemi | 2016 |
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Drug Resista | 2016 |
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Topics: Adenine; Adult; Aged; B-Lymphocytes; Chimerism; Cohort Studies; Female; Germinal Center; Graft vs Ho | 2016 |
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Comb | 2017 |
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
Topics: Adenine; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperi | 2018 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.
Topics: Adenine; Administration, Oral; Area Under Curve; Humans; Infusions, Intravenous; Leukemia, Hairy Cel | 2004 |
566 other studies available for adenine and B-Cell Chronic Lymphocytic Leukemia
Article | Year |
---|---|
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Case-Control Studies; Cohort Stud | 2021 |
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; | 2021 |
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pharmaceutical Preparations; Piperidines; P | 2021 |
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphoc | 2021 |
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
Topics: Adenine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Leukemia, Lymphoc | 2021 |
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py | 2022 |
Ibrutinib's off-target mechanism: cause for dose optimization.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2021 |
Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2021 |
Treatment with ibrutinib does not induce a
Topics: Adenine; Clonal Evolution; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tumor Suppre | 2022 |
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Cause of Death; Comorbidity; Disease Management; Female; Hu | 2022 |
Ibrutinib skin toxicities: Report of two cases.
Topics: Adenine; Aged; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cel | 2022 |
Successful treatment of cutaneous Acanthamoeba castellanii infection with miltefosine in a patient with chronic lymphocytic leukaemia on ibrutinib.
Topics: Acanthamoeba castellanii; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylcholine | 2022 |
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Transcriptome | 2022 |
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.
Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear | 2021 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Leukemia, Lymphoc | 2022 |
Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Blister; Hemorrhage; Humans; Leukemia, Lymphocyt | 2022 |
Is there a role for anti-CD20 antibodies in CLL?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD2 | 2021 |
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzam | 2021 |
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
Topics: Adenine; Adult; Cardiac Tamponade; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged | 2022 |
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Sin | 2022 |
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Mult | 2022 |
Atypical "accelerated" chronic lymphocytic leukemia with abnormal lymphocyte chromatin clumping, bone involvement, and exceptional response to Imbruvica.
Topics: Adenine; Aged; B-Lymphocytes; Chromatin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip | 2022 |
[Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
Topics: Adenine; Aged; Cryptococcosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Protein Kinase Inhi | 2022 |
Research progress in overcoming ibrutinib drug resistance.
Topics: Adenine; Adult; Antineoplastic Agents; Drug Resistance; Drug Resistance, Neoplasm; Humans; Leukemia, | 2022 |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2022 |
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt | 2022 |
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Leukemia, Lymphocytic, C | 2022 |
The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
Topics: Adenine; Adult; Constriction, Pathologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidine | 2022 |
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Retros | 2022 |
Campylobacter infection in 4 patients treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Campylobacter Infections; Diarrhea; Humans; Leukemia, | 2022 |
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Primary Myelofibrosis | 2022 |
Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2022 |
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, | 2022 |
Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nocardia Infections; Piperidines | 2022 |
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2022 |
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyt | 2022 |
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Topics: Adenine; Calcium; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
A CAPTIVATE-ing new regimen for CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2022 |
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Australia; Duration of Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2022 |
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2022 |
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; | 2022 |
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamus | 2022 |
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
Topics: Adenine; Chromosomes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; p21-Activated Kinases; Piperid | 2022 |
Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Product Surveillance, P | 2022 |
Ibrutinib frontline in young patients with CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Rituximab | 2022 |
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2022 |
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progres | 2022 |
A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Topics: Adenine; Aged, 80 and over; Endothelial Cells; ErbB Receptors; Glomerulonephritis, Membranoprolifera | 2022 |
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.
Topics: Adenine; Humans; Laboratories, Clinical; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piper | 2022 |
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2022 |
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort.
Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines | 2023 |
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cr | 2022 |
Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia.
Topics: Adenine; Colorectal Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pa | 2022 |
An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
Topics: Adenine; Adult; Aged, 80 and over; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 2022 |
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.
Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2022 |
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient S | 2022 |
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leu | 2022 |
Richter transformation to aggressive plasmablastic neoplasm related to selection of a
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Plasma Cells | 2023 |
Severe Postoperative Bleeding Secondary to Ibrutinib Intake.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2023 |
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2023 |
Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.
Topics: Adenine; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kin | 2023 |
Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Tre | 2023 |
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Tum | 2023 |
Bleeding complication following a shave biopsy in a patient taking ibrutinib.
Topics: Adenine; Biopsy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibit | 2022 |
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Hu | 2023 |
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies | 2023 |
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2023 |
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Rituximab; Secondary Prevention | 2023 |
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Topics: Adenine; Aspergillosis; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; | 2023 |
New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Recurrence | 2023 |
Ibrutinib outperforms FCR in CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituxi | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Topics: Abnormal Karyotype; Adenine; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11 | 2019 |
Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amyloid Precursor Protein Secretases; Animals; Calcium; Dia | 2020 |
Autoimmune hemolytic anemia, adverse event to venetoclax.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2019 |
Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
Topics: Adenine; Aged; Cryoglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; | 2019 |
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Proli | 2019 |
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Immunocompromised Host; Invasive Fungal Inf | 2019 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb | 2019 |
The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cunninghamella; Humans; Immunocompromised Host; | 2019 |
Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidine | 2020 |
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; | 2019 |
Ibrutinib-associated oral ulcers.
Topics: Adenine; Aged; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metr | 2020 |
Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy | 2019 |
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Topics: Adenine; Aged; Antineoplastic Agents, Immunological; Female; Health Care Costs; Health Resources; Hu | 2019 |
[Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
Topics: Adenine; Aged; Antibodies, Monoclonal; Autoimmune Diseases; Female; Humans; Leukemia, Lymphocytic, C | 2019 |
[Richter syndrome successfully treated with ibrutinib monotherapy: two case reports].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidine | 2019 |
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
Topics: Adenine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Ma | 2020 |
Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Canada | 2019 |
[Aspergillus spondylodiscitis in a patient treated with ibrutinib].
Topics: Adenine; Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Asp | 2020 |
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Topics: Adenine; Animals; Cell Line, Tumor; Enzyme Stability; HEK293 Cells; HSP90 Heat-Shock Proteins; Human | 2020 |
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Aged, 80 and over; Cryptococcosis; Dermatomycoses; Female; Humans; Leukemia, Lymphocytic, C | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2019 |
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2019 |
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Topics: Adenine; Aged; Aged, 80 and over; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Fe | 2020 |
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Leukemia, Lymphocytic, Chroni | 2019 |
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged Bicyclo Co | 2019 |
Two-drug combination benefits patients with chronic lymphocytic leukemia.
Topics: Adenine; B-Lymphocytes; Drug Combinations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidin | 2020 |
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Prot | 2020 |
A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Topics: Adenine; Area Under Curve; Female; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluor | 2020 |
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2020 |
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chromatin; Epigenome; Epigenomics; Gene Expression Pro | 2020 |
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Topics: Adenine; Cell Proliferation; Disease Progression; Humans; Immunotherapy; Integrin alpha4; Leukemia, | 2020 |
Ibrutinib-induced polyneuropathy: A case report.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2020 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leuk | 2020 |
Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Topics: Adenine; Aged; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Ki | 2020 |
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Topics: Adenine; Adult; Aged; Antigens, CD19; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibil | 2020 |
Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
Topics: Adenine; Aged; Aspergillosis; Aspergillus; Central Nervous System Infections; Humans; Leukemia, Lymp | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Col | 2020 |
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidi | 2021 |
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Dose-Response Relationship, Drug; Female; | 2020 |
An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Topics: Adenine; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 11; Exercise; Humans; Leuk | 2020 |
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Incidence; Leukemia, Lympho | 2020 |
Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; M | 2021 |
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds | 2020 |
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Bridge | 2020 |
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
Topics: Adenine; Antineoplastic Agents; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Leukemia, Lymp | 2020 |
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molec | 2021 |
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benza | 2020 |
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
Topics: Adenine; Feasibility Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2020 |
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocyt | 2021 |
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; | 2020 |
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavi | 2020 |
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; | 2020 |
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Disease Management; Female; Follow-Up | 2021 |
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; | 2020 |
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Topics: Adenine; Aged; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Leukemia, | 2020 |
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles | 2020 |
[Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Meningitis, Cryptococcal; Piperidines; Pyra | 2020 |
Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Glucose; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipid Metabolism; Piperidines; Pyr | 2020 |
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2021 |
LC-FACSeq is a method for detecting rare clones in leukemia.
Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mu | 2020 |
Patterns of use and safety of ibrutinib in real-life practice.
Topics: Adenine; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B- | 2021 |
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tu | 2020 |
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Decision-Making; Female; France; H | 2020 |
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; H | 2020 |
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Betacoronavirus; Comorbidity; | 2020 |
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resist | 2020 |
Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
Topics: Adenine; Ambulatory Care; Antineoplastic Agents; Appointments and Schedules; Betacoronavirus; Canada | 2020 |
Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2020 |
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
Topics: Adenine; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Diagnostic Errors; Female; Humans | 2020 |
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Topics: Adenine; Antigens, CD19; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocyte | 2021 |
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Myco | 2020 |
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Drug Synergism; Histamine Antagonists; Huma | 2020 |
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Receptor | 2021 |
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Ly | 2020 |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Topics: Adenine; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase | 2020 |
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2020 |
Bringing hospital care closer to patients amidst COVID-19.
Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans | 2020 |
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Hemostasis; Humans; Leukemia, Lymphocytic, Chronic | 2020 |
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Costs; Female; Health | 2020 |
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr | 2020 |
[Haemorrhagic complications following ibrutinib intake after dermatological surgery].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2020 |
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Piperidine | 2020 |
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Topics: Adenine; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplast | 2020 |
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Aspergillosis; Aspergillus fumi | 2020 |
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation | 2020 |
ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Topics: Adenine; Adult; Anaplastic Lymphoma Kinase; Biomarkers; Female; Histiocytosis; Humans; Leukemia, Lym | 2021 |
Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
Topics: Adenine; Aged; Ecthyma; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pseudomon | 2021 |
Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Immunoglobulin A; Infect | 2021 |
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Cost Savings; Female; Health Care Costs; Humans; Immunotherapy; Leukemia, Lymphocytic | 2020 |
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Pyrazoles; Pyrimidi | 2021 |
Ibrutinib-Induced Skin Rash
Topics: Adenine; Aged; Biopsy; Exanthema; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Ce | 2021 |
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2020 |
Enterobius vermicularis Infection of the Lung Associated With the Use of Ibrutinib in a Patient With Chronic Lymphocytic Leukemia.
Topics: Adenine; Enterobiasis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung; Piperidines | 2020 |
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance, | 2020 |
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance, | 2020 |
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance, | 2020 |
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Drug Resistance, | 2020 |
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Biomarkers, Tumor; Chemokine CXCL13; Female; Follow-Up Studies; Humans; Leukemia, Lym | 2021 |
Cost-effectiveness targeting CLL.
Topics: Adenine; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazol | 2020 |
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Deglutition Disorders; Female; Huma | 2021 |
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, | 2021 |
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
Topics: Adenine; Aged; Biomarkers; Biopsy; Cardiac Tamponade; Echocardiography; Female; Humans; Leukemia, Ly | 2021 |
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Hum | 2021 |
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Topics: Adenine; Adult; Aged; Biomarkers, Tumor; CD40 Antigens; Female; Follow-Up Studies; Gene Expression R | 2021 |
Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Biomarkers, Tumor; Drug Resistance, Neoplasm; Genetic Testing; High-Throughput Nucleotide S | 2021 |
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognos | 2021 |
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyr | 2021 |
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
Topics: Adenine; Aged; Cross Infection; Humans; Incidence; Inpatients; Leukemia, Lymphocytic, Chronic, B-Cel | 2021 |
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; An | 2021 |
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Catalytic Domain; COVID-19; Dasatinib; Humans; Leukemi | 2020 |
Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; | 2021 |
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
Topics: Adenine; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Br | 2021 |
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp | 2020 |
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2021 |
IBRUTINIB FOR CONTROL OF CHOROIDAL AND ORBITAL METASTASIS FROM CHRONIC LYMPHOCYTIC LEUKEMIA.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inh | 2023 |
Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged; Brain; Humans; Intracranial Hemorrhages; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2022 |
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib.
Topics: Adenine; Aged, 80 and over; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prote | 2020 |
Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
Topics: Adenine; Aged; Ecthyma; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Piperidine | 2021 |
Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymp | 2021 |
Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Topics: Adenine; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Lymphocytic, Chronic, B- | 2022 |
[Successful treatment with silver nitrate chemical cauterization for paronychia and granulation in a patient with chronic lymphocytic leukemia undergoing ibrutinib therapy].
Topics: Adenine; Aged; Cautery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paronychia; Piperidine | 2021 |
Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab.
Topics: Adenine; Bendamustine Hydrochloride; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 2021 |
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Topics: Adenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia | 2021 |
Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinemia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Ki | 2021 |
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2021 |
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Topics: Adenine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gl | 2021 |
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cysteine; Drug Resistance, Neoplasm; Humans; Leukemia, | 2021 |
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
Topics: Adenine; COVID-19; Humans; Immunity, Innate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pr | 2021 |
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Drug Synergism; Female; Heterocyclic Compounds, | 2021 |
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Movement; Humans; Leukemia, Lymphocytic, Chronic, | 2021 |
Cerebral aspergillosis in a patient on ibrutinib therapy.
Topics: Adenine; Adrenal Cortex Hormones; Aged; Aspergillosis; Aspergillus fumigatus; Brain Diseases; Humans | 2021 |
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Cell Line, Tumor; Cell Movement; Forkhead Box Protein | 2021 |
Immediate reaction to ibrutinib amenable to oral desensitization.
Topics: Adenine; Aged; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Leukemia, Lympho | 2021 |
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosomes, Human, Pair 2; Cohort | 2021 |
[Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia].
Topics: Adenine; Aged; Humans; Immunoglobulin M; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chroni | 2021 |
A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Female; Flow Cytometry; | 2020 |
An Eschar-like souvenir from a journey to Colombia: Ecthyma gangrenosum as a differential diagnosis of tropical diseases in immunocompromised patients - a case report.
Topics: Adenine; Administration, Intravenous; Aged; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Col | 2021 |
Select Antitumor Cytotoxic CD8
Topics: Adenine; CD8-Positive T-Lymphocytes; Cells, Cultured; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2021 |
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Topics: Adenine; Aged; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidin | 2021 |
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Topics: Adenine; Aged; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; | 2021 |
Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2021 |
Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Topics: Adenine; Aged; Databases, Factual; Drug Prescriptions; Female; Health Care Costs; Humans; Italy; Leu | 2021 |
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Topics: Acute Kidney Injury; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B | 2021 |
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.
Topics: Adaptive Immunity; Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; | 2021 |
Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Female; Humans; Leukemia, Lymphocytic, Ch | 2021 |
Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
Topics: Activities of Daily Living; Adenine; Aged; Cytokines; Female; Follow-Up Studies; Humans; Leukemia, L | 2021 |
Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
Topics: Adenine; Adenocarcinoma of Lung; Aged; ErbB Receptors; Humans; Leukemia, Lymphocytic, Chronic, B-Cel | 2021 |
Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Cell Adhesion; Cell Survival | 2021 |
Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Adult; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; L | 2022 |
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Ne | 2021 |
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
Topics: Adenine; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Retrospectiv | 2021 |
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Topics: Adenine; Aged; Biopsy; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chr | 2021 |
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Topics: Adenine; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Cell Line, Tumo | 2022 |
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
Topics: Adenine; Antineoplastic Agents, Immunological; Clonal Evolution; Clone Cells; Humans; Immunoglobulin | 2021 |
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Clonal Evolution; Female; Humans; Leuke | 2021 |
Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
Topics: Adenine; Aged; Chylothorax; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pleur | 2022 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes, | 2022 |
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors | 2021 |
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
Topics: Adenine; Aged; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell | 2021 |
Effect of Ibrutinib on Hmphocytic Leukemia: a Single-Center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protei | 2022 |
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytomegalo | 2021 |
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Leukemia, Lymphocytic, Chronic, B-Cel | 2021 |
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri | 2021 |
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cel | 2021 |
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidine | 2021 |
Targeted therapies: Ibrutinib: new option for relapsed MZL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py | 2017 |
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; C2 Domains; Drug Resistance, Neoplasm; Humans; Leukemi | 2017 |
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
Topics: Adenine; Adult; Aged; Cell Proliferation; Cytokines; Female; Humans; Leukemia, Lymphocytic, Chronic, | 2017 |
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2017 |
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; France; Humans; Leukemia, Ly | 2017 |
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2017 |
The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Humans; Leukemia, Lymphocytic, C | 2017 |
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Topics: Adenine; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; D | 2017 |
A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimid | 2018 |
Is HBV prophylaxis required during CLL treatment with ibrutinib?
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Biomarkers; Hepatitis B; Humans; Leukemia, Lymphoc | 2017 |
Imbruvica
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Le | 2017 |
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Topics: Adenine; Aged; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Disease Progression; | 2017 |
Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; | 2017 |
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, A | 2017 |
The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
Topics: Adenine; Aminoimidazole Carboxamide; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Synerg | 2017 |
Ibrutinib may impair serological responses to influenza vaccination.
Topics: Adenine; Humans; Influenza Vaccines; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; | 2017 |
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma | 2018 |
Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
Topics: Adenine; Communicable Diseases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B | 2018 |
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Topics: Adenine; Aged; Cell Transformation, Neoplastic; Disease Progression; Humans; Leukemia, Lymphocytic, | 2017 |
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; | 2017 |
Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2017 |
Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
Topics: Adenine; Antiviral Agents; HIV; HIV Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2018 |
Splenic rupture following temporary cessation of ibrutinib.
Topics: Adenine; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lympho | 2017 |
Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.
Topics: Adenine; Aged; Case-Control Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; M | 2018 |
Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Autoantibodies; Glutamate Decarboxylase; Humans; Insulin Antibodies; Leukemia, Lympho | 2018 |
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; B-Lympho | 2017 |
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.
Topics: Adenine; Adult; Antineoplastic Agents; Clinical Decision-Making; Cost-Benefit Analysis; Genomics; Hu | 2017 |
Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman.
Topics: Adenine; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Exfoliatins; Female; Humans; Immunoco | 2018 |
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, | 2017 |
Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Ge | 2017 |
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Topics: Adenine; Aged; Biomarkers, Tumor; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Hum | 2018 |
Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neutro | 2018 |
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Topics: Adenine; Aged; B-Lymphocytes, Regulatory; B7-H1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T- | 2018 |
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Topics: Adenine; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assay | 2017 |
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; | 2018 |
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Topics: Adenine; Drug Substitution; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pro | 2018 |
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Topics: Adenine; Animals; Antigens, CD; Cell Adhesion; Coculture Techniques; Fibroblasts; Humans; Immunophen | 2018 |
Survival adjusting for crossover: phase 3 study of ibrutinib
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Clin | 2018 |
Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
Topics: Adenine; Agammaglobulinemia; Aged; Bacterial Infections; Humans; Immunoglobulins; Leukemia, Lymphocy | 2018 |
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis; | 2018 |
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
Topics: Adenine; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Midd | 2018 |
Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Topics: Adenine; Adult; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-C | 2018 |
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecu | 2018 |
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2018 |
Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Co | 2018 |
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Atrial Fibrillation; Case-Control Studies; Electrocardiography | 2018 |
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Adhesion; Humans; Immunoglobulin M; Integrin alph | 2018 |
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Line, Tumor; Drug Delivery Sys | 2018 |
Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Topics: Adenine; Aged; Cryptococcosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pi | 2019 |
Venetoclax Data Prompt Rethink of CLL Therapy.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2018 |
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Central Nervous System; Central Nervous System N | 2018 |
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comor | 2018 |
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Topics: Adenine; Aged; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillo | 2018 |
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease Progression; Drug-Related Side Effects and Adverse | 2018 |
CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri | 2018 |
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Topics: Adenine; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Culture; C | 2018 |
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Fatty Acids, Nonesterified; Female; Humans; Leukemia, Lymphocytic, Chronic, B- | 2018 |
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
Topics: Adenine; Aged; Antiviral Agents; Fatal Outcome; Feasibility Studies; Female; Hepatitis B; Hepatitis | 2018 |
Ibrutinib-Induced Neutrophilic Dermatosis.
Topics: Adenine; Antineoplastic Agents; Chromosomes, Human, Pair 17; Drug Eruptions; Female; Humans; Leukemi | 2018 |
Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Piperidines; Pyraz | 2018 |
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu | 2018 |
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2018 |
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Drug Subs | 2018 |
Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
Topics: Adenine; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukem | 2018 |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2018 |
Ibrutinib: coming of age?
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pyraz | 2018 |
Ibrutinib and fungus: an invasive concern.
Topics: Adenine; Adult; Fungi; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrim | 2018 |
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Disease-Free S | 2018 |
Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Arthritis; Humans; Leukemia, Lymphocytic, Chroni | 2019 |
Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
Topics: Adenine; Aged; Electrocardiography; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidi | 2016 |
Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Topics: Adenine; Clinical Trials, Phase III as Topic; Humans; Infections; Leukemia, Lymphocytic, Chronic, B- | 2018 |
Five years of ibrutinib in CLL.
Topics: Adenine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; | 2018 |
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Elec | 2018 |
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aut | 2019 |
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Design | 2018 |
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; Echocard | 2018 |
Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
Topics: Adenine; Antineoplastic Agents, Immunological; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immu | 2018 |
Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
Topics: Adenine; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Py | 2018 |
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2019 |
Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Eosinophilia; Humans; Immunoglobulin E; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middl | 2018 |
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Humans; Leukemia, Lymphocytic, Chronic | 2018 |
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Cell Line, Tumor; Drug Resist | 2018 |
Unusual cause of sinusitis and cough.
Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Midd | 2018 |
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Topics: Adenine; Aged; Antifungal Agents; Aspergillus fumigatus; B-Lymphocytes; Humans; Leukemia, Lymphocyti | 2019 |
No longer too exhausted to run.
Topics: Adenine; Antibodies, Bispecific; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Pipe | 2018 |
Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
Topics: Adenine; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Costs and Cost Analysis; Female; Hu | 2018 |
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
Topics: Academic Medical Centers; Adenine; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Disease-Free | 2018 |
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Topics: Adenine; Aged; Antineoplastic Agents; B-Lymphocytes; Down-Regulation; Female; Gene Expression Profil | 2018 |
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Topics: Adenine; Age Factors; Aged; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Female; Humans; L | 2018 |
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Gene Expression Regul | 2018 |
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocyti | 2018 |
Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.
Topics: Adenine; beta 2-Microglobulin; Cell Death; Disease Progression; Humans; Immunoglobulin G; Injections | 2018 |
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macular Edema; | 2019 |
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells; | 2018 |
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Topics: Adenine; Base Sequence; Disease Progression; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocyti | 2019 |
A new triple threat to CLL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; | 2018 |
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Pr | 2019 |
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein-Tyro | 2019 |
Superior vena cava syndrome with concomitant upper extremity deep vein thrombosis.
Topics: Adenine; Aged; Female; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyr | 2019 |
Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Topics: Adenine; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Ly | 2019 |
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antigens, CD19; Apoptosis; B-Lymphocytes; Cell Proliferation; Disease Models, Anim | 2018 |
Is less equal with ibrutinib dose?
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pilot Projects; Piperidines; Pyrazoles; Pyr | 2018 |
γδ T cells for immunotherapy.
Topics: Adenine; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyri | 2018 |
A rare colonic manifestation of chronic lymphocytic leukemia.
Topics: Adenine; Aged; Colon, Sigmoid; Colonic Polyps; Female; Humans; Intestinal Mucosa; Leukemia, Lymphocy | 2019 |
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Proliferation; Cell Survival; Humans; Leukemia, L | 2019 |
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine | 2019 |
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Topics: Adenine; Aged; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2019 |
Cryopreservation of primary B cells minimally influences their signaling responses.
Topics: Adenine; B-Lymphocytes; CD40 Ligand; Cells, Cultured; Cryopreservation; Flow Cytometry; Humans; Leuk | 2018 |
Ibrutinib: searching for a partner drug.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2019 |
Concurrent treatment with two B-cell receptor pathway inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein | 2019 |
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2019 |
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agen | 2019 |
Alliance to iLLUMINATE the chemo-free sign.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2019 |
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease; | 2019 |
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human | 2019 |
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Topics: Adenine; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip | 2019 |
Ibrutinib-associated T-cell pseudolymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Diagnosis, Differential; Humans; Leukemia, Lymph | 2019 |
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; My | 2019 |
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
Topics: Abdomen; Adenine; Aged; Fatal Outcome; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Ch | 2019 |
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Cycle Proteins; Chromatin; Drug Combinations; Dru | 2019 |
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Topics: Adenine; Biomarkers, Tumor; Circadian Rhythm; Drug Therapy, Combination; Gene Expression Regulation, | 2019 |
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aspergillosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucormycosis; Neoplas | 2019 |
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alternative Splicing; Animals; Antineoplastic Agents; | 2019 |
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib.
Topics: Adenine; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; P | 2019 |
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; He | 2019 |
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Topics: Adenine; Animals; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 2019 |
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic | 2019 |
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2019 |
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2020 |
Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-C | 2019 |
Targeting CD20 takes the backseat in CLL.
Topics: Adenine; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyr | 2019 |
Fever and Rash in an Adult: Varicella Re-infection in Conjunction with Newly Diagnosed Chronic Lymphocytic Leukemia.
Topics: Acyclovir; Adenine; Adult; Antiviral Agents; Chickenpox; Dermatitis; Fever; Humans; Leukemia, Lympho | 2019 |
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplast | 2019 |
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neopl | 2019 |
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Atrial Fibrillation; A | 2019 |
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Topics: Adenine; Aged; Anticoagulants; Antineoplastic Agents; Drug Approval; Female; Hemorrhage; Humans; Inc | 2019 |
Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.
Topics: Adenine; Female; Foot Dermatoses; Hand Dermatoses; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; M | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL.
Topics: Adenine; Aged; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2019 |
Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Topics: Adenine; Case-Control Studies; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relation | 2019 |
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytokine | 2020 |
Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cryptococcosis; Fatal Outcome; Humans; Leukemia, Lymph | 2019 |
Ibrutinib: the home run for cure in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chroni | 2019 |
Ibrutinib is safer than we think.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Managing patients with ibrutinib-resistant CLL: don't stop ibrutinib until you are ready with the next therapy.
Topics: Adenine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2019 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Topics: Adenine; Antineoplastic Agents; beta 2-Microglobulin; Bridged Bicyclo Compounds, Heterocyclic; Datab | 2019 |
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Topics: Adenine; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Re | 2019 |
Ibrutinib and Venetoclax - Doubling Down on CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cardiomyopathies; Female; Humans; Late Onset Dis | 2020 |
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Topics: Adenine; Cohort Studies; Female; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; H | 2020 |
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
Topics: Adenine; Antineoplastic Agents; Comorbidity; Disease Progression; Drug Resistance, Neoplasm; Female; | 2019 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cl | 2019 |
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Topics: Adenine; Adult; Antineoplastic Agents; Compassionate Use Trials; Humans; Leukemia, Lymphocytic, Chro | 2019 |
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; P | 2019 |
New first-line options in CLL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pi | 2019 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphoc | 2019 |
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm | 2019 |
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Survival; Drug Resistance, Neoplasm; Energy Metab | 2019 |
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di | 2019 |
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Ce | 2019 |
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
Topics: Adenine; Aged; Animals; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping | 2013 |
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Prote | 2013 |
A mechanism-driven treatment for chronic lymphocytic leukemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Female; Humans; Leukemia, Lymph | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Imm | 2013 |
Targeting the B-cell signalling pathway in CLL and MCL.
Topics: Adenine; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piper | 2013 |
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Survival; Disease Mode | 2014 |
A new era of treatment for chronic lymphocytic leukaemia?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2014 |
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CD40 Ligand; Disease-F | 2014 |
Imbruvica--next big drug in B-cell cancer--approved by FDA.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Drug | 2014 |
Boldly Targeting Kinases without mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Leukemia, Lymphocytic, Chroni | 2014 |
Idelalisib, ibrutinib show benefits in CLL.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 2014 |
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
Topics: Adenine; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Endoplasmic Reti | 2014 |
Ibrutinib: targeting the hidden CLL.
Topics: Adenine; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Piperidines | 2014 |
New approved indication for ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, | 2014 |
Ibrutinib resistance in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, L | 2014 |
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Binding Sites; Drug Resistance, Neoplasm; Exome; | 2014 |
Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Topics: Adenine; Aged; Allopurinol; Antimetabolites; Antineoplastic Agents; Chromosome Deletion; Chromosomes | 2015 |
Changes in the treatment landscape for chronic lymphoid leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lympho | 2014 |
Ibrutinib treatment of CLL: the cancer fights back.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Progression; Drug Resis | 2014 |
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female; | 2014 |
[Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2014 |
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Topics: Adenine; Adenosine Diphosphate; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cel | 2015 |
Ibrutinib: better combined with other drugs?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fem | 2014 |
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor | 2015 |
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Evolution, Molecular; Human | 2014 |
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplasti | 2015 |
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2015 |
Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; | 2014 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibo | 2015 |
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Animals, Newborn; Atrial Fibrillation; Gene E | 2014 |
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Cohort Studies; DNA Mutational Analysis; Drug | 2014 |
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 12; Female; Humans; Leukemia, Lymp | 2015 |
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Female; | 2015 |
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Cli | 2015 |
FDA grants accelerated approval for ibrutinib for CLL.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Leukemia, | 2014 |
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes; | 2015 |
Ibrutinib has some activity in Richter's syndrome.
Topics: Adenine; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell | 2015 |
Understanding cancer cell survival is key to patient survival.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mu | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance | 2015 |
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2015 |
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2015 |
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2015 |
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2015 |
The efficacy of ibrutinib in the treatment of Richter syndrome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Murine-Derived; Antineop | 2015 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamust | 2015 |
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Health Expenditures; Humans; Leuk | 2015 |
Life after ibrutinib? A new unmet need in CLL.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazol | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-D | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, | 2015 |
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dr | 2015 |
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Chronic Disease; Disease Progression; Factor Analysis, | 2015 |
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; | 2015 |
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Topics: Adenine; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cell Prolifera | 2015 |
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Combo Therapy Effective for Relapsed CLL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials | 2015 |
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclohexylamines; Dru | 2015 |
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Adhesion; Female; Fibronectins; Humans; Int | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Pr | 2015 |
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cytogenetic Analysis; DNA Mutational Analys | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Biomarkers, Tumor; Cli | 2015 |
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Delet | 2015 |
Extramedullary haematopoiesis in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; B-Lymphocytes; Bone Marrow; Clone Cells; Exons; Genes, p53; Hematopoiesis, Extramedul | 2015 |
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Clinical Trials as Topic; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chron | 2015 |
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Topics: Adenine; Antigens, CD20; Antineoplastic Agents; Biopsy; Bone Marrow; CD55 Antigens; Clinical Trials, | 2016 |
Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
Topics: Adenine; Antineoplastic Agents; Biomarkers, Tumor; CARD Signaling Adaptor Proteins; DNA Mutational A | 2016 |
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.
Topics: Adenine; Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, L | 2015 |
Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy.
Topics: Adenine; Antimetabolites, Antineoplastic; Biopsy; Drug Therapy, Combination; Humans; Leukemia, Lymph | 2016 |
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspases; Dose-Response Relationship, | 2016 |
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut | 2016 |
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut | 2016 |
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut | 2016 |
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Aut | 2016 |
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Anti-Idiotypic; B-Lymphocytes; Cell Line, | 2016 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Surviva | 2015 |
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Topics: Adenine; Animals; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Resistance, Neoplasm; Hum | 2016 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Calcium Signaling; Humans; Interferon-gamma; | 2016 |
Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Isoquinolines; Leukemia | 2015 |
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Anti | 2016 |
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung D | 2016 |
Occult HBV reactivation induced by ibrutinib treatment: a case report.
Topics: Adenine; Aged, 80 and over; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piper | 2015 |
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Blotting, Western; Case- | 2016 |
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neu | 2016 |
[Ibrutinib prescription in B-cell lymphoid neoplasms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistan | 2016 |
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Central Nervous System Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2017 |
Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Osteolysis, Essential; Piperid | 2016 |
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Bri | 2016 |
Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
Topics: Adenine; Adult; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, C | 2017 |
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, | 2016 |
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Le | 2016 |
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
Topics: Adenine; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combi | 2016 |
Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Bio | 2016 |
The use of ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2016 |
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion Molecules; Cell L | 2016 |
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor | 2016 |
CLL: ibrutinib and transplantation ride together.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Calcification, Physiologic; Combined Modality Therapy; Female; | 2017 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; | 2016 |
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2016 |
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Compassionate Use T | 2016 |
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Apoptosis; Cell Transdiffere | 2016 |
Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
Topics: Adenine; Aged; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Age | 2016 |
The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Apoptosis; B-Lymphocytes; Cell Cy | 2016 |
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Topics: Adenine; Angiopoietin-1; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; | 2016 |
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Res | 2016 |
Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.
Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System; Humans; Immune Reconstitution Infl | 2017 |
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.
Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazole | 2016 |
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.
Topics: Adenine; Humans; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazole | 2016 |
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antigens, CD19; B-Lymphocytes; Biomarkers; Cell Proliferation; Cluster Analysi | 2017 |
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Disease | 2017 |
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Topics: Adenine; Antigens, CD20; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Leukemia, | 2016 |
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Topics: Adenine; Amino Acid Substitution; Animals; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplas | 2016 |
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cysteine; Humans; Kinetics; Leu | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; | 2016 |
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Huma | 2016 |
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
Topics: Adenine; Anticoagulants; Atrial Fibrillation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2016 |
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Disease Management; Fe | 2016 |
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Transformation, Neoplastic | 2016 |
Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
Topics: Adenine; Agammaglobulinemia; Aged; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; | 2016 |
Ibrutinib holds promise for patients with 17p deletion CLL.
Topics: Adenine; Chromosome Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles | 2016 |
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoe | 2018 |
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell | 2016 |
Ibrutinib-induced pyoderma gangrenosum.
Topics: Adenine; Cyclosporine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Ma | 2016 |
Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Chromosome Aberrations; Dr | 2017 |
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Biomarkers; Biopsy; Blood Cell Count; Female; Humans; Leukemia | 2017 |
Targeting BTK through microRNA in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzofurans; Cell Survival; Clone Cells; Drug | 2016 |
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Cytochrome P-450 CYP3A; Drug In | 2017 |
EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Diagnosis, Differential; Disease Prog | 2017 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner | 2017 |
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Comorbidity; Female; Humans; Incidence | 2017 |
Ibrutinib in the real world patient: many lights and some shades.
Topics: Adenine; Age Factors; Clinical Studies as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pip | 2016 |
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Animals; Antibodies, Monoclonal; Apoptosis; Cell Proliferation; Humans; Leukemia, Lymphocyt | 2017 |
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Monitoring; Female; Hemorrhage; Humans; Leukemia, Lymp | 2017 |
Ibrutinib-Induced Lymphocytosis: Cytological Features.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Chromo | 2017 |
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.
Topics: Adenine; Aged; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; | 2017 |
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Hig | 2017 |
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Proliferation; | 2017 |
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2017 |
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Topics: Adenine; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B | 2017 |
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Death; Cell Proliferation; Deuterium Oxide; | 2017 |
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines | 2018 |
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Topics: Adenine; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; A | 2017 |
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Deprescriptions; Disease Progression; Drug-Related Side Eff | 2017 |
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2017 |
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Li | 2017 |
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; DNA; Drug Resistance, Neoplasm; | 2017 |
Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Topics: Adenine; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Humans; Leukemia, Lymphocytic, Chronic, B-Cel | 2017 |
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2017 |
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemat | 2017 |
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; CD52 Antigen; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperi | 2017 |
Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2017 |
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela | 2017 |
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
Topics: Adenine; Calcium-Binding Proteins; Cell Line, Tumor; Down-Regulation; EGF Family of Proteins; Endoth | 2017 |
Ibrutinib-resistant CLL: unwanted and unwonted!
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines | 2017 |
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Bac | 2017 |
Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia.
Topics: Adenine; Caspases; CD47 Antigen; Cell Death; Dynamins; GTP Phosphohydrolases; Humans; Leukemia, Lymp | 2009 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Cell Activating Factor; B-Lympho | 2011 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells, | 2012 |
B-cell receptor inhibitors in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia | 2011 |
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blotting, Western; Cell Adhesion; Cell Move | 2012 |
G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
Topics: Adenine; Algorithms; Base Sequence; bcl-2-Associated X Protein; Cell Line, Tumor; Gene Expression Re | 2005 |
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplas | 2006 |